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Abstract 
Glioblastoma (GBM) is the most common malignant brain tumour and has 
an extremely poor prognosis. The invasion of tumour cells into normal brain 
tissue makes complete surgical removal impossible; GBM is also resistant to 
treatment with chemotherapy and radiotherapy. Our aim was to investigate 
how GBM cell proliferation, survival and invasion is affected by the solid 
tumour microenvironment. Although GBM is highly vascularised, the 
abnormal structure and function of tumour blood vessels results in an 
inadequate supply of oxygen (hypoxia). Hypoxia is known to promote 
tumour progression; however, the effect of hypoxia on cell proliferation has 
not been well characterised. We performed a systematic investigation into 
the effects of different oxygen levels on the cell cycle. In contrast to the 
prevailing hypothesis, we found that long-term exposure to 
pathophysiological levels of hypoxia (1–8% O2) does not affect cell 
proliferation and viability and that even severe hypoxia (0.1% O2) has only 
minimal effects. We next sought to characterise the effect of hypoxia in 
multicellular tumour spheroids: 3D cell clusters that replicate important 
aspects of the tumour microenvironment. We characterised spheroids in 
terms of proliferation, survival and oxygenation and found that, in this more 
complex model, hypoxia was associated with reduced proliferation. We then 
used spheroids to develop a novel method for imaging cellular migration 
and invasion in 3D using lightsheet fluorescence microscopy (LSFM). We 
imaged spheroids over 24 h and then quantified the movements of up to 1200 
cells per spheroid in terms of speed and straightness of movement. We were 
able to compare the movement of cells in different regions of spheroids, 
gaining insight into the behaviour of quiescent cells in the core of large 
(~500 µm), heterogeneous spheroids that had been exposed to hypoxia. This 
technique can be used to investigate the effect of the tumour 
microenvironment on cell motility and to gain insight into the mechanism of 
drugs that hinder the process of invasion.  
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1.1 Cancer 
Cancer is a major contributor to global disease burden, with 14 million new 
cases and 8 million cancer deaths occurring each year (1). In the UK, cancer is 
the responsible for 29% of all deaths (2). In nearly all cancers, death is caused 
by the spread of cancer to other parts of the body (metastasis), where it 
interferes with normal organ function. While cancer remains a major 
contributor to mortality, intensive research into the causes of cancer over the 
last 40 years has led to the development of more effective treatments and 
significant improvements in survival. In 1971, only 24% of patients 
diagnosed with cancer were alive 10 years later, but by 2011 the 10 year 
survival rate had increased to 49% (3). However, while the outlook for many 
cancers is now favourable, for others the survival rate remains extremely 
poor (Fig 1.1). Environmental and lifestyle factors such as smoking, drinking, 
diet, and obesity are implicated in the majority of cancers. The biggest 
preventable cause of cancer is smoking, which is responsible for 20% of new 
cancer cases in the UK (4). Infection is also an important cause of cancer, 
particularly in developing nations (5).  
Cancer is a disease caused by uncontrolled cellular proliferation coupled 
with the ability of cells to invade away from the primary tumour, either by 
invading neighbouring tissue or by spreading to distant organs. Tumours 
that lack the the ability to invade are benign and not cancerous. All cancers 
share a number of acquired hallmarks that underlie their malignant 
properties; these properties are discussed in detail in Hanahan and 
Weinberg’s seminal paper ‘The Hallmarks of Cancer’ (6). Cancer cells are 
able to generate their own proliferative signals and are insensitive to the anti-
growth signals that regulate proliferation in normal cells. While normal cells 
have limited replicative capability, cancer cells have unlimited replicative 
potential and are resistant to apoptosis. Cancer cells are also able to stimulate 
the formation of new blood vessels from existing blood vessels 
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(angiogenesis), which provides the oxygen and nutrients that are essential 
for tumour expansion. As our knowledge of cancer has improved, two 
additional hallmarks have emerged: reprogramming of cellular energetics 
and the avoidance of immune destruction (7). The acquisition of these 
hallmarks is a result of genetic mutations that enhance the activity of 
tumour-promoting genes (oncogenes) and reduce the effectiveness of tumour 
suppressor genes. Mutations in genes which normally keep genetic 
alterations to a minimum, such as DNA-repair genes, increases the likelihood 
that oncogenes and tumour suppressor genes will become mutated (8). To 
gain further insights into tumourigenesis, it is becoming increasingly clear 
that tumours need to be considered in the context of their microenvironment. 
The role of the tumour microenvironment in tumour progression is a topic 
that will be discussed throughout this thesis.  
 
Figure 1.1. Changes in cancer survival rates from 1971–2011. The figure shows the 
percentage of people who survive for 10 years after being diagnosed with cancer in the 
indicated tissues. Survival data were obtained from (3).  
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1.2 Central nervous system tumours 
The central nervous system (CNS) comprises the brain and spinal cord. CNS 
tumours can occur due to the abnormal growth of cells originating in the 
CNS (primary tumours) or because of metastatic dissemination from a 
tumour in another location in the body (metastatic tumours). Primary 
tumours can arise from any tissue in the CNS, including neuroepithelial 
tissue, the meninges, cranial nerves and pituitary gland (9). The most 
common tumour is the meningioma, a typically benign tumour that develops 
in the meninges. The second most common tumour is the glioma, a type of 
neuroepithelial tumour that develops from glial cells. Gliomas are the most 
common malignant CNS tumours, accounting for 80% of cases (10). Gliomas 
are categorised by the World Health Organisation as grades I-IV, with a 
higher grade indicating increased malignancy (9). Glial cells are electrically 
non-excitable cells that perform a number of supportive functions for 
neurons. Four main types of glial cells are found in the mature CNS: 
astrocytes, oligodendrocytes, microglia and ependymal cells. 
Oligodendrocytes form an electrically insulating layer around neurons 
known as the myelin sheath, ependymal cells line the ventricles and the 
spinal canal, and microglia have immunological functions (11). The normal 
functions of astrocytes include providing mechanical, metabolic and 
neurotrophic support to neurons, regulating blood flow, synaptic 
transmission and ion concentrations in the extracellular space, and 
responding to tissue damage.  Once thought to provide only supportive 
functions, it is now known that astrocytes participate in CNS signalling 
through Ca2+ signalling and the release of gliotransmitters (12-14). Glioma 
cells have inherited many of the biological traits of their glial ancestors, 
which make important contributions to disease progression  (15). 
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1.3 Glioblastoma  
Glioblastoma (GBM) is a Grade IV astrocytic tumour that accounts for over 
half of all gliomas. It is an extremely aggressive tumour with a poor 
prognosis; even with the best available treatments, median survival is just 14 
months after diagnosis and most patients die within two years (16). Around 
three cases per 100,000 people occur every year, making it the most common 
primary malignant brain tumour. GBM can occur de novo without any 
evidence of a less malignant precursor (primary GBM), or due to progression 
from a lower grade glioma (secondary GBM). Primary GBM occurs most 
frequently, accounting for 95% of all cases. Unless otherwise specified, all 
future references to GBM refer to primary GBM. While GBM can occur at any 
age, it occurs most frequently in patients between 50 and 70 years of age and 
in men (17). Headache is the most common presenting symptom, followed 
by memory loss, deficits in language and motor skills and cognitive changes. 
Other common symptoms include personality changes, seizures, nausea and 
visual problems (18).  
 
1.3.1 Pathology 
Seventy percent of GBMs occur in the frontal and temporal lobes of the 
cerebral cortex, with the remainder occurring in the parietal and occipital 
lobes and deeper brain structures (Fig 1.2A, B) (19).  Although GBMs can also 
develop in the brainstem, cerebellum and spinal cord, this is extremely rare. 
GBMs are both cellularly and molecularly heterogeneous tumours. 
Histopathologically, they are characterised by heterogeneous cell 
morphology, abnormal nuclei, a high mitotic rate, vascular thrombosis, 
microvascular proliferation and necrosis. The last two features are essential 
diagnostic criteria for GBM, distinguishing it from grade III anaplastic 
astrocytoma (20). The only established environmental risk factor for GBM is 
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therapeutically administered X-irradiation (21). The origin of GBM is 
controversial; it could develop from the malignant transformation of neural 
stem cells, neural precursor cells (NPCs), or mature differentiated cells. In the 
adult brain, neurogenesis is restricted to the subventricular zone (SVZ) of the 
lateral ventricles and the subgranular zone of the hippocampus (22). The 
bulk of the evidence tends to support NPCs as the cell of origin; however, 
there is currently not enough evidence to rule out the involvement of neural 
stem cells or differentiated cells (22, 23). A further possibility, consistent with 
the heterogeneous nature of GBM, is that it originates from different 
pathways in multiple cellular sources (24).  
The most frequent genetic alteration in GBM is loss of heterozygosity on the 
long arm of chromosome 10, which occurs in 70% of patients. EGFR 
amplifications, p16INK4a deletion, TP53 and PTEN mutations are also 
common, occurring in 25–36 % of patients (25). EGFR is an oncogene that 
encodes the epidermal growth factor receptor (EGFR), a transmembrane 
protein that promotes cell proliferation (26). P16INK4a, TP53 and PTEN are 
all tumour suppressor genes involved in the control of cell proliferation and 
survival (27-29). Based on gene expression profiles, GBM has been classified 
into four molecular subtypes: pro-neural, neural, mesenchymal and classical 
(30). These subtypes are associated with the expression of markers associated 
with different neural lineages. For example, the mesenchymal subtype is 
characterised by PTEN mutations and the expression of mesenchymal and 
astrocytic markers, while the classical group is characterised by EGFR 
mutations and the expression of NPC and stem cell markers. Treatment 
efficacy also varies by subtype; aggressive treatment significantly improves 
survival in the classical and mesenchymal types, but not the proneural type, 
which is more common in patients with secondary GBM. The finding that 
different subtypes are associated with different neural lineages supports the 
hypothesis that GBM can arise from more than one cell type. There is 
considerable intratumoural heterogeneity in GBM and spatially distinct 
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samples from the same tumour have been found to fall into different 
subtypes. Furthermore,  multiple cell lineages have been found to co-exist 
within a single sample (31). This heterogeneity presents significant 
challenges for the treatment of GBM.  
 
 
 
 
 
 
Figure 1.2. Location and characteristics of glioblastoma (GBM). (A). Cross-sectional view of 
the right cerebral hemisphere of the brain; relevant structures are indicated. This image is 
under a CC-BY licence from Wellcome Images but has been altered into a Derivative Work 
by the addition of text (32). (B). GBM commonly occurs in the frontal lobes of the cerebral 
cortex, as seen in this MRI image. Image was adapted from (33). (C). GBM cells show a 
characteristic pattern of invasion along existing structures such as (a) under the meninges 
(b), perivascularly and (c)  along white matter tracts such as the corpus callosum; (d) 
indicates a characteristic region of necrosis. Tumour cells are illustrated in blue, mitotic 
tumour cells in black, neurons in green and blood vessels in red. Adapted from (34).  
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1.3.2 Treatment  
The gold standard of treatment for GBM is maximal surgical resection of the 
tumour followed by radiotherapy and chemotherapy with temozolomide (16, 
35). However, the survival of patients has shown little improvement in the 
past thirty years and treatment remains palliative. The main obstacles to 
curative treatment are the invasion of GBM cells into neighbouring tissue 
(Fig 1.2C), which makes total surgical resection impossible, and their 
resistance to treatment with chemotherapy and radiotherapy (15, 36-39). 
Even when gross total surgical resection has been achieved (determined by 
the removal of enhancing regions on MRI), 85% of tumours recur within the 
resection cavity margin in macroscopically normal tissue; despite treatment 
with radiotherapy and chemotherapy. The other 15% of tumours recur at 
more distal sites (38). Treatment with temozolomide is only of benefit to 
patients with epigenetic silencing of the O6-methylguanine-DNA 
methyltransferase (MGMT) gene by promoter methylation (35, 40). MGMT is 
a DNA-repair protein that repairs the temozolomide-induced alkylation of 
the O6 position of guanine by transferring the alkyl group to a cysteine 
acceptor residue within its own sequence (41). Around half of GBM patients 
have tumours with MGMT methylation (35).  
While molecularly targeted therapies have been successful in improving the 
outlook for many types of cancer, to date this approach has proved 
unsuccessful in GBM (42, 43). The difficulty of getting therapeutic 
compounds across the blood-brain barrier (BBB) presents a significant 
challenge (Fig 1.3) (44). One approach that has been trialled to improve local 
drug delivery is the implantation of biodegradable wafers containing 1, 3-bis 
(2-chloroethyl)-1-nitrosourea (BCNU), also known as carmustine. BCNU 
wafers are associated with a modest increase in survival; however, their use 
is controversial and reports of high complication rates have led some 
clinicians to conclude that they should not be used in the treatment of GBM 
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because the risks outweigh the benefits (45-47). While some investigations 
have reported a lower incidence of adverse events, the controversy 
surrounding the use of BCNU wafers means that they have not been widely 
adopted as a treatment for GBM (48).  
 
 
 
 
 
 
 
 
 
Figure 1.3. The blood-brain barrier (BBB). Image shows a cross-section of an arteriole in the 
cerebral cortex from a modified merged confocal image obtained from (49). Neurons are 
depicted in green and astrocytes in red. The arteriole consists of endothelial, smooth muscle 
and leptomeningeal cells. Brain endothelial cells have reduced caveolae and are connected 
by tight junctions. The tight junctions act as a physical barrier, forcing most molecules to 
move transcellularly. Small gaseous and lipophilic molecules can freely diffuse through the 
cell membrane while the traffic of small hydrophilic molecules is either permitted or 
excluded by membrane transport systems. However, large hydrophilic molecules are 
generally excluded from the brain. Astrocyte endfeet encompass >99% of the vascular 
surface (12, 49, 50).  
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1.4 Regulation of proliferation 
Cellular proliferation is the result of an ordered set of events termed the cell 
cycle, which is tightly regulated in normal cells. The cell cycle is composed of 
four sequential phases: G1, S, G2 and M phase (Fig 1.3). During G1 phase, cells 
are sensitive to extracellular signals and, ordinarily, will only progress to S 
phase if stimulated to do so by mitogenic growth factors (51).  However, one 
of the hallmarks of cancer is that cells are able to proliferate in the absence of 
growth factors (6, 52). Once the cell passes a restriction point in late G1, cell 
cycle progression is no longer dependent on growth factors but is controlled 
by cyclin-dependent kinases (CDKs) that phosphorylate and inactivate cell 
cycle genes (51). CDKs only become active when they have formed a 
complex with cyclin proteins, the levels of which oscillate throughout the cell 
cycle. The activity of CDKs is regulated by cyclin-dependent kinase 
inhibitors (CDKIs) such as p16, p21 and p27,  which inhibit the cyclin-CDK 
complexes and cause cell cycle arrest (53).  
Genetic mutations that interfere with cell cycle regulation occur frequently in 
cancer, resulting in one of its defining features: uncontrolled cell 
proliferation. As previously mentioned, one of the most common genetic 
mutations in GBM is the deletion of p16INK4a, which encodes p16. TP53 is 
one of the most commonly mutated genes in all cancers, including GBM (54). 
TP53 encodes the tumour suppressor protein p53, an important regulator of 
the cell cycle, which is activated in response to cell stress or DNA damage. 
P53 prevents the accumulation of DNA damage during cell division either by 
activating the expression of p21, which causes cell cycle arrest, or by 
initiating apoptosis. The level of p53 expression dictates whether cell cycle 
arrest or apoptosis is initiated (55, 56). Therefore, mutations in TP53 
contribute to two of the hallmarks of cancer: insensitivity to growth 
suppressors and the evasion of apoptosis. 
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Figure 1.4. The cell cycle. G1 phase is a period of growth in preparation for S phase, in 
which DNA replication occurs. G2 phase is a further period of growth. The cell cycle 
culminates in M phase, in which mitosis occurs. 
 
1.5 Tumour microenvironment 
The tumour microenvironment can be defined as the molecules and 
parenchymal or stromal cells that surround tumour cells in vivo. Tumours are 
characterised by an environment depleted of oxygen and nutrients, with 
high extracellular levels of lactate and acidosis (57). The tumour 
microenvironment  contributes to the acquisition of many of the hallmarks of 
cancer and is recognised as a critical factor throughout tumourigenesis (7). 
Therapies targeting the tumour microenvironment are considered to be a 
promising alternative to the traditional approach of targeting tumour cells 
directly (58). The complex interactions between tumour cells and different 
components of the microenvironment have led to the concept of the tumour 
as an organ  (59). In the brain, the parenchyma is comprised of neurons and 
glia, while the stromal compartment is made up of the cells that form blood 
vessels and the meninges. Many of these cells develop abnormal 
characteristics as a result of their proximity to tumour cells.  
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1.5.1 Interactions with parenchymal cells   
Under normal conditions in the adult CNS, mature astrocytes do not 
proliferate; however, astrocytes undergo a number of changes in response to 
injury or disease, termed reactive astrogliosis. The expression of the 
intermediate filament protein glial fibrillary acid protein (GFAP) is increased 
and astrocytes can become hypertrophic and proliferate. In more severe 
cases, this can result in the formation of a glial scar (13). Reactive astrocytes 
are present around the periphery of gliomas and can be difficult to 
distinguish from tumour cells, which also express GFAP (60). Astrocytes are 
known to secrete neurotrophic factors such as TGF-α, SDF1 and GDNF, 
which can promote glioma proliferation (61). The unique biology of gliomas 
means that, unlike epithelial cancers, gliomas are surrounded by ‘normal’ 
cells derived from the same lineage as tumour cells. Therefore, the secretion 
of factors that promote glioma growth may have similar effects on glial cells 
(62). Tumour-associated astrocytes develop changes in gene expression, a 
subset of which are associated with a poorer prognosis in the proneural 
subtype of GBM (63). Furthermore, gliomas are able to recruit glial 
progenitor cells that become transformed and develop a similar gene 
expression pattern to glioma cells. These cells take on many of the properties 
of tumour cells and can become the predominant cell type in gliomas (62). 
GBMs also attract NPCs, which migrate from the SVZ to surround both the 
main tumour mass and individual cells that are infiltrating the parenchyma. 
In contrast to astrocytes and progenitor cells, NPCs exert anti-tumour 
activity and are associated with a survival advantage in animal models (64, 
65). The number of NPCs peaks 14 days after tumour cell implantation and 
then begins to decline, possibly due to glioma-induced differentiation. The 
peritumoural accumulation of NPCs is most profound in the young brain 
and declines with age, in line with the decline in NPC population, which 
may provide an explanation for the increased incidence of GBM in older 
adults.  
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Only a few studies have investigated interactions between neurons and 
glioma cells. Excitatory neuronal activity has been shown to support glioma 
growth through the secretion of growth factors and mitogens such as 
neuroligin-3. Mitogenic signalling by neurons provides a potential 
explanation for perineuronal satellitosis - the clustering of invading GBM 
cells around neuronal cell bodies. The expression of NLGN3, the gene 
encoding neuroligin-3, is associated with a shorter survival time in patients 
with GBM, suggesting that interactions between neurons and tumour cells  
can play an important role in tumour progression (66). Glutamate is the main 
excitatory neurotransmitter in the CNS and extracellular levels are normally 
tightly regulated to ensure proper synaptic function and prevent toxicity to 
neurons. While normal astrocytes take up excess glutamate from the 
extracellular space, this activity is reversed in glioma cells, which release 
high concentrations of glutamate. This causes the excitotoxic death of 
surrounding neurons and provides a growth advantage to gliomas (67, 68). 
Unlike other soft tissue tumours, which have unlimited physical growth 
capacity, brain tumour growth is limited by the skull. While brain tissue can 
be displaced, it cannot be compressed and its macroscopic structure is 
typically unaltered despite tumour expansion and widespread tissue 
invasion. The excessive release of glutamate allows glioma cells to create the 
necessary room to expand by destroying existing tissue, and is thought to be 
the cause of epileptic seizures in patients with GBM (69).  
 
1.5.2 Tumour vasculature and oxygenation 
As the diffusion limit of oxygen in tissue is only around 150 µm, tumours 
need to need to develop new blood vessels in order to expand  (70, 71). 
GBMs are among the most highly vascularised solid tumours and 
microvascular proliferation is a defining feature of GBM (20, 72). However, 
these blood vessels are typically enlarged, thickened, tortuous and deformed, 
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with evidence of degeneration and frequent thrombosis (60, 73). They are 
also hyperpermeable, leading to oedema and increased interstitial fluid 
pressure. This causes an increase in intracranial pressure that necessitates the 
routine use of corticosteroids for symptomatic relief in patients with GBM 
(74-76). Intuitively, vessel hyperpermeability seems advantageous for drug 
delivery, which is especially difficult in the brain due to the BBB. However, 
the resulting increased interstitial pressure interferes with vascular pressure 
gradients and blood flow and is detrimental to drug delivery (77, 78). 
Gliomas are initially able to expand by co-opting existing vessels; however, 
vessel regression and further tumour expansion result in cell death and the 
induction of angiogenesis (79). The abnormal structure and function of these 
new blood vessels result in inadequate perfusion and an insufficient supply 
of oxygen (hypoxia) (80).  
Hypoxia contributes to the acquisition of many of the hallmarks of cancer 
and is associated with poor patient prognosis in the majority of solid 
tumours (81, 82). In gliomas, hypoxia is associated with higher grade 
tumours and decreased patient survival time (83, 84). Hypoxia contributes to 
treatment resistance in tumours by reducing the effects of radiotherapy, 
which requires molecular oxygen to be fully effective, and by increasing the 
expression of drug efflux transporters (85, 86). The cellular response to 
hypoxia is orchestrated by the transcription factor hypoxia-inducible factor 
(HIF), which increases the expression of genes that promote cell survival in 
low oxygen conditions. Many of HIF’s target genes are known to contribute 
to tumour progression by enhancing pro-tumour processes such as 
angiogenesis, glycolysis, cell survival, invasion and metastasis (87). 
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1.5.2.1 Therapeutic targeting of angiogenesis  
Vascular endothelial growth factor (VEGF) is the principle mediator of 
hypoxia-induced angiogenesis. Pre-clinical studies have shown that anti-
VEGF treatment can normalise tumour vasculature, reduce interstitial fluid 
pressure and improve oxygen supply, allowing for increased drug delivery 
and an enhanced response to radiotherapy (88-91). It was hoped that 
treatment with bevacizumab, a humanised monoclonal antibody against the 
VEGF-A ligand, would improve the prognosis for patients with GBM. The 
results of phase III clinical trials showed that the addition of bevacizumab to 
standard treatment significantly improved progression-free survival and 
reduced the need for treatment with corticosteroids. However, there was no 
improvement in overall survival and, over time, treatment with bevacizumab 
was associated with neurocognitive decline, worsening symptoms and a 
reduction in quality of life (92, 93). These results indicate that treatment with 
bevacizumab has only transient benefits and may even be harmful in the 
longer term. The recurrence pattern of GBM in patients treated with 
bevacizumab suggests an increase in infiltrative growth (94, 95). Anti-VEGF 
treatment has been shown to induce hypoxia and increase the expression of 
multiple factors that act to promote both angiogenesis and invasion (96). 
Anti-angiogenesis therapy can also increase alternative methods of 
neovascularisation, such as vascular co-option and the development of new 
blood vessels from circulating bone marrow-derived cells (97). The 
disappointing failure of bevacizumab highlights the complexity of the 
tumour microenvironment and the ability of tumour cells to adapt to 
changes in this environment.  
1.5.2.2 Normal and pathological oxygen levels in the brain 
In vitro, cells are typically cultured in 20% O2, which is representative of the 
level of oxygen in the atmosphere. However, the oxygenation of biological 
tissues varies throughout the body in a tissue-specific manner, ranging from 
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around 1% O2 in the skin to 8% O2 in the intestines. The normal level of 
oxygen in the human brain is 5–6% O2 (98-100). In brain tumours, there is 
considerable variability in the level of oxygen both within and between 
tumours due to micro-regional heterogeneity in the supply of oxygen  (98). 
This variability can make it challenging to draw conclusions about brain 
tumour oxygenation; however, at least two studies have reported 
significantly lower oxygen levels in brain tumours compared to the 
surrounding tissue (101, 102). The results of a number of studies that have 
investigated the oxygen levels in gliomas using oxygen sensitive probes are 
summarised in Table 1.1. The reported mean oxygen values in these studies 
range from 0.97–4.35%, with an overall mean of 1.43% O2. These results 
support the conclusion that the oxygen levels in GBM are lower than in 
normal brain tissue.  
Table 1.1 ǀ Mean values for intra-tumoural oxygen levels in patients with gliomas. The 
partial pressure (mmHg) of O2 is reported alongside the equivalent O2 percentage. GA = 
General Anaesthetic. 
Author N O2 mmHg O2 % GA Glioma type 
Beppu et al. (102) 16 9.2 ± 5.8 1.21 N High grade 
Whittle et al. (103) 12 21 ± 7.9 2.76 N GBM 
Collingridge et al. (104) 10 
7 
3 
3 
5.6 ± 2 
10.3 ± 4.9 
11.1 ± 9.6 
33.1 ± 4.6 
0.74 
1.35 
1.46 
4.35 
Y 
Y 
N 
N 
High grade 
Low grade 
High grade 
Low grade 
Rampling et al. (105) 10 7.25 ± 8.12 0.97 Y GBM 
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1.5.2.3 Spatial and temporal aspects of hypoxia 
Within tumours, there is both spatial and temporal heterogeneity in 
oxygenation. The regular temporal variation in oxygen supply is referred to 
as cycling hypoxia. At least two timescales are known to co-exist: a short 
timescale, which has a frequency of several cycles per hour, and a longer 
timescale that operates over hours to days. The short timescale is due to 
fluctuations in microvessel red blood cell flux, while the longer timescale is 
thought to be caused by vascular remodelling (106-108). Several studies have 
reported that cycling hypoxia is more potent than chronic hypoxia, as 
evidenced by increased HIF-1α stabilisation, cellular invasion and resistance 
to radiotherapy (109, 110). Cycling hypoxia contributes to tumour 
malignancy by increasing the expression of HIF target genes such ABCB1, 
which encodes p-glycoprotein: a well-known drug efflux transporter that 
increases resistance to chemotherapy (111). Tumours are also characterised 
by spatial heterogeneity in oxygen levels.  Pistollato et al. used image-guided 
surgery to characterise the distribution of hypoxia in GBM and found 
evidence for an intratumoural hypoxic gradient, consisting of a peripheral 
oxygenated layer, an intermediate mildly hypoxic layer and a highly hypoxic 
core. They found that cell phenotype correlated with the level of hypoxia, 
with more immature cells concentrated in the highly hypoxic core. Cells 
derived from the core and intermediate layers of tumours also showed 
increased protein expression of MGMT and resistance to 
temozolomide (112).  
1.5.2.4 Regulation of HIF activity 
HIF is a heterodimer consisting of α and β subunits. The α subunit exists as 
several different isoforms: HIF-1α, HIF-2α  and HIF-3α  (113-115). HIF-1α is 
ubiquitously expressed and HIF-1α protein levels are upregulated in the 
majority of tumours (116). The expression of HIF-2α and HIF-3α is more 
restricted and their role in tumour hypoxia has not been extensively 
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investigated. While HIF-β is constitutively expressed, HIF-α is constantly 
degraded under normal oxygen conditions (normoxia) (117). This oxygen-
dependent degradation is regulated by the prolyl-hydroxylase domain 
(PHD) proteins (PHD1, PHD2 and PHD3) which hydroxylate HIF-α. 
Hydroxylation leads to the recognition of HIF-α by the von Hippel-Lindau 
tumour suppressor protein (VHL), which ubiquitinates HIF-α’s oxygen-
dependent degradation domain and tags it for proteasomal degradation 
(Fig 1.5) (118-121). Under hypoxic conditions, as the PHD proteins lack the 
oxygen required to hydroxylate HIF-α,  itis not recognised by VHL and 
escapes degradation (122). This allows HIF-α and HIF-β to heterodimerise in 
the nucleus where HIF-α is predominantly located (117, 123, 124). Once 
dimerised, HIF binds to hypoxia response elements (HREs) and initiates the 
transactivation of its target genes (121). In addition to this oxygen-dependent 
degradation, HIF is also subject to oxygen-independent regulation by growth 
factors, metabolites, reactive oxygen species and transition metals (125, 126).  
 
1.6 Tumour metabolism 
1.6.1 Cellular  respiration 
It has been known that tumours display altered cellular metabolism since the 
first half of the 20th century; however, a detailed understanding of this 
phenomenon has only emerged over the last decade (127). In normal aerobic 
tissue, cellular respiration consists of three stages that result in the 
production of adenosine triphosphate (ATP) from glucose (Fig 1.6). The first 
stage, glycolysis, occurs in the cytosol. During this stage, one molecule of 
glucose is converted into two molecules of pyruvate, with a net gain of two 
molecules of ATP. Pyruvate enters the mitochondria where it is converted 
into CO2 and acetyl-CoA, which enters the citric acid cycle (CAC). In this 
second stage, the carbons in acetyl-CoA are oxidised to CO2, reducing NAD+ 
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Figure 1.5. The oxygen-dependent regulation of HIF-1α. Under normal oxygen conditions, 
HIF-1α is hydroxylated by the PHD proteins, leading to its recognition and ubiquitination by 
VHL and subsequent degradation by the proteasome. In low oxygen conditions, HIF-1α is 
able to accumulate in the nucleus and dimerise with HIF-β. The dimerised protein binds to 
hypoxia response elements (HREs) where it initiates transactivation of its target genes. 
to NADH and FAD to FADH2. The final stage of respiration is oxidative 
phosphorylation (OxPhos), in which electrons are transferred from NADH 
and FADH2, along the electron transport chain (ETC) in the inner 
mitochondrial membrane, to O2. The ETC creates a proton gradient which is 
used to drive the production of ATP by ATP synthase (128). These three 
stages of cellular respiration result in the net total gain of 38 molecules of 
ATP per molecule of glucose (129).  
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1.6.2 The Warburg effect 
As the final electron donor in the ETC is O2, in conditions where O2 is limited 
OxPhos is not possible and cellular metabolism halts at glycolysis. In this 
scenario, pyruvate stays in the cytosol where it is converted to lactate by 
lactate dehydrogenase, regenerating NAD+ in the process and allowing 
further cycles of glycolysis (128). Many tumours show a preference for 
glycolytic metabolism under aerobic conditions (aerobic glycolysis). This 
phenomenon is termed the Warburg effect, after Otto Warburg who was the 
first to document it (130, 131). The Warburg effect is exploited clinically by 
the use of positron-emission tomography (PET) to detect tumours, which 
show increased uptake of the radiolabelled glucose analogue 2-[18F]fluoro-2-
deoxy-D-glucose (132). Tumour metabolism is an attractive therapeutic 
target and there are several glycolysis inhibitors under various stages of 
development (133). Otto Warburg’s central hypothesis (the Warburg 
hypothesis) was that injured respiration, followed by an increase in 
glycolysis, is the cause of all cancers (130). However, subsequent research has 
challenged this theory. Cell lines derived from a number of tumours have 
been shown to predominantly utilise OxPhos as a source of energy (134, 135). 
Furthermore, the metabolism of tumour cells is highly dependent on the 
availability of energy substrates. When glucose is not available, HeLa 
cervical cancer cells remodel their mitochondrial structure and protein 
composition to derive energy exclusively from OxPhos (136). Similarly, 
breast cancer cells increase OxPhos in response to glucose deprivation and 
decrease OxPhos in response to hypoxia. However, when hypoxia occurs 
concomitantly with aglycemia, OxPhos is not decreased as, under these 
conditions, ATP can only be produced by the mitochondria (137). It is clear 
that cancer cells can coordinate nutrient and oxygen sensing and adapt their 
metabolism accordingly. Therefore, cellular metabolism is sensitive to cell 
culture conditions. The high level of glucose routinely used in cell culture 
inhibits respiration and OxPhos in cancer cells (the Crabtree effect). Static 
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monolayer culture has also been shown to increase glycolysis, compared to 
rotary cell culture, due to decreased O2 diffusion (138). In glioma cells, the in 
vitro growth environment has been shown to cause a shift towards 
glycolysis, creating lipid and ETC abnormalities (137, 139, 140).   
 
Figure 1.6. Regulation of cellular metabolism. Key enzymes involved in glycolysis, the 
citric acid cycle, lipid, protein and nucleotide synthesis are illustrated. Growth factor 
signalling can activate phosphoinositide 3-kinase (PI3K) signalling, increasing glycolysis 
through hexokinase 2 (HK2) and phosphofructokinase activity. Mutations in isocitrate 
dehydrogenase 1 (IDH1) prevent the enzyme from catalysing the production of α-
ketoglutarate from isocitrate, resulting in the production of (R)2-hydroxy-glutarate instead, 
reducing cytosolic NADPH production. Adapted from (141).  
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1.6.3 The role of hypoxia in cellular metabolism 
Hypoxia is a potent inducer of glycolysis that also causes the active 
downregulation of OxPhos, reducing oxygen demand and ensuring the 
continued supply of ATP. HIF-1α plays an essential role in the regulation of 
cellular metabolism under hypoxic conditions. HIF target genes are found at 
almost every step of glycolysis; from the entry of glucose into the cell via 
GLUT1 and GLUT3, through to the removal of lactate from the cell by the 
monocarboxylate transporter MCT4 (142). In partnership with Christophe 
Sandt’s group at the synchrotron SOLEIL, our group carried out an 
investigation into hypoxia-induced metabolic changes in GBM cell lines and 
primary cells using fourier transform infrared (FTIR) microspectroscopy. 
Although there was metabolic variability between cell lines, all cells showed 
an increase in lipids when incubated in hypoxia, and U87 cells showed an 
increase in glycogen. These changes were harder to detect when cells had 
been exposed to long-term hypoxia, suggesting that they had begun to adapt 
to the changes in their environment (143).  Hypoxia has also been shown to 
cause an increase in the storage of lipids in lipid droplets (144).  
 
1.6.4 Normal metabolism in the brain 
The human brain is an energetically costly organ, comprising just 2% of body 
weight but consuming 20% of the energy supply (145). The adult brain 
predominantly utilises glucose for OxPhos; however, around 10-12% is used 
for aerobic glycolysis and there are significant regional variations in 
metabolism. Compared with the rest of the brain, aerobic glycolysis is 
significantly elevated in the medial and lateral parietal and prefrontal 
cortices (146). Aerobic glycolysis plays an important role in normal brain 
function; it is increased during brain activation and is associated with 
synaptic plasticity (147, 148). While most tissues are able to derive energy 
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from different substrates depending on their availability, the brain derives its 
energy almost exclusively from glucose, on which it is reliant to maintain 
normal function. As the entry of neuroactive compounds, such as glutamate 
and aspartate, is restricted by the BBB, the brain is forced to synthesise these 
compounds from glucose (149).   
 
1.6.5 Metabolic alterations in GBM 
The metabolomic profile of GBM is characterised by accelerated anabolic 
metabolism, reflecting the need for the increased production of nucleotides, 
proteins and lipids in rapidly dividing cells (150, 151). In vitro, the 
metabolism of glioma cells has been found to be cell line dependent, with 
some cell lines displaying an OxPhos-dependent phenotype while others 
display a glycolytic-dependent phenotype with functional OxPhos. The 
OxPhos-dependent cell lines are extremely resistant to glucose starvation, 
suggesting that OxPhos dependency may have developed as a result of the 
need to cope with nutrient deficiency (152). A microdialysis study carried out 
in patients with GBM found a significantly higher lactate:pyruvate ratio in 
tumour tissue than peritumoural tissue, suggesting that aerobic glycolysis is 
increased in gliomas (153). In vivo studies in mice and humans using 13C-
labelled glucose have revealed that GBMs are metabolically complex, 
utilising glucose for the CAC, aerobic glycolysis and the synthesis of 
macromolecular precursors (154, 155). The oxidation of blood-borne glucose 
was found to contribute to less than 50% of the total acetyl-CoA, indicating 
that gliomas are able to oxidise alternative substrates. Stored lipid supplies 
are one possible alternative; altered lipid metabolism is a feature of many 
tumours including gliomas, which display increased lipid levels and fatty 
acid synthesis (156).  
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Metabolic remodelling in tumours can occur as a result of changes in the 
microenvironment, such as hypoxia, or because of the deregulated signalling 
that occurs during malignant transformation (Fig 1.5) (141). Hexokinase 
(HK), the enzyme that catalyses the first step of glycolysis, exists as four 
different isoforms (HK1, HK2, HK3, HK4). While HK1 is ubiquitously 
expressed, the expression of HK2 is more restricted. HK2 is aberrantly 
expressed in many tumours (157). In GBM, its expression is associated with 
decreased OxPhos and increased lactate production, increased cellular 
proliferation, and a reduction in patient survival time. HK2 activity is 
regulated by growth-factor induced phosphoinositide 3-kinase (PI3K) 
signalling (158). PI3K is negatively regulated by phosphatase and tensin 
homolog (PTEN); however, the PTEN gene is frequently deleted in GBM, 
resulting in overactive PI3K signalling. The induced expression of PTEN in 
PTEN-null cells is associated with increased aerobic glycolysis (159). 
Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1), the 
enzyme that catalyses the oxidative decarboxylation of isocitrate to produce 
α-ketoglutarate (α-KG), occur in the majority of secondary GBMs but  in only 
7% of primary GBMs (160). IDH1 mutations occur early in tumorigenesis and 
are a favourable prognosis factor, associated with a doubling in survival time 
(161, 162). Mutations in the IDH1 gene (IDH1mt) cause the enzyme to lose the 
ability to catalyse the production of α-KG from isocitrate, and gain the ability 
to reduce α-KG to the suspected oncometabolite (R)2-hydroxyglutarate [(R)-
2HG] (Fig 1.6) (163). (R)-2HG has been found to potentiate PHD activity, 
promoting HIF-1α degradation (164). HIF1-α target genes, including many 
essential for glycolysis such as LDHA, are downregulated in IDH1mt gliomas. 
These findings suggest that a reduced glycolytic capacity may contribute to 
slower tumour growth and a better prognosis in IDH1mt tumours. However, 
the inhibition of IDH1mt  impairs the growth of IDH1mt glioma cells and 
increases the expression of glial differentiation markers (165). Although this 
area of research has generated a great deal of interest, the consequences of 
IDH1 mutation for tumorigenicity are still poorly understood (166). 
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1.7 Cellular invasion 
1.7.1 Patterns of invasion  
The diffusely infiltrative nature of GBM is a major reason for treatment 
failure. It follows that cellular invasion is of crucial importance in GBM 
despite the fact that, in contrast to other malignant tumours, the occurrence 
of metastasis is extremely rare. In a review of the literature, Kalokhe et al. 
identified only 79 case reports of GBM metastasis in the last 50 years. To put 
this into perspective, between 10,000 and 12,000 cases of GBM occur each 
year in the United States alone (167). Unlike solid tumours in other areas of 
the body, or tumours that have metastasised to the brain, GBM is not reliant 
on intravascular or lymphatic spread. Rather, GBM shows a unique pattern 
of invasion, with single cells invading throughout the extracellular space (15, 
168). The margins of GBM are poorly delineated and invading cells are 
capable of migrating long distances. Early attempts to cure patients by the 
complete removal of the affected brain hemisphere were unsuccessful due to 
tumour recurrence in the remaining hemisphere (169). Hans-Joachim 
Scherer’s careful histological examination of gliomas in 1938 has contributed 
much to our knowledge of the invasive behaviour of these tumours (170).  
Scherer coined the phrase ‘secondary structures’ to refer to the structures 
formed by glioma cells as they invaded the pre-existing tissue architecture. 
These include perineural and perivascular growth as well as growth in and 
around white matter tracts (Fig 1.2C). The migration of glioma cells along 
existing structures closely mimics neuronal migration during embryonic 
development, in which immature neurons travel along radial glia and 
neuronal axons, and adult neurogenesis, in which neuroblasts migrate along 
the vasculature to reach their final destination (171). In vivo imaging studies 
and studies using slice cultures generated from rat brains have shown that 
GBM cells preferentially invade along blood vessels, along which they move 
faster and more efficiently (172, 173). This causes astrocyte endfeet to be 
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displaced from the vasculature and disrupts the BBB. Astrocyte-vascular 
coupling is lost, allowing GBM cells to seize control of vascular tone (174). 
Single invading GBM cells can also induce vascular remodelling and 
angiogenesis (173). The preference of GBM cells for perivascular migration is 
thought to be explained in part by the release of  bradykinin by endothelial 
cells, which acts as a chemoattractant and enhances invasion by increasing 
matrix metalloproteinase (MMP) activity (175).  
 
1.7.2 Metastatic dissemination 
One possible explanation for the extremely low incidence of metastasis in 
GBM is that the cells are unable to invade into blood vessels (intravasation) 
and enter the circulatory system. In studies using animal models, GBM cells 
have been seen to invade along the surface of blood vessels; however, 
invasion into the vessels has not been observed (172, 176, 177). It has been 
suggested that GBM cells may be unable to breach the BBB; however, this is 
frequently disrupted in GBM due to the abnormal nature of the vasculature 
(178). While tissue disruption during surgery may well be responsible for 
cells seeding into the circulation in a proportion of cases, extracranial 
metastases are also documented in patients who have not undergone any 
surgical intervention (179). Other explanations for why GBM typically does 
not metastasise include the short survival of patients, which means 
metastases may not have time to develop or may not be detected, and the 
absence of a lymphatic system in the brain (167, 180). However, in 2015 two 
labs independently reported the discovery of a lymphatic vessel network in 
the dura of the meninges, overturning the long-held belief that the brain does 
not have a lymphatic system (181, 182).  
The most common sites for metastasis to occur outside the CNS are bone, 
lymph nodes and the lung (167). Due to the rarity of metastasis in GBM, 
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patients are able to become organ donors after their death. However, there 
are 11 reports of recipients developing GBM metastasis in donated organs 
following transplantation (183). This suggests that the historical view of GBM 
being confined to the CNS is untrue. Muller et al. recently investigated the 
existence of circulating tumour cells (CTCs) in the peripheral blood of 
patients with GBM. They found that CTCs were present in 21% of patients 
and that there was no relationship between surgery and detection of CTCs 
(184). The discrepancy between the proportion of patients with CTCs and the 
proportion that develop metastasis suggests that GBM cells are able to enter 
the circulation, but find their new extraneural environment to be 
unfavourable to growth. It is possible that tumour cells lodge in distant 
organs in a dormant state until immunosuppression, caused by radiotherapy 
and chemotherapy or, in organ donor recipients, immunosuppressive drugs, 
renders the environment more favourable and allows cells to proliferate (180, 
184).  
 
1.7.3 Molecular mechanisms of invasion 
In order to invade away from the tumour mass, cells need to move through 
the extracellular matrix (ECM): the secreted molecules of the extracellular 
space. The ECM of the adult human brain is mainly composed of 
proteoglycans, hyaluronic acid and tenascin. It is densely packed, with pore 
sizes of just 38-64 nm. The matrix proteins that are common in other tissues, 
such as collagen, fibronectin, and laminin, are almost absent in brain 
parenchymal ECM; however, they are present in the vascular and subpial 
basement membranes (185-187). Integrins are transmembrane receptors that 
link the interior of the cell to the ECM. They provide a mechanical link, 
through the actin cytoskeleton, and a sensory link, through signal 
transduction pathways. Integrins are key regulators of numerous cellular 
processes including adhesion, migration, proliferation and survival (188). 
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Integrin αVβ3 is mainly expressed on angiogenic endothelial cells and 
promotes tumour angiogenesis alongside αVβ5 (189).  However, in gliomas, 
αVβ3 is also expressed in tumour cells and its expression correlates with 
tumour grade, with increased expression in GBM compared to low-grade 
gliomas (190). Inhibition of αVβ3 has been shown to reduce glioma migration 
and invasion, suggesting that it may play an important role in contributing to 
the invasive phenotype of GBM (191, 192).  
The activity of proteinases, which degrade the ECM and create space for 
tumour cells to migrate, is essential for invasion. The MMPs are a large 
family of proteinases that, collectively, are capable of degrading a broad 
range of substrates including all ECM components. They are overexpressed 
in almost all human tumours and their activity is correlated with increased 
tumour aggressiveness and a poorer prognosis (193). MMP-2, MMP-9 and 
MMP-14 are overexpressed in GBM compared to lower grade gliomas and 
normal brain tissue (194). As well as promoting migration and invasion, 
MMPs have also been shown to regulate proliferation, survival and 
angiogenesis (193). The tumour microenvironment is an important regulator 
of glioma invasion and MMP expression. Multiple studies have 
demonstrated that hypoxia increases glioma invasion and that this effect is 
mediated by HIF-1α (195-197). HIF-1α increases the expression of numerous 
factors that facilitate invasion, such as MMP-2, MMP-9, integrin αVβ3 and 
αVβ5 (196, 198, 199). Cell-cell interactions are also important in regulating 
invasion: astrocytes produce active MMP-2 when cultured with glioma cells 
and the inhibition of gap junctions in astrocyte-glioma co-cultures has been 
shown to prevent glioma migration (200-202). Although MMP inhibitors 
reduce glioma invasiveness in vitro, they have performed poorly in clinical 
trials (203, 204). 
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1.8 Three-dimensional cell culture  
The majority of in vitro cancer research has been conducted using cells 
cultured as two-dimensional monolayers on plastic or glass surfaces. 
However, these conditions fail to replicate important aspects of the cellular 
environment that occur in vivo, such as cell-cell and cell-matrix interactions, 
matrix stiffness and gradients in soluble factors such as oxygen, nutrients, 
growth factors and cytokines (205). Three-dimensional (3D) cell culture 
systems have been established in an attempt to more faithfully reproduce 
characteristics of the tumour environment. Broadly, these culture systems fall 
into two categories: those that rely on exogenous support from a matrix or 
scaffold, and those that are independent of exogenous support.  Cells can be 
grown in hydrogels derived from components of the ECM, such as collagen, 
or in hydrogels made from agarose or synthetic polymers. A popular choice 
of matrix for mimicking the ECM is Matrigel: a reconstituted basement 
membrane extract from the Engelbreth-Holm-Swarm mouse sarcoma, 
composed of approximately 60% laminin, 30% collagen IV and 8% entactin 
plus numerous growth factors. A number of commercial companies have 
developed pre-fabricated hard scaffolds made from substances such as 
polystyrene. These provide structural support for cells but are engineered to 
be highly porous, allowing for cell-cell contact and migration throughout the 
scaffold (206).  
Important considerations when choosing a 3D cell culture method include 
how well it represents the in vivo environment, how practical and 
reproducible the method is, and how well it has already been characterised. 
The choice of matrix has been shown to strongly influence cell behaviour and 
response to drugs, with cells cultured in synthetic scaffolds more closely 
resembling monolayer cultures than cells cultured in biologically-derived 
matrixes (207). When embedding cells in hydrogels, it is important to 
mitigate the effects of growth inhibition by solid stress. Solid stress can occur 
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in gels containing just 0.3% agarose, and markedly increases when higher 
concentrations of agarose are used (70). A further challenge of growing cells 
in scaffolds of matrixes is that the cells can be difficult to retrieve for 
biochemical analyses.  
 
1.8.1 The multicellular tumour spheroid model 
The multicellular tumour spheroid model is a well-characterised model in 
which cells are grown as a 3D cluster in the absence of any exogenous 
support. The model was developed in the 1970s by Sutherland to mimic 
nodular carcinomas and avascular regions of tumours (Fig 1.7) (208, 209). 
Spheroids show a spatial gradient in oxygen availability, which mimics the 
intratumoural hypoxic gradient reported in GBM, as well as gradients in 
nutrients and pH (210-214). These gradients can cause a metabolic switch, 
resulting in enhanced glycolytic metabolism in spheroids compared to 
monolayer cultures (215). Spheroids also show a characteristic concentric 
pattern of cell proliferation and viability. Typically, spheroids consist of a 
necrotic core, an intermediate layer of quiescent cells, and an outer layer of 
proliferating cells concentrated around the periphery of the spheroid (214, 
216, 217). Gradients in soluble factors begin to occur in spheroids when they 
reach around 200 µm, and central necrosis at 500 µm; however, the size at 
which necrosis develops is cell line dependent. Changes in metabolism have 
also been observed in small spheres, before the onset of nutrient or oxygen 
gradients. Santini et al. compared osteosarcoma cells grown as a monolayer 
and as very small spheroids (50-80 μm) using high-resolution proton nuclear 
magnetic resonance spectroscopy. The cells cultured as spheroids displayed 
different metabolic characteristics, suggesting an effect of spatial 
arrangement on cellular metabolism (218).  
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Figure 1.7. The multicellular tumour spheroid model. Tumour spheroids share important 
characteristics with solid tumours, such as gradients in oxygen and nutrients. Like tumours, 
they contain a mixture of proliferating, quiescent and necrotic cells. Adapted from (209). 
The cellular and molecular heterogeneity of spheroids makes them a better 
model for solid tumours than homogeneous monolayer cultures. Spheroid 
culture preserves the  genomic profile of primary GBM cells, which is rapidly 
altered when the cells are subjected to standard cell culture conditions (219). 
The results of in vitro drug screening often only poorly correlate with the 
results of in vivo tests; for this reason, drug testing in spheroids is emerging 
as a necessary intermediate between testing in monolayer cultures and 
testing in animals (220). Drug diffusion in spheroids closely replicates 
diffusion in tumour tissue, furthermore, the hypoxic core of spheroids 
contains higher levels of p-glycoprotein, mimicking the hypoxic drug 
resistant areas found in solid tumours (221, 222). Typically, the effects of 
therapeutic drugs are reduced in the 3D environment; however, in some 
cases, their activity is increased (223-225). Spheroids can also be used to 
screen for drugs that target dormant tumour regions, which are resistant to 
treatment with cytostatic drugs. An investigation by Wenzel et al. revealed 
that respiratory chain inhibitors are most effective in the quiescent centre of 
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spheroids, while the proliferating outer region of spheroids is more sensitive 
to cytostatic drugs (226).  
The 3Rs of animal research refer to the principles of replacement, reduction 
and refinement (227). According to these principles, every effort should be 
made to develop experimental methods that replace the use of animals 
(replacement), minimise the number of animals used (reduction), and cause 
animals the minimum amount of distress (refinement). The use of 3D cell 
cultures, such as multicellular tumour spheroids, can help to fulfil the 
principles of replacement and reduction. The increased physiological 
relevance of these models over 2D cell cultures offers an alternative option to 
in vivo experiments. Furthermore, the use of spheroids in drug screening 
assays can lead to more effective selection of compounds, reducing the 
number of compounds that need to be tested in animals (220).    
 
1.9 Aims of the project 
The overall aim of this project was to investigate the effect of the solid 
tumour microenvironment on GBM cells. Firstly, we aimed to investigate the 
effect of different levels of oxygen on cell proliferation in cells cultured as a 
monolayer. Next, we aimed to explore the effects of hypoxia in a more 
physiologically relevant model of GBM. We wished to establish a 
multicellular tumour spheroid model, which we aimed to characterise in 
terms of cell proliferation, survival, oxygenation and energetic status. We 
further aimed to assess the effects of hypoxia on these characteristics. Finally, 
we aimed to carry out live cell imaging of spheroid invasion using lightsheet 
microscopy. We wished to quantify the movements of cells moving within 
spheroids, as well as the movements of cells invading into ECM. We also 
aimed to assess the suitability of this technique as a 3D invasion assay for 
characterising the effects of drugs that target the invasion process.  
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Chapter 2: 
Materials and Methods 
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2.1 Chemicals and reagents 
Unless otherwise stated, cell culture reagents were purchased from Gibco 
(USA), plasticware from Corning (USA), RNA extraction and qPCR reagents 
from Roche (Switzerland), and all other chemicals and reagents from Sigma-
Aldrich (USA). 
 
2.2 Cell culture  
2.2.1 Cell lines and propagation 
U251 cells were obtained from CLS (Germany, #300385), U87 cells from 
ATCC (UK, #HTB-14), HeLa cells from ECACC (UK, #93021013) and HEK 
293TN cells from System Biosciences (USA, #LV900A-1). D566 cells were a 
generous gift from Professor DD Bigner (Duke University Medical Centre, 
USA). The shPHD2 HeLa cells were a gift from D Hoogewijs, D Stiehl and R 
Wenger (University of Zürich, Switzerland) and the shPHD3 HeLa cells were 
a gift from Sarah Taylor (University of Liverpool, UK). Cells were 
maintained in culture medium as listed in Table 2.1. Cells were cultured in T-
75 flasks and subcultured every 2–3 days when they had reached 80-90% 
confluence. Cells were counted using a Bio-Rad (UK) TC20 automated cell 
counter and seeded at the required density. Cells were maintained in a 
humidified incubator at 37 °C, 5% CO2 (Sanyo, Japan).  
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Table 2.1 Cell lines and culture medium.  
Cell line Origin Culture medium 
U251, D566 GBM 10% v/v FBS, 1% v/v NaPyr & 
1% v/v NEAA in MEM 
U87  GBM  10% v/v FBS & 1% v/v NaPyr 
in MEM 
Primary GBM 
(GBM03, 
GBM04) 
GBM 20% v/v FBS, 1% v/v NaPyr, 
1% v/v NEAA & 1% pen-strep 
in MEM 
HeLa  Cervical carcinoma 10% v/v FBS & 1% v/v NEAA 
in MEM 
HeLa shPHD2 
& shPHD3 
HeLa cells stably knocked 
down for PHD2/PHD3 via 
small hairpin RNA 
(shRNA) 
10% v/v FBS, 1% v/v NEAA & 
10 μg/mL puromycin 
(Invitrogen, USA) in MEM 
HEK 293TN Human embryonic kidney  10% v/v FBS & 1% v/v NEAA 
in DMEM 
 
2.2.2 Tumour dissection and primary culture 
Samples of primary GBM tumours were received from patients undergoing 
craniotomy and resection. All patients gave informed written consent to 
donate their tissue to the Walton Research Tissue Bank, Walton Centre NHS 
Foundation Trust, which has full approval of the National Research Ethics 
Service (11/WNo03/2). Primary cell culture was carried out in accordance 
with the approved guidelines.  
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Tumour samples were transported in MEM plus 1% (v/v) penicillin-
streptomycin (pen-strep) and then mechanically dissected in a petri dish 
using a disposable scalpel (Swann-Morton, UK). The dissected samples were 
incubated in dissociation medium (10% (v/v) trypsin 10X, 1% (v/v) DNase 
and 1% (v/v) pen-strep in MEM) at 37 °C and triturated every 5 min (up to a 
maximum of 30 min) until a cell suspension was obtained. The trypsin 
reaction was stopped by the addition of growth medium (see Table 2.1 for 
details). Cells were centrifuged for 5 min at 3000 rpm; the supernatant was 
aspirated and the pellet resuspended in growth medium and seeded into a T-
75 flask. The resulting cell lines (designated GBM03 and GBM04) were 
maintained in culture for a maximum of three passages.  
2.2.3 Hypoxic incubation 
For experiments requiring hypoxia, cells were incubated in a Don Whitley 
Scientific (UK) H35 Hypoxystation (1% O2) or a New Brunswick Galaxy 48R 
hypoxic incubator (Eppendorf, Germany; 0.1% and 8% O2). Cells were 
maintained at 37 °C, 5% CO2 and the air humidified.  
2.2.4 Etoposide treatment 
Cells were treated with 10–20 μM etoposide for 24 h.  
2.2.5 Spheroid culture 
To generate multicellular tumour spheroids, 2.4 x 104 U87 cells were seeded 
in 1 mL of filtered growth media. Media was filtered through a 0.22 μm PES 
filter using a bottle-top vacuum filter system. The cell suspension was 
pipetted (50 μl per well) into a 96-well Perfecta3D Hanging Drop plate (3D 
Biomatrix, USA) where it formed a hanging droplet. After three days, the 
cells had compacted from a loose aggregate and formed a compact spheroid. 
Spheroids were transferred to a 35 mm non-treated culture dish using a 
P1000 pipette and media was exchanged every 2-3 days.  
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2.3 Flow cytometry  
Cells were seeded into 6 cm tissue culture dishes (1 x 105 cells per dish) and 
incubated in different levels of O2 for up to five days.  
2.3.1 Cell viability analyses 
Adherent cells were washed with phosphate-buffered saline (PBS), 
trypsinised and suspended in Hank’s balanced salt solution (HBSS) together 
with the floating fraction of cells. The cell suspension was pipetted into a 96-
well plate, stained with FITC Annexin V (Invitrogen, 1:500) and incubated 
for 15 min in the dark at room temperature (RT). Propidium iodide (PI) was 
added at a final concentration of 4 μg/mL immediately prior to analyses. 
Samples were analysed using a Guava EasyCyte Flow Cytometer and cell 
viability was established using GuavaSoft software (EMD Millipore, USA).  
2.3.2 Cell cycle analyses 
Cells were washed with PBS, trypsinised and resuspended in 0.1% (v/v) 
Triton X-100 in PBS. PI and ribonuclease A were added at a final 
concentration of 10 μg/mL. Cells were analysed by flow cytometry and the 
percentage of viable and apoptotic cells was established using GuavaSoft 
software. The proportion of cells in G0/G1, S and G2/M phases was 
established using Modfit software (Verity Software House, USA). 
 
2.4 Real-time reverse transcription PCR (qRT-PCR) 
RNA was extracted using a High Pure RNA Isolation Kit according to the 
manufacturer’s instructions. RNA was eluted in 30 μl elution buffer and 
quantified using a Nanodrop 1000 spectrophotometer (Thermo Scientific, 
USA). Reverse transcription of 1 μg mRNA to cDNA was carried out using a 
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SuperScript VILO cDNA synthesis kit (Invitrogen, USA). cDNA was diluted 
1:20 in DNase/RNase-free water and stored at -20 °C until required. 
Reactions were performed in triplicate using 10 μl LightCycler SYBR Green I 
Master, 6 μl DNase/RNase-free H2O, 2 μl cDNA and 0.5 μM of each primer. 
Primers are detailed in Table 2.2. qPCR was performed using a LightCycler 
480 and results were analysed using LightCycler 480 software (version 
1.5.0.39). For qPCR parameters, see Chapter 3. The values for target genes 
were normalised to cyclophilin A and expressed as fold change from the 
control values (20% O2).  
Table 2.2 Primers used for qPCR 
Primer name Forward sequence Reverse sequence 
Cyclophillin A gctttgggtccaggaatgg gttgtccacagtcagcaatggt 
p21  agctgccgaagtcagttcctt gttctgacatggcgcctcct 
p27 tccggctaactctgaggaca gaagaatcgtcggttgcagg 
E2F1  ccgccatccaggaaaaggtg gtgatgtcatagatgcgccg 
 
2.5 Western blotting 
2.5.1 Sample preparation 
Cells were seeded in 6 cm tissue culture dishes and subjected to various 
treatments. Seeding density was adjusted so that cells would be almost 
confluent at the time of harvesting. Cells were washed with PBS, placed on 
ice, and lysed using 150 μl RIPA buffer (50 mM Tris-HCl ph 7.5, EDTA 1 mM, 
EGTA 1 mM, Na3VO4 1 mM, 1% (v/v) Triton X-100, 50 mM sodium fluoride, 
5 mM sodium pyrophosphate, 19 mM sodium B-glycerophosphate and 
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0.1 mM phenylmethylsulfonyl fluoride) plus phosphatase inhibitor cocktail 
(1:1000). The cells were detached using a cell scraper and transferred into a 
1.5 mL Eppendorf tube. Samples were rotated at 4 °C for 45 min and 
centrifuged for 15 min at 14 000 x g, 4 °C. The supernatant was collected and 
protein content quantified using a Thermo Scientific Pierce BCA Protein 
Assay Kit.  
2.5.2 Protein separation and transfer 
Protein samples were mixed in a 4:1 ratio with 5x Laemmli buffer (final 
concentration: 60 mM Tris-Cl [pH 6.8], 2% (w/v) SDS, 10% (v/v) glycerol, 
5% (v/v) β-mercaptoethanol, 0.01% (w/v) bromophenol blue) and denatured 
by heating at 100 °C for 5 min. Proteins were resolved on 4% stacking gels 
(0.4 M Tris base [pH 6.8], 4% (v/v) acrylamide, 0.65 ng/μl APS and 0.325% 
(v/v) Temed) and 10% SDS-polyacrylamide gels (0.4 M Tris base [pH 8.8], 
0.1% (w/v) SDS, 10% (v/v) acrylamide, 0.25 ng/μl APS and 0.125% (v/v) 
Temed). Thirty to forty micrograms of protein were loaded per well and 8 μl 
of protein ladder (Precision Plus Protein All Blue Standards, Bio-Rad) was 
loaded into the end well. Gels were submerged in running buffer (25 mM 
Tris, 192 mM glycine and 3.4 mM SDS) and ran at 100–130 V until adequate 
separation was achieved. Proteins were transferred onto a 0.2 μm 
nitrocellulose membrane (Bio-Rad) by electroblotting transfer with a tank 
system. The transfer was carried out for 1.5 h at 300 mA, 4 °C using transfer 
buffer (20% (v/v) ethanol, 25 mM Tris and 192 mM glycine). 
2.5.3 Detection of protein 
Membranes were blocked with 5% (w/v) non-fat milk in TBST (0.2 M Tris 
[pH 7.6], 0.14 M NaCl and 0.1% (v/v) Tween-20) for 1 h at RT. Primary 
antibodies were applied following three washes with TBST and membranes 
were incubated overnight at 4 °C in a 50 mL falcon tube on a roller mixer. 
Secondary antibodies were applied after three washes in TBST and 
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membranes were incubated for 1 h at RT on an orbital shaker. All antibodies 
were prepared in 5% (w/v) BSA in TBST; see Table 2.3 for details of primary 
and secondary antibodies used. Following a further three washes in TBST, 
membranes were incubated with Super Signal West Pico Chemiluminescent 
substrate (Thermo Scientific) for 2 min and imaged using a Syngene Gel 
Imaging G-box (Geneflow, UK). Images were taken every 2 min and were 
integrated into previous images for up to 40 min.  
Table 2.3 Antibodies used for immunoblotting 
Antibody  Dilution Host species Source Cat No 
HIF-1α 1:1000 Mouse BD Biosciences, 
USA 
610959 
p21 1:500 Rabbit Santa Cruz, USA sc-397 
p53 1:1000 Mouse Santa Cruz sc-126 
β-actin 1:1000 Mouse Abcam, UK ab8226 
Cyclophilin A 1:1000 Rabbit Abcam ab3563 
Anti-mouse 
HRP conjugated  
1:5000 Horse Cell Signalling 
Technology, USA 
7073  
Anti-rabbit HRP 
conjugated  
1:3000 Goat Cell Signalling 
Technology 
7074  
 
2.6 Live cell imaging of cell cycle length 
In the hypoxic condition, D566 cells were incubated in 1% O2 for 72 h prior to 
imaging. Twenty-four hours prior to imaging, 75 x 104 cells were seeded in a 
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35 mm glass-bottomed dish (Greiner Bio-One, UK). The dish was mounted 
on a PeCon CO2-O2 controller incubator (PeCon, Germany) on the stage of an 
LSM 510 confocal microscope (Zeiss, Germany). Cells were maintained at 
37 °C, 5% CO2 and either 1% or 20% O2 and imaged using a Plan-Neofluar 
10x objective (NA 0.3) for 48 h. The sample was illuminated with a 543 nm 
laser and transmitted light was detected. Images were captured using Zen 
2012 software (Zeiss). Cell cycle length was determined by tracking 
individual cells manually using the open source image analyses software Icy, 
version 1.5.4.2, and recording the length of time between the first and second 
observed cell divisions.  
 
2.7 Stable cell line production 
The U87-H2BmRFP and U87-PercevalHR stable cell lines were made using 
lentiviral transduction. HEK 293TN cells were seeded into six 10 cm dishes at 
a density of 1.5 x 106 cells per dish. Cells were transfected with the lentiviral 
construct the following day using a vector:packaging:env ratio of 4:2:1 (see 
Table 2.4). The plasmids were transfected using polyethylenimine (PEI) at a 
ratio of 2:1 PEI:DNA in DMEM. A media change was performed three days 
after seeding. Three days after transfection, the supernatant was harvested, 
centrifuged at 500 x g for 10 min and filtered through a 0.45 μm PES filter. 
Ultracentrifugation was carried out following the protocol described by 
Kutner et al. (228). Viral particles were resuspended in 600 μl PBS, aliquoted 
into screw cap microfuge tubes, frozen in crushed dry ice and stored at -80 °C 
for future use. For transduction, 2 x 105 U87 cells were seeded into a T-25 
flask and 250 μl (H2B-mRFP) or 10 μl (PercevalHR) of the concentrated virus 
was applied. A media change was performed after 24 h.  
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Table 2.4 Plasmid information 
Plasmid Addgene plasmid no. Mass (ng) for 1 x 10 cm2 dish 
pHIV-H2BmRFP 18982 9 714 
FUGW-PercevalHR 49083 9 714 
psPAX2 12259 4 857 
pMD2.G 12260 2 428 
 
2.8 Spheroid characterisation  
2.8.1 Pimonidazole hydrochloride (PIMO, HypoxyprobeTM-1) staining  
PIMO was added to spheroids in growth media at a final concentration of 
200 μM 24 h prior to fixation.  
2.8.2 Spheroid fixation and sectioning 
Spheroids were washed three times with PBS and fixed in 4% 
paraformaldehyde (PFA) for 45 min at RT. Spheroids were washed again 
three times and then transferred into 20% sucrose for 72 h at 4 °C. After this 
cryoprotective step, spheroids were transferred into Peel-A-Way disposable 
embedding moulds (Polysciences, USA) and the sucrose was aspirated and 
replaced with cryomatrix (Thermo Scientific). Samples were centrifuged at 
700 rpm for 3 min before being snap frozen on dry ice and transferred to -
80 °C. Samples were cut into 10 μm sections using a CM1860 Cryostat (Leica, 
Germany). Sample sections were transferred onto Superfrost Plus microscope 
slides (Thermo Scientific) and stored at -20 °C.  
Chapter 2                                                                                                                     43 
2.8.3 Immunofluorescence 
Slides were allowed to thaw for 10 min at RT and a Dako PAP pen was used 
to draw a hydrophobic barrier around the circumference of the sample 
sections. Samples were washed three times with PBS and then incubated in 
50 mM NH4CL for 20 min to quench autofluorescence. Samples were blocked 
and permeablised with 1% (v/v) Triton X-100 and 0.4% (v/v) Tween20 in 1% 
(w/v) BSA in PBS for 20 min and then incubated with primary antibody for 
1 h. Samples were washed three times with blocking solution and then 
incubated in secondary antibody for 30 min in the dark. All antibodies were 
diluted in blocking solution; for details of primary and secondary antibodies 
see Table 2.4. Samples were washed again three times with blocking solution, 
stained with Hoechst 33342 (1:1000, Invitrogen) for 20 min, and then washed 
three times with PBS and once with water. Dako fluorescent mounting 
medium was used to mount 50 mm glass cover slides (VWR) onto the 
sections.  
Table 2.4 Antibodies used for immunofluorescence.  
Antibody Dilution Host species Source Cat No 
CA IX 1:500 Rabbit Abcam ab15086 
GLUT1 1:500 Rabbit Abcam ab652 
MCT4 1:500 Rabbit Santa Cruz Sc-50329 
PIMO 1:1000 Mouse Hypoxyprobe  HP1-100Kit 
Alexa Fluor 
488 anti-rabbit 
1:500 Goat Invitrogen a-11008 
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2.8.4 EdU staining and detection 
5-ethynyl-2’-deoxyuridine (EdU, Invitrogen) was added to spheroids in 
growth media at a final concentration of 20 nM 24 h prior to spheroid 
fixation. Following the fixation and sectioning steps already described, 
samples were washed with 3% (w/v) BSA in PBS followed by a 20 min 
incubation in 0.5% (v/v) Triton X-100 in PBS. EdU was detected using the 
Click-iT EdU Alexa Fluor 647 Imaging Kit (Invitrogen) according to the 
manufacturer’s instructions.  
2.8.5 Confocal microscopy  
Spheroid sections were imaged using an LSM 780 confocal microscope 
(Zeiss, Germany) with an EC Plan-Neofluar 20x objective (NA 0.5). Alexa 
Fluor 488 was excited using a 488 nm laser and emitted light detected using a 
473–597 nm bandpass filter (MBS 488/561/633, DBS1 mirror). Hoechst was 
excited using a 405 nm laser and emitted light detected using a 415 nm 
longpass filter (MBS 405, DBS1 mirror). Alexa Fluor 647 and PI were excited 
using a 561 nm laser and emitted light detected using a 620 nm longpass 
filter (MBS 458/561, DBS1 mirror). Samples expressing PercevalHR were 
excited with 488 nm and 405 nm lasers and emitted light was collected using 
a 499–552 nm bandpass filter. Images were captured using Zen 2012 
software. 
2.8.6 Quantification of spheroid immunofluorescence 
Spatial intensity analysis was carried out on background-subtracted images 
using the open-source platform for biological-image analyses, Fiji (229). For 
each spheroid, ten concentric regions of interest (ROI) were selected, each 
10% smaller than the last (Fig 2.1). As each of these ROIs overlapped, the 
integrated density for the non-overlapping regions was calculated by 
subtracting the integrated density of the next smallest ROI from the total for 
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every ROI, except the smallest. This gave us integrated density values for ten 
separate regions of the spheroid. The mean fluorescence intensity (MFI) was 
calculated by dividing the integrated density for each region by its area. MFI 
was normalised to the centre (GLUT-1, MCT4 and PIMO) or the periphery of 
the sphere (EdU) by dividing the MFI for each ROI by the MFI of the central 
ROI. The fractional distance was calculated by dividing the average radius of 
each ROI, measured in pixels, by the average radius of the largest ROI. 
Normalised MFI values were plotted against fractional distance to show the 
distribution of fluorescence within each spheroid.   
 
Figure 2.1. Spatial intensity analyses. An analysis of the distribution of fluorescence 
intensity in spheroid sections was carried out using Fiji. (A). The initial region of interest 
(ROI), shown as a yellow line, was selected so that it encompassed the entire spheroid. (B). 
The size of the initial ROI was measured so that the subsequent ROIs, each 10% smaller than 
the last, could be created. Mean fluorescence intensities were calculated for the non-
overlapping regions between ROIs as described above.  
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2.9 Lightsheet fluorescent microscopy 
2.9.1 Sample preparation 
Spheroids were prepared for imaging by aspirating the growth media and 
replacing it with 50% ice-cold Matrigel and 50% growth media plus 25 mM 
Hepes. For drug treated spheroids, 0.5 μM 17-AAG (Abcam) or 2 μM 
cilengitide (Adooq Bioscience, US) was added to the growth media. A Teflon 
plunger (Zeiss) was used to draw the spheroid into a fluorinated ethylene 
propylene (FEP) tube (S 1815-04, BOLA, Germany). The tube was cut with 
scissors to release it from the plunger and one end was sealed with a small 
amount of parafilm. A glass capillary (inner diameter 1.5 mm) was mounted 
in the lightsheet sample holder and the FEP tube placed partially inside the 
capillary. The sample holder was mounted in the Lightsheet Z.1 (Zeiss) 
sample chamber, where the sample was immersed in water at 37 °C for the 
duration of the experiment.  
2.9.2 Image acquisition 
Samples were excited with a 561 nm laser and 10x excitation objectives; 
emitted light was collected through a 576–615 band pass filter using a 20x W 
Plan-Apochromat objective and 1 x zoom. Images were acquired every 3 min 
with a z-step of 1.66 µm, starting approximately 50 µm in front of the 
spheroid. Lightsheet Z.1 Zen software (Zeiss) was used to acquire images 
using online dual side fusion with pivot scan. Images were detected using a 
pco.edge scientific complementary metal–oxide–semiconductor (sCMOS) 
camera. 
2.9.3 Image processing 
Image processing was carried out using a HP Z640 computer workstation 
(Hewlett-Packard, US) equipped with six central processing units (CPUs; 
Intel Xeon E5-2620v3 2.4 GHz) and 128 GB of DDR4 random access memory 
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(RAM). We devised a method of reducing the size of the lightsheet data prior 
to analyses, using a macro written in Fiji by Dr. David Mason, image analyst 
in the Liverpool Centre for Cell Imaging (Appendix 1.1). This was essential 
due to the extremely large file sizes produced (up to 0.75 TB for one 
experiment). The macro loads one time point at a time and downsamples the 
data by decreasing bit depth from 16 bit to 8 bit and performing 2 x binning. 
A further processing step was carried out prior to analyses in order to deal 
with sample drift. This was carried out in Fiji, using the descriptor-based 
series registration plugin developed by Preibisch et al. (230). Registration was 
carried out using a translational transformation model and consecutive 
matching of images with a range for all-to-all matching of two.  
2.9.4 Cell tracking and data analyses  
Segmentation and tracking were carried out using Imaris 8.2.0 (Bitplane, 
Belfast). Tracking was carried out using an autoregressive motion algorithm, 
with a maximum distance of 6 μm and a maximum gap size of zero. A filter 
was applied to remove any tracks that were shorter than eight time points 
(24 min). Once tracking was complete, track and spot statistics were exported 
into excel files. MATLAB  (Mathworks, US) was used to further process these 
statistics. A wrapper script (Appendix 1.2.1) was used to batch process files 
using the data processing script (Appendix 1.2.2) or the figure plotting script 
(Appendix 1.2.3). All MATLAB scripts were written by Dr. David Mason.  
The data processing script calculates spot speed and straightness as a 
function of radial distance from the centre of the spheroid. When the script is 
run, the user is asked to input the coordinates of the centre of the spheroid. 
Spot position, spot speed, track position, track straightness and mean track 
speed are then imported from the excel files generated using Imaris. For each 
spot, the Euclidian distance from the centre of the spheroid is calculated 
using the spot position information.  This allows spot speed and straightness 
to be calculated as a function of radial distance from the centre of the 
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spheroid. Spot straightness was calculated by dividing the sum of 
displacements between the preceding and proceeding two spots by the 
distance between the first and last spot. Spots located outside of the initial 
spheroid outer boundary were categorised as invading, while spots inside 
the boundary were categorised as non-invading. The spatial location of the 
outer boundary of each spheroid was defined by taking the mean of the ten 
furthest out spots present in the first frame of the experiment and adding 5%. 
For the large spheroids, the region inside the spheroid boundary was 
divided by three to calculate the inner, middle and outermost region of the 
spheroid. The data processing script was also used to determine the 
cumulative distribution of spot speeds by distance from the centre of the 
spheroid, over time.  
The figure plotting script was used to plot histograms and beehive plots for 
the output variables for each condition. A representative selection of these 
graphs are included in Chapter 5, section 5.2. As so many graphs were 
generated, it would have been impractical to include them in the appendix. 
Instead, we have made them available online using the image management 
software Zegami (Zegami, UK). Using Zegami, it is possible to view all of the 
graphs that were generated and sort them by condition and graph type. The 
Zegami database has been made available with the help of Dr. David Mason.  
 
2.10 Statistical analyses  
Statistical significance was determined by Analysis of Variance (ANOVA) 
followed by Dunnett’s test or Fisher’s LSD test, where appropriate, using 
SPSS statistical software (IBM, USA). 
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Chapter 3: 
The effects of low oxygen levels on 
glioblastoma cell proliferation and 
survival 
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3.1 Introduction 
The level of oxygen is recognised as a critical aspect of the tumour 
microenvironment. Hypoxia is associated with tumour aggressiveness and is 
known to increase angiogenesis, treatment resistance and invasion (81). 
However, the effect of hypoxia on cell proliferation is less well characterised. 
We aimed to address this gap in the literature by performing a systematic 
investigation into the effect of different oxygen levels on GBM cell 
proliferation and survival. Next, we wished to use live single-cell imaging to 
gain quantitative information on the dynamic relationship between HIF-1α 
and the cell cycle. We planned to transfect GBM cells with fluorescent 
ubiquitination-based cell cycle indicators (Fucci). These are cell cycle 
reporters that have been formed by fusing proteins whose expression levels 
oscillate during the cell cycle with fluorescent proteins (231). We have the 
facilities to perform time-lapse confocal fluorescence microscopy in an 
oxygen-controlled environment, allowing us to compare cell cycle 
characteristics under different oxygen conditions. We aimed to further 
explore the relationship between HIF-1α and the cell cycle using 
mathematical modelling and a systems biology approach. This approach has 
been successfully used by our group to examine the temporal regulation of 
HIF-1α expression, revealing the existence of a HIF-PHD negative feedback 
loop with important consequences for cell fate (232). To increase the 
relevance of our findings, we hoped to replicate the results obtained in cell 
lines in primary GBM cells. We were successful in characterising the 
relationship between different oxygen levels and cell proliferation and 
survival; this work has been published as an article in PeerJ (233), which has 
been included in this chapter. Unexpectedly, the results of flow cytometry 
experiments revealed that hypoxia has only minimal effects on cell 
proliferation. As such, we decided not to pursue our original aims relating to 
single-cell imaging and mathematical modelling of the relationship between 
HIF-1α and the cell cycle.  
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3.2 Cell cycle progression in glioblastoma cells in 
unaffected by pathophysiological levels of hypoxia  
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3.3 Additional results  
3.3.1 Live cell imaging of cell cycle length  
The results of the previously described flow cytometry experiments 
indicated that 1% O2 does not alter cell cycle distribution. However, we 
wanted to confirm that there was not an overall lengthening of the cell cycle 
in hypoxia, which would not be detected by flow cytometry. To determine 
the effect of hypoxia on cell cycle length, we pre-incubated D566 cells in 
1% O2 for 72 h and then imaged them in 1% O2 over the course of 48 h. We 
found that cell cycle length was similar between cells incubated in 20% O2 
and cells incubated in 1% O2 (Fig 3.1). These preliminary results were in line 
with our previous findings, indicating that cell proliferation is unaffected by 
1% O2. As such, we decided not to carry out any further live cell imaging 
experiments relating to the relationship between the cell cycle and hypoxia.  
 
Figure 3.1. Cell cycle length. D566 cells were either incubated and imaged in 20% O2 (52 
cells, N = 1; M = 19.71, SD = 2.83), or pre-incubated in 1% O2 for 72 h prior to imaging in 1% 
O2 for 48 h (42 cells, N = 1; M = 16.37, SD = 3.20). Cell cycle length was determined by 
measuring the time that had elapsed between two subsequent cell divisions.  
  
Chapter 3                                                                                                                     71 
3.3.2 The expression of p53 is not altered by hypoxia  
We were interested in whether the cell death observed in U251 and U87 cells 
after 48 h in 0.1% O2 was associated with an increase in p53, as p53 is known 
to regulate both cell cycle progression and cell survival (28). P53 protein 
expression was assessed after 24–72 h exposure to hypoxia. However, neither 
1% O2 nor 0.1% O2 altered the level of p53 in any of the cell lines tested (Fig 
3.2). We next wished to assess whether p53 was active in our cell lines, as 
both U251 and D566 cells harbour TP53 mutations (234). To assess whether 
p53 was active, we treated cells with etoposide; a topoisomerase II inhibitor 
used for the treatment of cancer which causes DNA damage and p53 
activation (235). We found that only U87 cells responded to etoposide with 
an increase in p53 protein, confirming that p53 is non-functional in D566 and 
U251 cells. These results indicate that the response to hypoxia is similar in 
TP53 wild type and TP53 mutated GBM cells, and that the cell death 
observed in severe, long-term hypoxia is not related to p53 activation.  
 
Figure 3.2. Western blots of p53 protein expression. (A). Cells were incubated 20%, 1% and 
0.1% O2 for the indicated time points. Protein expression was measured by western blot. 
Images are representative examples of three experiments. (B). Cells were treated with 20 μM 
etoposide for 24 h. Images are representative of two (U251 cells) or three (U87 and D566 
cells) experiments.  
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3.3.3 The relationship between PHD proteins and the cell cycle response 
to hypoxia 
We were interested in whether we could alter the cellular response to 
hypoxia by knocking down PHD2 and PHD3, which regulate the oxygen-
dependent degradation of HIF-1α. Previous work by our group has 
demonstrated the existence of a HIF-PHD negative feedback loop (Fig 3.3). 
The initial sharp increase in HIF-1α expression under low oxygen conditions 
is followed by a decrease, caused by the transactivation of PHD2 by HIF-1α. 
When PHD2 is expression is silenced, the result is a steady accumulation in 
HIF-1α. In contrast, when PHD3 is silenced, HIF-1α accumulation is 
unaltered (232). Previous research has suggested that PHD3 may promote 
cell cycle progression in hypoxia, while PHD1 has been shown to regulate 
progression through mitosis (236-238).  
 
Figure 3.3. HIF-1α–PHD2 negative feedback loop. HIF-1α increases the expression of 
PHD2, which, under normal oxygen conditions, hydroxylates HIF-1α leading to its 
degradation.  
We examined the effects of low oxygen levels on the cell cycle of wild type 
(WT) HeLa cells, shPHD2 HeLa cells (a gift from D Hoogewijs, D Stiehl and 
R Wenger, University of Zürich) and shPHD3 HeLa cells (a gift from Sarah 
Taylor, University of Liverpool). Firstly, we compared the cell cycle profiles 
of all three cell lines under normal oxygen conditions. Compared with WT 
HeLa cells, shPHD2 cells had significantly fewer cells in G1 phase and more 
cells in S phase (Fig 3.4A). However, the proliferation rate of the cell lines 
was similar (Fig 3.4B). We then assessed the effects of 1% and 0.1% O2 on cell 
cycle distribution. In WT HeLa cells we saw a non-significant increase in cells 
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in G1 phase after 24 h and 48 h in 0.1% O2, but by 72 h the cell cycle profile 
had returned to normal (Fig 3 in the PeerJ paper). In shPHD2 HeLa cells, 
there was a significant reduction in cells in G1 phase after 24 h in 1% O2; 
however, this effect was only transient. In shPHD3 HeLa cells, there was a 
significant increase in cells in G1 phase after 24 h and 48 h in 0.1% O2. 
However, as with the WT cells, this difference had disappeared by 72 h (Fig 
3.4C). While shPHD3 cells are more sensitive to hypoxia, these results 
indicate that cell cycle response to hypoxia is similar in WT, shPHD2 and 
shPHD3 HeLa cells.  
 
Figure 3.4. PHD3 depletion increases sensitivity to hypoxia. (A) Cell cycle profiles of wild 
type (WT), shPHD2 and shPHD3 HeLa cells in 20% O2. Cell cycle profiles were obtained 
using flow cytometry. (B) Cell proliferation in 20% O2, as measured by cell counting using 
flow cytometry, did not differ between the three cell lines. (C). shPHD2 and shPHD3 cells 
were incubated in 20%, 1% and 0.1% O2 for the indicated time points. shPHD3 cells were 
more sensitive to hypoxia and showed a significant increase in cells in G1 phase after 24–48 h 
in 0.1% O2. Figure shows the mean + SEM of three experiments (A, C) and the mean + SD of 
two experiments (B). *p < .05, ** p < .01. blot.   
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3.4 Discussion 
We were successful in investigating the effect of different levels of oxygen on 
cell proliferation in cells cultured as a monolayer. However, our results do 
not support the hypothesis that physiologically relevant levels of hypoxia 
cause cell cycle arrest. Even in severe hypoxia, the accumulation of cells in G1 
phase observed in D566 cells was transient and disappeared after 72 h in 
0.1% O2, suggesting that cells can adapt to very low levels of oxygen. In 
addition, we did not observe any molecular changes associated with cell 
cycle arrest or cell stress, such as an increase in p21, p27 or p53. We had 
originally planned to further investigate the relationship between hypoxia 
and the cell cycle using live cell imaging and mathematical modelling. 
However, as all of our results indicated that hypoxia does not play a 
significant role in cell cycle regulation, we decided not to pursue this line of 
investigation.   
We found no increase in p53 in U87 cells, which are TP53 WT, when cells 
were exposed to severe hypoxia. Previous research has shown that p53 is 
stabilised in hypoxia; however, in these studies, cells were exposed to anoxia 
(<0.02% O2) (239, 240). It is possible that p53 activity is only increased in 
anoxia, not hypoxia. In line with this hypothesis, Hammond et al. reported 
p53 accumulation at 0.02%, but not 2% O2 (241). However, Pan et al. failed to 
observe p53 accumulation even in 0.02%, unless hypoxia was combined with 
acidosis or nutrient deprivation (242). This picture is further complicated by 
several reports of hypoxia resulting in the suppression of p53 activity (243-
245). The relationship between hypoxia and p53 is far from clear, with results 
varying according to the cell line as well as the severity and duration of 
hypoxia (for review, see (246)).  
A factor that further complicates the interpretation of research into hypoxia 
and cell cycle arrest or cell survival is the practice of serum-starving cells in 
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order to synchronise them in G1 phase (236). Serum starvation causes stress 
related morphological and molecular changes, such as cell rounding and an 
increase in p53 expression and apoptosis, and sensitises tumour cells to 
DNA-damaging agents (247, 248). It is possible that serum starvation has 
unintended effects when used in combination with an additional stressor 
such as hypoxia. Therefore, the results of such experiments should be 
interpreted with caution.  
In line with previous research, we found that PHD3 depletion increased 
sensitivity to hypoxia and caused an accumulation of cells in G1 phase. 
Hoegel et al. have shown that PHD3 enhances the G1 to S transition of 
hypoxic carcinoma cells by decreasing the stability of p27 (237). The transient 
G1 phase arrest observed in shPHD3 cells mirrored the response of D566 cells 
incubated in severe hypoxia. We saw no change in p27 mRNA expression in 
D566 cells; however, we did not examine p27 protein expression. Hoegel et 
al. reported that PHD3 stabilises p27 post-translationally by decreasing the 
phosphorylation of the protein at serine 10. Therefore, it is possible that 
changes in p27 protein expression may cause the transient cell cycle arrest 
observed in D566 cells.  
In summary, we have performed a systematic investigation into the effects of 
low oxygen levels on cell proliferation and survival, the results of which 
have lead us to conclude that pathophysiological levels of hypoxia (0.1–1% 
O2) do not cause cell cycle arrest. The level of oxygen and duration of 
exposure are important determinants of the cellular response to hypoxia; 
however, GBM cells are able to proliferate and survive even in severe 
hypoxia.  
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Chapter 4: 
Characterisation of a glioblastoma 
multicellular tumour spheroid model  
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4.1 Introduction 
In the last chapter, we established the effects of different oxygen levels on the 
proliferation and survival of cells cultured as a monolayer. We recognised 
that this is a poor representation of the solid tumour microenvironment and, 
having characterised the effects of hypoxia on GBM cells using a simplified 
system, sought to increase the complexity of the model by culturing cells as 
multicellular tumour spheroids. Spheroids share important characteristics 
with solid tumours, such as gradients in oxygen and nutrients (see Chapter 1, 
section 1.8.1), which made them our preferred model for all further 
investigations. Several methods can be used to generate spheroids. One 
approach is to coat tissue culture dishes with substrates that cells struggle to 
adhere to, such as agar. Another approach is to keep cells in suspension 
using spinner flasks or rotary cell culture systems. The hanging drop method 
involves seeding cells in a droplet of media that is suspended in air. Gravity 
causes the cells to aggregate and, over the course of several days, form a 
compact spheroid. The main advantages of the hanging drop technique over 
other methods is that spheroids can be generated quickly and their size and 
age can be precisely controlled (249). This makes the production of 
homogeneous spheroids possible and allows for more reproducible results.  
We wished to characterise GBM spheroids in terms of cell proliferation, 
survival and indicators of oxygenation and cellular energetics. We 
anticipated that spheroids would show spatial heterogeneity in these 
characteristics. Cell proliferation is typically concentrated around the 
periphery of spheroids, while the cores of spheroids are often necrotic. As the 
diffusion limit of O2 in tissue is thought to be 150 μm, we anticipated that 
spheroids would display a hypoxic core (70, 71). We further hypothesised 
that spheroids would show spatial heterogeneity in markers of cellular 
energetics, with energy production decreasing as a function of distance from 
the spheroid periphery. We aimed to investigate cellular energetics in live 
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spheroids using Perceval High Range (PercevalHR), a fluorescent biosensor 
that senses ATP:ADP ratio. Perceval was constructed by integrating a 
circularly permuted monomeric version of the GFP derivative Venus 
(cpmVenus) into a bacterial regulatory protein (GlnK1) that undergoes a 
conformational change upon ATP binding. ATP binding alters the excitation 
spectrum of the construct such that excitation is increased at 490 nm and 
decreased at 405 nm while ADP binding has the opposite effect. Competition 
for the binding site means that the fluorescent response depends on the 
ATP:ADP ratio, allowing the protein to act as a ratiometric sensor (259). 
However, the original sensor saturated at low ATP:ADP ratios (<5:1), which 
limited its usefulness in mammalian cells. In 2013, Tantama et al. reported the 
development of an optimised version of the sensor, PercevalHR, which 
senses a greater range of ATP:ADP ratios (0.4–40:1) (260).  
 
We also chose to examine the expression of glucose transporter 1 (GLUT1), 
monocarboxylate transporter-4 (MCT4) and carbonic anhydrase-IX (CAIX) 
because the expression of these proteins is closely associated with both 
hypoxia and cellular metabolism. GLUT-1 facilitates the transport of glucose 
across the plasma membrane, while MCT4 exports lactate from glycolytically 
active cells. The expression of both of these proteins increases in hypoxia in a 
HIF-1 dependent manner; GLUT-1 expression is also increased by glucose 
deprivation (250-254). CAIX catalyses the hydration of CO2 into protons and 
bicarbonate ions, which is thought to facilitate CO2 excretion. This helps to 
maintain an alkaline intracellular pH and contributes to maintaining cell 
survival in the acidic solid tumour microenvironment (213, 258). CAIX 
expression is induced by HIF-1 and the close associated between CAIX and 
hypoxia has led to it being considered an endogenous marker for hypoxia 
(255-257). We anticipated that the expression of GLUT1, MCT4 and CAIX 
would be spatially regulated in a manner corresponding to the availability of 
oxygen and nutrients.   
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Our aims for this chapter were as follows: 
1. To optimise the culture of GBM spheroids. 
2. To characterise spheroids in terms of cell proliferation, survival, 
oxygenation and energetic status.  
3. To assess the effects of hypoxia (1% O2) on the above characteristics.  
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4.2 Results 
4.2.1 Optimisation of spheroid generation 
We found that cell culture media contains many small particulates that 
interfere with spheroid formation (Fig 4.1B). To overcome this problem, we 
used filtered media when making spheroids. Spheroids were generated by 
pipetting 50 μl of U87 cell suspension into 96-well hanging drop plates (Fig 
4.1A). After three days, when the cells had aggregated and formed a compact 
spheroid, spheroids were transferred to 35 mm suspension culture dishes. If 
left in the hanging drop plate, there is a risk of the droplets evaporating or 
falling off. We aimed to produce spheroids of 400– 500 μm because previous 
research has suggested that spheroids of this size will experience gradients in 
nutrients and oxygen (261, 262). We found that an initial quantity of 1200 
cells per 50 μl droplet produced spheroids of the desired size seven days 
after seeding (Fig 4.1C, Fig 4.1D).  
 
4.2.2 Choice of method for characterising spheroids 
We had hoped to be able to characterise whole spheroids using 
immunofluorescence followed by lightsheet microscopy. However, we found 
that nuclear stains and antibodies showed poor penetration under these 
conditions and, at best, labelled only the outer half of spheroids (Fig 4.2). We 
also found that the image resolution in the centre of spheroids was poor as 
the effects of light scattering are increased when imaging at depth, limiting 
the penetration of light and causing a reduction in resolution and contrast 
(263). Tissue clearing methods can be used to make large samples more 
permeable and optically transparent (264, 265). Following a protocol 
described by Wenzel, we tried dehydrating spheroids in an ascending 
ethanol serious (50%, 70%, 85% and 99% ethanol for 5 min each) before 
clearing them in a 1:1 (v/v) mix of benzyl alcohol/benzyl benzoate (BABB) 
Chapter 4                                                                                                                   81 
(226). However, we found that this method was too harsh and caused 
spheroids to disintegrate. Furthermore, BABB is known to drastically reduce 
the fluorescence of fluorophores (265, 266).  
 
Figure 4.1. Spheroid formation and growth. (A). Cell suspension was pipetted into a 96-well 
hanging drop plate. The wells are surrounded by a reservoir containing PBS to prevent the 
evaporation of the hanging drops. At first, cells form a loose aggregate but after three days 
they form compact spheroids. Adapted from www.3dbiomatrix.com. (B). Unfiltered cell 
culture media contains particulates which cells adhere to. (C). Spheroid diameter (average of 
three measurements per spheroid) at the specified time points was quantified using ImageJ. 
Figure shows the M + SD of three spheroids (N = 1). (D). Images of spheroids generated 
using 600 or 1200 cells at three, seven and 14 days after seeding, Scale bar is 200 μm.  
Chapter 4                                                                                                                   82 
 
Figure 4.2. Poor penetration of Hoechst in intact spheroids. Whole spheroids were fixed in 
4% PFA for 45 min at RT, permeablised as described in Chapter 2, section 2.8.3,  then stained 
with Hoechst 33342 (1:1000) for 45 min. Spheroids were embedded in 1% low-melt agarose 
and imaged using a 20x objective on a Lightsheet Z.1 (Zeiss) microscope. Fluorescence was 
excited with a 405 nm laser and emitted light detected using a 490 nm shortpass filter.  
There are other clearing methods which are better at preserving fluorescence 
and may be better tolerated by spheroids, such as CLARITY (267). However, 
these processes can be lengthy and many of the steps require optimisation. 
We were also concerned about being able to determine whether any changes 
observed in fluorescence reflected changes in protein expression, or were an 
artefact of limited solvent or antibody penetration. Although the aim of the 
current chapter was to develop and characterise a GBM spheroid model, our 
ultimate aim was to carry out live cell imaging of spheroids. Therefore, we 
decided not to optimise the imaging of whole immunostained spheroids any 
further and to overcome the antibody penetration problem by sectioning 
spheroids before performing immunofluorescence.  
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4.2.3 Proliferation gradients in spheroids 
We characterised the proliferation of cells in spheroids using 5-ethynyl-2´-
deoxyuridine (EdU), a thymidine analogue that incorporates into cellular 
DNA during DNA replication. A terminal alkyne group replaces the methyl 
group in the 5 position, allowing EdU to be detected by a copper-catalysed 
reaction between the alkyne group and a fluorescent azide (click chemistry) 
(268-270). The small size of the dye means that, unlike 5-bromo-2´-
deoxyuridine staining, DNA does not need to be denatured in order for EdU 
to be detected (268). We found that one-week-old spheroids grown in 20% O2 
showed a proliferation gradient, with the majority of proliferating cells 
concentrated within 100 μm of the spheroid periphery. The interior of these 
spheroids contained a mixture of proliferating and quiescent cells (Fig 4.3A). 
Interestingly, when spheroids were incubated in 1% O2 for 24 h, proliferating 
cells were only observed within 100 μm of the spheroid periphery (Fig 4.3A; 
Fig 4.3B). In two-week-old spheroids grown in 20% O2, we saw a similar 
pattern of proliferation to the hypoxic spheroids, with proliferating cells 
concentrated in a narrow band around the spheroid periphery (Fig 4.3A). 
This shows that proliferation is affected by the 3D multicellular spheroid 
environment and, in spheroids, is reduced under conditions of low oxygen.  
 
4.2.4 Spheroid oxygenation status  
We characterised the oxygen status of spheroids using pimonidazole 
hydrochloride (PIMO), a 2-nitroimidazole that is reduced in hypoxic cells. 
This leads to the formation of stable adducts with thiol groups that can be 
detected using an antibody. The binding of a similar compound, 
misonidazole, increases steeply at 10mm Hg (equivalent to 1.3% O2) and 
PIMO has been shown to have similar kinetics (271, 272). We found an 
inconsistent pattern of PIMO staining in one-week-old spheroids grown in 
20% O2. A number of spheroids showed small areas of staining in a pattern 
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clearly indicative of a hypoxic core. However, some spheroids had no PIMO 
staining at all and, paradoxically, some showed an increase in staining 
around the periphery. PIMO staining was evident throughout spheroids that 
had been incubated in 1% O2 for 24 h, with a slight increase towards the 
periphery (Fig 4.4A; Fig 4.4B). We were interested in whether hypoxia would 
affect cell survival in spheroids and so used PI staining to detect the presence 
of dead cells. One-week-old spheroids grown in 20% O2 appeared healthy 
with few PI positive cells; in contrast, spheroids that had been exposed to 
hypoxia showed had a number of PI-positive cells near their core.  
 
Two-week-old spheroids grown in 20% O2 showed a donut-like pattern of PI 
and PIMO staining, with viable, non-hypoxic cells concentrated in the outer 
100 µm of spheroids (Fig 4.4C). These spheroids displayed considerable 
cellular heterogeneity, consisting of proliferating, quiescent, and necrotic 
cells with varying levels of oxygenation. These results suggest that the one-
week-old spheroids are not large enough to develop the hypoxic core that is 
present in the larger two-week-old spheroids. Furthermore, in the spheroid 
model, hypoxia appears to reduce cell viability. While the two-week-old 
spheroids are a good model for tumour tissue in terms of heterogeneity, the 
large necrotic core means that the viable cell population is relatively small. 
As we aimed to compare cellular energetics and motility in the core of 
spheroids with the periphery, it was important that the majority of cells in 
spheroids were viable. We therefore chose to continue our investigations 
using the one-week-old spheroids, which contain a larger population of 
viable cells.  
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Figure 4.3. Proliferation gradients in spheroids. (A). Representative images of EdU staining 
in fixed and sectioned spheroids. (B). Immunofluorescence was quantified by spatial 
intensity analysis, as described in Chapter 2, section 2.8.6. The profiles of 12 spheroids 
incubated in 20% O2 and 13 spheroids incubated in 1% O2 (N = 2) are illustrated. The graph 
shows the normalised mean fluorescence intensity (MFI) plotted against the fractional radius 
of the spheroid. Scale bar is 100 μm.  
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Figure 4.4. Spheroid oxygenation and viability. (A). Representative images of PIMO and PI 
staining in one-week-old spheroids. (B). Immunofluorescence was quantified by spatial 
intensity analysis. The profiles of 19 spheroids incubated in 20% O2 (N = 3) and ten 
spheroids incubated in 1% O2 (N = 2) are illustrated; each symbol corresponds to the profile 
of an individual spheroid. The graph shows the normalised mean fluorescence intensity 
(MFI) plotted against the fractional radius of the spheroid. (C). Representative images of 
PIMO and PI staining in two-week-old spheroids (N = 1). Scale bar is 100 μm.  
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4.2.5 GLUT-1, MCT4 and CAIX expression in spheroids 
We anticipated that the expression of GLUT-1, MCT4 and CAIX might be 
spatially regulated. We found that GLUT-1 (Fig 4.5A; Fig 4.5C) and CAIX 
(Fig 4.6B) both showed a homogeneous distribution in one-week-old 
spheroids cultured in 20% or 1% O2. MCT4 expression was also generally 
homogenous, with a slight increase in expression in the peripheral layer of 
spheroids cultured under both oxygen conditions (Fig 4.5B; Fig 4.5C). We 
had expected to see an increase in the expression of these proteins in 
spheroids incubated in hypoxia; however, little difference was observed. 
 
4.2.6 Ratiometric imaging of spheroid energetics  
We hypothesised that energy production in spheroids may decrease as a 
function of distance from the spheroid periphery. To investigate whether 
cellular energetics are spatially regulated in spheroids, we generated a U87 
cell line stably expressing PercevalHR using lentiviral transduction. As 
PercevalHR is sensitive to changes in pH, it is necessary to monitor and 
adjust for pH, especially in spheroids where intracellular pH may vary (260, 
273). We hoped to monitor changes in intracellular pH using Carboxy 
SNARF-4F 5-(and-6) AM acetate (SNARF), a fluorescent dye that undergoes 
a pH-dependent wavelength shift. To determine absolute pH values and 
calibrate the PercevalHR signal, the SNARF signal needs to be calibrated by 
incubating cells with solutions of varying pH in the presence of the 
ionophore nigericin. We attempted to carry out the calibration procedure in 
cells cultured as a monolayer; however, we found that cells would detach 
almost immediately when incubated in the requisite solutions. This meant 
that we were unable to perform the calibration and, therefore, unable to 
exclude the effects of pH from any changes observed in the PercevalHR 
signal.  
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Our preliminary experiments indicated that there was little change in the 
PercevalHR signal throughout one-week-old spheroids grown in 20% O2. In 
spheroids exposed to 1% O2, there was an overall loss of signal at the centre 
of the spheroid (Fig 4.6B). This loss of signal occurs in the region in which we 
have seen PI staining, and may therefore be caused by necrosis. However, we 
did not observe a loss of signal in the core of the two-week-old spheroids, 
which we know to be necrotic, although there was a change in the 
ratiometric signal. Further experiments are necessary to determine the cause 
of the loss of signal in hypoxic spheroids and to confirm whether changes in 
the ATP:ADP ratio occur in the viable regions of spheroids. However, as we 
were unsuccessful in correcting for changes in intracellular pH we did not 
carry out any further investigations using the PercevalHR sensor.  
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Figure 4.5. GLUT-1 and MCT4 expression in spheroids. (A) GLUT-1 expression and (B) 
MCT4 expression in one-week-old spheroids. (C). Immunofluorescence was quantified by 
spatial intensity analysis. For GLUT-1, the profiles of 23 spheroids incubated in 20% O2 (N = 
3) and 11 spheroids incubated in 1% O2 (N = 2) are illustrated. For MCT4, the profiles of ten 
spheroids incubated in 20% O2 (N = 2) and four spheroids incubated in 20% O2 (N = 1) are 
shown. The graph shows the normalised mean fluorescence intensity (MFI) plotted against 
the fractional radius of the spheroid. Scale bar is 100 μm.   
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Figure 4.6. PercevalHR and CAIX expression in spheroids. (A). Representative images of 
U87-PercevalHR spheroids imaged after (i) one week in 20% O2, (ii) six days in 20% O2 plus 
24 h in 1% O2 , or (iii) two weeks in 20% O2 (N = 1). Image shows fluorescence emitted when 
samples were excited with a 488 nm or 405 nm laser. Emitted fluorescence was collected 
using a 499-552 nm bandpass filter. Emitted light when excited at 488 nm was divided by the 
emitted light when excited at 405 nm to produce a ratiometric image. (B). Representative 
images of CAIX expression in one-week-old spheroids (N = 2). Scale bar is 100 μm.  
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4.3 Discussion  
We have optimised the production of GBM spheroids that are ~ 450 μm in 
diameter after a week in culture and characterised these spheroids in terms 
of their proliferation, oxygenation and viability under different conditions. 
The increased quiescence of cells towards the core of spheroids is often 
presumed to be a result of hypoxia. For example, Laurent et al. (216) found 
that actively proliferating cells were localised to the outer 150 μm of 
spheroids and attributed this phenomenon to a reduction in the supply of 
oxygen and other nutrients. While some of our one-week-old spheroids did 
display small regions of hypoxia at their core, this pattern was not consistent 
enough to explain the proliferation gradient, which itself was very consistent. 
However, we did see fewer proliferating cells when spheroids were 
incubated in 1% O2 for 24 h. In monolayer cultures, we have shown that the 
proliferation of U87 cells is unaffected by 0.1–1% O2. Therefore, it is unlikely 
that hypoxia alone is causing cellular quiescence in spheroids, but it may act 
as a contributing factor in combination with the added stresses of the 3D 
spheroid environment. It has previously been shown that EMT6/Ro mouse 
mammary tumour cells proliferate when exposed to low pH (pH 6.6) or low 
oxygen (0.8% O2), but when the two are combined they cease to proliferate 
(274). Similarly, a combination of low oxygen and low glucose results in 
reduced spheroid volume (275). A potential molecular mechanism for the 
sensing of these microenvironmental changes is p53. Pan et al. found that p53 
was not induced by hypoxia alone, but responded to the nutrient-deprived 
and acidic hypoxic microenvironment (242).  
We found that GLUT-1 was expressed throughout spheroids, with no 
evidence of a gradient in expression in either oxygen condition. It is unlikely 
that there were steep gradients in glucose concentrations in our spheroids as 
uniform glucose distributions have previously been found in spheroids of up 
to 600 μm in diameter. In larger spheroids, central glucose concentrations 
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have been found to decline as a function of spheroid size. However, even in 
spheroids of up to 1600 μm, central glucose concentrations do not fall below 
3 μmol/g, which is a concentration sufficient for maintaining cell growth in 
monolayer cultures (214). We found that MCT4 was also expressed 
throughout spheroids cultured under both oxygen conditions, with a slight 
increase in expression towards the spheroid periphery. Walenta et al. have 
shown that oncogene-transfected rat embryonic fibroblast spheroids have 
steep lactate gradients, with very low levels in the outermost layer of cells 
compared to the rest of the spheroid, and very high levels in the core (214). 
The observed increase in MCT4 expression suggests that the low level of 
lactate observed at the periphery of spheroids may not just be due to 
proximity to the spheroid:media interface and enhanced diffusion, but a 
consequence of the increased extrusion of lactate by MCT4.  
As with GLUT-1, we found that CAIX was expressed homogeneously 
throughout spheroids in both oxygen conditions. CAIX is known to play an 
important role in the spatial regulation of pH in spheroids. Swietach et al. 
have shown that when CAIX is expressed the intracellular pH gradient in 
spheroids is reduced; however, the extracellular pH gradient is increased. 
This effect was evident in spheroids as small as 200 μm (213, 273). The strong 
uniform expression of CAIX in our spheroids may contribute to the 
maintenance of a more uniform intracellular pH, supporting the viability of 
cells in the core of the spheroid. We were expecting to see an increase in the 
expression of CAIX, GLUT-1 and MCT4 in spheroids exposed to hypoxia; 
however, little to no difference was observed. The relatively high level of 
expression of these proteins in spheroids under normal oxygen conditions 
may explain why we did not see any changes in hypoxia. Gliomas are known 
to be highly glycolytic and overexpress both MCT4 and CAIX, while GLUT-1 
expression has been shown to increase significantly in spheroid cultures 
compared to monolayers (152, 215, 276-278). Furthermore, although hypoxia 
is the most well-known inducer of CAIX, its expression in tumours does not 
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overlap completely with regions of hypoxia (257, 278). CAIX is also regulated 
by the signalling of proteins known to be dysregulated in GBM, such as 
EGFR and PI3K, and its expression is increased in dense cultures in a HIF-1α 
independent manner (279, 280).  
As the diffusion limit of O2 in tissue is ~150 μm, we anticipated that 
spheroids >300 µm would display a hypoxic core (70, 71). However, only 
some of the one-week-old spheroids showed evidence of a hypoxic core and 
many showed no evidence of hypoxia at all. The variation in oxygenation 
may be due to variations in spheroid size. Previous reports of the levels of 
oxygen in the core of spheroids of 400–500 μm, made using microelectrodes, 
range from 0–8% O2 (211, 281). The level of oxygen in spheroids has also 
been shown to vary between cell lines as tissue oxygenation is dependent on 
the comsumption of oxygen as well as the supply (211, 214). EMT6/Ro 
spheroids have been shown to reduce their oxygen consumption as their size 
increases, reflecting the ability of cells to adapt their metabolic rate to suit 
their environment (210). We have confirmed that the age and size of 
spheroids are critical; while one-week-old spheroids were healthy with 
occasional small areas of hypoxia, two-week-old spheroids had large regions 
of hypoxia and necrosis. It is not clear why PIMO staining was observed at a 
depth of 100 μm from the spheroid surface in the two-week-old spheroids 
but not the one-week-old spheroids. One possibility is that these differences 
reflect changes in oxygen consumption in larger spheroids. We also found 
the proliferation gradient to be much sharper in two-week-old spheroids. 
This effect is unlikely to be solely due to gradients in oxygen and nutrients; if 
this were the case we would expect to see a similar pattern in the one-week-
old spheroids. It is possible that older spheroids experience higher 
concentrations of factors that inhibit growth, such as waste products (282, 
283).  
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We saw little PI staining in the one-week-old normoxic spheroids, increased 
staining in the core of hypoxic spheroids and substantial PI staining in two-
week-old spheroids. This is in line with previous investigations, which have 
found the viable rim in large spheroids to be 100–250 μm in diameter (214, 
284). It is unlikely that hypoxia alone causes substantial cell death as we have 
shown that U87 cells can tolerate oxygen concentrations as low as 0.1% O2 for 
up to 48 h before viability is affected. However, as with quiescence, hypoxia 
is likely to be an aggravating factor. Walenta et al. found that necrosis in 
spheroids was preceded by the emergence of anoxia in the core of spheroids 
followed by a decrease in central ATP, while Monz et al. also pinpointed 
anoxia as the cause of necrosis (214, 283). Low levels of oxygen and high 
levels of lactate, or low levels of both oxygen and glucose, have been shown 
to have combinatorial effects on the thickness of the viable rim (275, 283). 
Therefore, it is likely that cells are less able to cope with a low oxygen 
environment when there is a limited supply of glucose and a build-up of 
lactate. However, necrosis has been shown to emerge despite sufficient 
oxygen and glucose supply (210, 211, 285). Bertuzzi et al. carried out 
mathematical modelling to determine the cause of necrotic core formation. 
They argued that an insufficient ATP production rate is the underlying 
cause, as a deficit in ATP predicts the emergence of necrosis much better 
than either oxygen or glucose alone (284). 
 
We were not able to quantify changes in ATP levels using PercevalHR as we 
were unsuccessful in correcting for pH. However, from our preliminary 
experiments, changes in the ratiometric signal were only evident in areas that 
were likely to have been necrotic. Previous research has indicated a steady 
decline in central ATP with increasing spheroid size prior to the onset of 
necrosis (214). It is possible that more subtle changes in ATP were not 
detected by PercevalHR because of its limited range. The ratio of total 
ATP:ADP in mammalian brains is around 10:1; however, the ratio of free 
ATP:ADP, which is measured by Perceval, is estimated to be nearer to 150:1 
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due to the increased sequestration of ADP by cellular proteins compared to 
ATP (129). While PercevalHR’s range is improved compared to the original 
sensor, it can only sense ATP:ADP ratios between 0.4 and 40:1 and may not 
detect less extreme changes. An alternative option would be to use the 
ATeam indicators, fluorescence resonance energy transfer (FRET)-based 
indicators which act as a direct measure of ATP level. The sensors are 
unaffected by pH changes between pH 7.1 and 8.5; however, they are 
significantly affected by pH values lower than this (286). As intracellular pH 
has been shown to drop from 7.2 at the periphery of spheroids to as low as 
6.2 in the core, these sensors would require pH correction to be suitable for 
use in spheroids (213). 
 
In summary, we have successfully determined the starting cell number and 
culture time necessary to generate spheroids of 200–800 μm. We have 
characterised spheroids in terms of proliferation, oxygenation and survival. 
We have also revealed important differences between the effect of hypoxia 
on cells cultured as spheroids and cells cultured as a monolayer, with 
stronger effects on proliferation and survival observed in the more complex 
spheroid model. The combined results of experiments conducted in 
monolayers and spheroids indicate that the effect of hypoxia on tumour cells 
is dependent on the level of oxygen and duration of exposure as well as the 
cellular environment, which is critical because of the synergistic relationship 
between low oxygen levels and the availability of nutrients and 
concentration of waste products. The multicellular tumour spheroid model 
more closely mimics the arrangement of cancer cells and the environment to 
which they are exposed in vivo. We chose to continue to work with this 
model in the next chapter, in which we investigate cellular invasion in a 
spheroid model using lightsheet fluorescence microscopy.  
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Chapter 5: 
Live cell imaging of spheroid 
invasion using lightsheet 
fluorescence microscopy  
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5.1 Introduction 
The invasion of tumour cells into neighbouring tissue is a hallmark of cancer 
and a major cause of mortality (6). In GBM, the diffuse invasion of cells 
makes complete surgical resection impossible. As discussed in Chapter 1, the 
increased expression of integrin αVβ3 in GBM is thought to contribute to this 
invasive phenotype (190-192). Furthermore, GBM has been shown to express 
a range of cell adhesion molecules (α1, α3, α5, α6β1, αvβ3, ICAM-1, LFA-3, 
CD44, Lewisx, sialylated Lewisx, and sialylated LewisLewisx) at significantly 
higher levels than normal brain tissue (287). The molecular mechanisms of 
glioma invasion are a topic of great interest, which may have therapeutic 
potential. However, the majority of in vitro invasion assays are two-
dimensional, (for review see (288)), and as such are a poor representation of 
the tumour microenvironment. We aimed to use the multicellular tumour 
spheroid model, characterised in the previous chapter, to investigate cellular 
invasion in 3D.   
In the typical spheroid invasion assay, spheroids are plated on, or embedded 
in, ECM in a 96-well plate. The plates are imaged using an inverted 
microscope and invasion is quantified by measuring the distance that cells 
have migrated away from the spheroid (289-292). While this technique has 
the advantage of being high-throughput, it only provides information about 
the movement of cells in the x-y plane and does not provide any information 
about the migration of cells within spheroids. A further disadvantage is that 
it is not possible to track the movements of individual cells. The ideal 
imaging technique would allow us to track the invasion of individual cells in 
the x, y and z planes, and to track the migration of cells within spheroids, 
which can provide important information about the effect of the 3D 
organisation of cells on cell migration.  
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While it is possible to acquire 3D images using a confocal microscope, the 
depth penetration is poor. Two-photon microscopy has significantly 
improved depth penetration compared to confocal microscopy, which, in the 
past, has made it the most suitable technique for imaging thick samples. 
However, imaging living samples over long time courses can be challenging 
due to the effects of photobleaching and phototoxicity (293). The 
development of lightsheet fluorescence microscopy (LSFM), also known as 
single-plane illumination microscopy (SPIM), has overcome some of these 
challenges and led to a revolution in the imaging of large (> 1 mm) biological 
samples. LSFM was developed by Huisken et al. in 2004 and uses a plane of 
light, provided by dual illumination objectives, to provide optical sectioning. 
The sheet of light illuminates only the focal plane of the detection objective, 
resulting in reduced photobleaching and phototoxicity compared to confocal 
microscopy (Fig 5.1A) (294, 295). The sample is suspended in a liquid-filled 
chamber where it can be moved through the light sheet to produce a z-stack 
(Fig 5.1B). Light is detected by a charge-coupled device (CCD) or CMOS 
camera, which allows for very fast image acquisition compared to traditional 
point-scanning confocal laser-scanning microscopy, which measures pixel by 
pixel.  This makes LSFM an ideal technique for imaging cell movement in a 
large, tightly packed spheroid when z-stacks need to be acquired in rapid 
succession to facilitate the tracking of cells. To track cells it is necessary to 
compare images taken at different time points and identify which cells are 
the same. To do this accurately, the distance moved by an individual cell 
between subsequent images needs to be less than the distance between 
neighbouring cells. The ability to track individual cells is crucial to 
quantifying cell movement and allows us to gain insights into cell behaviour 
that are not possible with population measurements.  
While the seminal paper describing LSFM was published in 2004, it was not 
until late 2012 that the first commercial instrument, the Lightsheet Z.1 by 
Zeiss, came onto the market. In 2014, a Lightsheet Z.1 was installed in the 
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Liverpool Centre for Cell Imaging; it was one of the first commercial 
instruments to be installed in the UK. We decided to take advantage of this 
new instrument carry out live cell imaging of spheroid invasion. We aimed 
to quantify the movements of cells moving within spheroids, as well as the 
movements of cells invading into ECM. We hypothesised that invading cells 
would show increased speed or persistence of movement compared to non-
invading cells. We further hypothesised that cell motility may be spatially 
regulated in spheroids, with cells in the core of spheroids showing different 
characteristics to cells near the spheroid periphery. We also aimed to 
evaluate the suitability of this technique as a 3D invasion assay by treating 
spheroids with drugs that are known to alter the invasive capacity of glioma 
cells.  
 
Figure 5.1. Lightsheet fluorescence microscopy. (A). The sample is excited by a sheet of 
light, shaped by cylindrical lenses, which provides optical sectioning by illuminating only 
the focal plane. The detection objective is at a 90° angle to the two illumination objectives. 
Adapted from (296). (B). Both the sample and detection objective are immersed in a liquid-
filled chamber. The sample can be rotated around the y-axis to acquire multiple views. 
Adapted from (297).  
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5.2 Results 
5.2.1 Optimisation of sample preparation 
As discussed in the previous chapter, we found that image resolution is 
reduced in the centre of large spheroids. While resolution can be improved 
using tissue clearing methods, these techniques are not suitable for live cells. 
Therefore, we decided to carry out the majority of our experiments using 
smaller, three-day-old spheroids (around 250 μm in diameter). A nuclear 
marker is necessary to enable the automated tracking of cells as it facilitates 
object recognition by the tracking software. We have previously found that 
nuclear stains show poor penetration in spheroids. Therefore, we decided to 
create a cell line stably expressing a fluorescent histone H2B nuclear reporter 
protein by transducing U87 cells with the pHIV-H2BmRFP construct 
generated by Welm et al. (298). The use of red-shifted fluorescent proteins 
(RFPs) results in reduced autofluorescence, light scattering, and 
phototoxicity, making RFPs the most suitable spectral fluorescent protein 
variant for live-cell imaging in thick samples (299). 
We used these cells to form spheroids using the hanging drop method, as 
previously described. The most typical approach for preparing small samples 
for imaging using LSFM is to embed them in a hydrogel, such as agarose, 
which has a refraction index close to that of water. We initially attempted to 
embed spheroids in 1% low-melt agarose; however, we found that this 
sample mounting method was not suitable because the cells did not invade. 
Furthermore, agarose is not an ideal embedding medium because it is not a 
physiological substrate. We next tried embedding spheroids in collagen IV 
and MaxGel ECM (Sigma); however, we again found that the cells did not 
invade. A further problem was that the gel columns were not firm enough to 
be suspended in the imaging chamber without swaying or disintegrating, 
making them unsuitable for long time courses.  
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An alternative to embedding samples in a hydrogel is to contain them in FEP 
tubing, which has a refraction index close to that of water (300). We 
embedded spheroids in a 1:1 mix of Matrigel and cell culture media plus 
25 mM Hepes in an FEP tube (Fig 5.2). As well as creating conditions suitable 
for stable long-term imaging, a further benefit of this approach is that the 
sample chamber can be filled with water instead of media. This means that 
there is no need to dismantle and sterilise the chamber after each use as 
contamination is not an issue. Furthermore, much smaller volumes of 
expensive reagents, such as drugs, are required because the volume of the 
FEP tube is much smaller than the volume of the sample chamber.  
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Figure 5.2. Lightsheet sample mounting. (A). Illustration of sample mounting procedure. (i) 
From left to right, Teflon plunger, glass capillary and FEP tube. (ii). The Teflon plunger is 
used to draw the sample into the FEP tube. (iii). One end of the FEP tube is inserted into a 
glass capillary and the other sealed with parafilm. (iv). The capillary is mounted within the 
lightsheet sample holder apparatus. (B). Image of Lightsheet Z.1 microscope. (1) The sample 
holder is inserted through the top of the microscope. (2). The sample is then lowered into the 
sample chamber, where it is immersed in water maintained at 37 °C for the duration of the 
experiment.  
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5.2.2 Image acquisition and processing 
We found that it was difficult to discriminate nuclei from one another in 
images taken > 150 µm deep into spheroids due to a loss of image resolution. 
LSFM allows the possibility of taking several z-stacks from different angles 
in order to achieve good resolution from multiple views. By carrying out 
multi-view registration, the z-stacks from different angles can be fused to 
reconstruct an image of the whole spheroid as shown in Video 1. Videos for 
this chapter are available to view online using the following URL: 
http://bit.ly/LSFM-RR. However, we chose not to conduct our analyses of 
invasion of reconstructed spheroids for several reasons. Firstly, the file size 
would be doubled which would greatly increase the processing time. 
Secondly, the registration process is imperfect and can result in loss of 
resolution where the images from different views have been fused. Finally, 
we felt that imaging whole spheroids was unnecessary as enough cells (800–
1200) can be detected in the first half of the spheroid. As such, we chose to 
image only half of the spheroids.  
A further initial challenge was the size of the experiments, up to 250 GB for 
one 24 h single-channel experiment, which were too large to be opened on 
any of our image analyses computers. It was necessary to acquire images 
every 3 min as we found that increasing this time interval led to problems 
with cell tracking. We tried acquiring images in 8 bit but found that 
bleaching towards the end of the experiment led to a loss of signal that was 
exacerbated by the low bit depth. Thus, we opted for acquiring images in 16 
bit, then downsampling to 8 bit and performing 2x binning. This was done 
using a macro in Fiji, which processed each time point individually. A 
further image registration step was required to correct for sample drift, as we 
found that by the end of the experiment the sample had often moved 
towards the edge of the field of view or drifted out of view entirely. 
Although the file size had been reduced to around 20 GB, we found that the 
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files were still too large for our analyses computers and that the computers 
would either fail to open the file or run out of memory before registration 
was complete. To resolve this issue, we had to order a new computer with 
more memory (128 GB of RAM). The problems we had because of the size of 
the data and our initial lack of a suitable computer meant there was a 
considerable delay between acquiring the data and being able to process it. 
For a summary of the post-acquisition processing steps and approximate 
processing times, see Fig 5.3.  
 
Figure  5.3. Summary of post-acquisition processing steps. Fiji is used to reduce file size by 
downsampling and binning, and then to register the images to correct for sample drift. The 
processed images are converted into the native Imaris file format, which compresses the file 
further. Imaris is used to carry out cell segmentation and tracking and to obtain tracking 
statistics. The tracking data is then further analysed using Matlab. Approximate file sizes 
and processing times are shown for small (~250 µm) spheroids; for larger spheroids, the file 
size is closer to 750 GB and processing times increased accordingly. Additional information 
about the image processing and analyses is detailed in Chapter 2, section 2.9. 
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We found that an initial sample drift tended to occur in the first three hours 
of the experiment, before cells had begun to invade. Therefore, we chose to 
mount spheroids on the lightsheet microscope immediately after embedding 
but to delay imaging for three hours after sample mounting, to allow the 
sample to stabilise. We aimed to image spheroids for 24 h; however, due to 
problems with the sample drifting out of view towards the end of the 
experiment, spheroids were imaged for between 16 and 24 h.  
 
5.2.3 Tracking cell movements in three-day-old spheroids  
We were successful in carrying out live cell imaging of cell migration and 
invasion in spheroids for up to 24 h (Fig 5.4A; Video 2 http://bit.ly/LSFM-
RR). We defined migration as the movement of cells within the spheroid, 
invasion as the movement of cells in ECM, and motility as any kind of cell 
movement. As we wished to quantify these movements, we used the cell 
tracking software Imaris to track the trajectories of individual nuclei. Further 
analyses of cell movements were carried out using MATLAB and generated a 
large number of graphs. While summary statistics and representative 
beeswarm plots and histograms are included throughout this chapter, the 
full set of graphs can be viewed online using the image management 
software Zegami at http://tiny.cc/2016-LSFM-RR. Cell tracking and data 
analyses methods are described in more detail in Chapter 2, section 2.9.4. 
We wanted to obtain information about two characteristics that are 
important in determining how far a cell moves from its point of origin: cell 
speed and persistence of movement. To track the movement of objects over 
time, Imaris carries out image segmentation by identifying the features (e.g. 
nuclei) in each frame, which are referred to as ‘spots’. The tracking algorithm 
then looks at the spots present at each time point and links together spots 
that should be part of the same track. The total number of spots in an 
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experiment is equal to the number of spots identified in each time point 
summed together; thus, there are many more spots than tracks. While the 
track data can give us information about the average movements of a cell 
over the course of the whole experiment, the spot data allows us to take a 
more detailed look at what is happening. For example, we can calculate the 
instantaneous spot speed for a given spot by dividing the distance between 
the preceding and proceeding spots by the time interval. This allows us to 
obtain the speed of each spot at any one moment in time. We found that spot 
speeds within a single spheroid were highly variable, ranging from 0.2 to 
214 µm/h (Fig 5.4B, C), as were spot speeds within a single track (Fig 5.4B). 
However, while a few spots were moving very fast, the mean spot speed was 
21 µm/h and this was consistent between spheroids (Fig 5.9B). 
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Figure 5.4. Tracking cell movements in three-day-old spheroids. (A). Maximum intensity 
projection images of a three-day-old U87-H2BmRFP spheroid embedded in 50% Matrigel, 
imaged at the indicated time points and tracked using Imaris. For imaging parameters, see 
Chapter 4, section 2.9.  Scale bar is 100 µm.  (B). Spot speed and straightness over a period of 
6 h for one randomly selected track. A straightness value of one indicates a direct path of 
movement while lower values indicate a less direct path. (C). Beeswarm plot of the speed of 
every spot (invading and non-invading) in one spheroid; the line indicates the mean value.  
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5.2.3.1 Analyses of spot speed and straightness  
We hypothesised that spot speed might vary according to whether cells were 
migrating within the spheroid or invading out into the Matrigel. As a higher 
proportion of cells have invaded by the end of the experiment, we also 
hypothesised that spot speed may vary over time. We found that mean spot 
speed was slightly higher in invading than non-invading cells; however, this 
difference was not significant (Table 5.1; Fig 5.6B). The distribution of spot 
speeds also remained consistent throughout the course of the experiment 
(Fig 5.6A).  
Figure 5.5. Definition of track straightness. Track straightness is calculated by dividing the 
track displacement by the total length of the track. Track displacement is the distance 
between the first and last spot position while track length is the total sum of the 
displacements within the track.  
In order to move away from its starting point, a cell needs to persist at 
moving in a certain direction. Persistence of movement can be measured by 
examining track straightness; a straightness value of one indicates that a spot 
is moving ‘as the crow flies’ while a straightness value closer to zero 
indicates a less efficient movement (Fig 5.5). We initially examined whether 
track straightness differed between invading and non-invading cells. 
However, by looking at a single straightness value for each track we run the 
risk of overlooking the variability that exists within the data set. As track 
straightness is akin to the average of spot straightness, it is not possible to 
look at the variation in spot straightness throughout the experiment and any 
extreme values will be averaged out. We chose to break track straightness 
down into windows of five time points (15 min in total) to gain greater 
insight into the movement of cells.  
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We found that spot straightness was highly variable over the course of the 
experiment and that spots frequently changed direction (Fig 5.4B; Video 3, 
http://bit.ly/LSFM-RR). As with spot speed, we then assessed whether spot 
straightness varied systematically as a function of spot position or time. 
There was a small but significant difference between invading and non-
invading spots, with invading spots having a higher straightness value 
(Table 5.1; Fig 5.7B). As with spot speed, spot straightness remained 
consistent throughout the experiment (Fig 5.7A). From this, we can conclude 
that invading cells are taking a straighter path of movement than cells 
migrating within the spheroid but moving at a similar speed. As both spot 
speed and straightness are consistent over time, we can be confident that 
spheroids are not adversely affected by the imaging conditions. Although 
there is an increase in invading cells towards the end of the experiment, this 
increase is not enough to affect the mean straightness value for the entire 
spheroid.  
Table 5.1 ǀ Three-day-old spheroid spot speed (µm/h) and straightness in 
non-invading and invading cells. The table shows the mean of three 
experiments ± SD. Ns = not significant.  
 Non-invading  Invading P value 
Spot speed  20.35 ± 1.24 23.83 ± 4.43 ns 
Spot straightness 0.64 ± .01 0.71 ± .012 .001 
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Figure 5.6. Three-day-old spheroid spot speed. (A). Normalised distribution of spot speed 
(invading and non-invading combined) in three spheroids as a function of time (t) from the 
start of imaging. (B). Normalised distribution of spot speed in invading and non-invading 
spots across all time points. Non-normalised graphs are available to view using Zegami at 
http://tiny.cc/2016-LSFM-RR. 
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Figure 5.7. Three-day-old spheroid spot straightness (A). Normalised distribution of spot 
straightness (invading and non-invading combined) in three spheroids as a function of time 
(t) from the start of imaging. (B). Normalised distribution of spot speed in invading and non-
invading spots across all timepoints. 
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5.2.4 The effects of drug treatment on invasion characteristics 
To assess the suitability of this technique as an assay for characterising 
inhibitors of invasion, we treated spheroids with 17-allylamino-17-
demethoxygeldanamycin (17-AAG) and cilengitide. Both drugs were added 
to the cell culture media during sample embedding. 17-AAG inhibits the 
growth and invasion of glioma cells by inhibiting heat shock protein 90 
(HSP90); a chaperone protein that regulates numerous signalling proteins, 
including those involved in cell proliferation, survival, migration and 
invasion (301-304). Cilengitide is an αvβ3 and αvβ5 integrin inhibitor with 
anti-tumour activity (305). Integrins are known to promote glioma growth 
and survival, and their central role in cellular adhesion and migration has led 
to the hypothesis that their inhibition may halt glioma invasion (306). 
However, evidence of the effect of cilengitide on invasion is mixed; while 
some reports document an anti-invasive effect (191, 307), others have found 
that it acts to promote migration and invasion (308, 309).  
 
Figure 5.8. The effects of cilengitide treatment on a monolayer culture. Cells treated with 
2 µM cilengitide for 24 h showed increased signs of rounding up and detaching from the 
dish Image is a representative example from one of two experiments. Scale bar is 100 µm. 
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We found that treatment with 0.5 μM 17-AAG clearly inhibited invasion (Fig 
5.9A; Video 4, http://bit.ly/LSFM-RR). In contrast, treatment with 2 µM 
cilengitide did not inhibit invasion (Fig 5.9A; Video 5, http://bit.ly/LSFM-
RR), although this concentration was sufficient to cause detachment in a 
monolayer culture (Fig 5.8). There was no difference in mean spot speed or 
straightness between control spheroids and cilengitide treated spheroids (Fig 
5.9B). In cilengitide treated spheroids, both mean spot speed and straightness 
were higher in invading than non-invading spots (Table 5.2). There was no 
difference in mean spot speed and straightness throughout the experiment. 
Therefore, cilengitide did not have any effect on migration or invasion out of 
spheroids. Conversely, in 17-AAG treated spheroids mean spot speed was 
significantly lower than in control spheroids (Fig 5.9B). While some spots 
were moving very fast, a higher proportion of spots were moving at a lower 
speed than in the control spheroids (Fig 5.9C). Mean spot straightness was 
also significantly lower in 17-AAG treated spheroids (Fig 5.9B). We found no 
difference in mean spot speed between invading and non-invading spots, 
although spot straightness was significantly increased in invading spots 
(Table 5.2). We also found that mean spot speed was significantly slower 
after 16 h (M = 11.77, SD = 0.57) compared to the beginning of the 
experiment (M = 17.60, SD = 0.57, p = 03), although there was no difference 
in spot straightness. This indicates that while 17-AAG treated cells are able to 
migrate within the spheroid, their speed and straightness of movement are 
reduced and they are unable to invade into the Matrigel. The reduction in 
spot speed over time is most likely to be a reflection of the time it takes for 
the drug to become effective.  
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Figure 5.9. Treatment with 17-AAG inhibits invasion in spheroids; cilengitide does not. 
Three-day-old spheroids were embedded in 50% Matrigel plus 0.5 μM 17-AAG or 2 μM 
cilengitide and imaged with LSFM. (A). Maximum intensity projection images of spheroids 
at the indicated time points. For imaging parameters, see Chapter 4, section 2.9.  Scale bar is 
100 µm. (B). Spot speed and straightness (invading and non-invading combined) were 
significantly reduced in spheroids treated with 17-AAG compared to control spheroids. 
Figure shows mean + SEM of three experiments. (C). Beeswarm plots of spot speed in 
spheroids treated with 17-AAG or cilengitide. Plots are representative examples from one of 
three experiments. The line indicates the mean value.  *** p ≤ 0.001 
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Table 5.2 ǀ 17-AAG and cilengitide treated spheroid spot speed (µm/h) and 
straightness. The table shows the mean of three experiments ± SD. Ns = not 
significant.  
  Non-invading  Invading P value 
Cilengitide Spot speed 20.66± 1.32 23.64 ± 1.05 .038 
 Spot straightness 0.64 ± .01 0.69 ± 0.01 .001 
17-AAG Spot speed 13.79 ± 0.69 16.24 ± 5.19 ns 
 Spot straightness 0.60 ± .01 0.70 ± 0.03 .011 
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Figure 5.10. 17-AAG treated spheroid spot speed and straightness over time. Normalised 
distribution of (A) spot speed and (B) spot straightness in three spheroids as a function of 
time (t) from the start of imaging (invading and non-invading spots combined).  
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5.2.5 Plotting spheroid invasiveness 
We wished to find a simple way of comparing the invasiveness of spheroids. 
From the beeswarm plots of invading spot speed, we can see that both the 
number and speed of invading spots is reduced in spheroids in which 
invasion has been inhibited (Fig 5.11A). However, the number of invading 
spots will vary according to the size of the spheroid. Another way of 
determining spheroid invasiveness is to plot the normalised cumulative 
number of spots by distance, over time. In invasive spheroids, the spatial 
distribution shifts over time as cells invade out into the Matrigel, while in 
non-invasive spheroids the distribution remains the same (Fig 5.11B).  
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Figure 5.11. Quantifying spheroid invasion. (A). Beeswarm plots of invading spot speed in 
a single control, 17-AAG or cilengitide treated spheroid. The line indicates the mean value. 
(B). Normalised cumulative number of spots in a single spheroid (invading and non-
invading combined) by distance as a function of time (t) from the start of imaging. In the 
control and cilengitide experiments, the curve shifts to the right over time as cells invade out 
from the spheroid. In 17-AAG treated spheroids, the curve remains the same because 
invasion is inhibited.  
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5.2.6 Imaging larger, hypoxic spheroids 
We conducted our initial experiments using three-day-old spheroids as their 
smaller size allows for increased resolution throughout the spheroid and 
decreased file size compared to one-week-old spheroids. While smaller 
spheroids are easier to image, gradients in soluble factors typically do not 
occur until spheroids reach ~500 µm. To increase the complexity of our 
model, we next examined invasion in larger, one-week-old spheroids that 
had been incubated in 1% O2 for 24 h (Fig 5.12A; Video 6). We have 
previously shown that, under these culture conditions, proliferation is 
restricted to the periphery of the spheroid (Chapter 4, Fig 4.3). It is also well 
known that exposure to hypoxia increases invasiveness (196, 310). We 
wanted to assess whether spot speed and straightness differed between 
three-day-old spheroids and one-week-old spheroids that had been exposed 
to hypoxia. We were also interested in whether spot speed and straightness 
in larger spheroids would vary according to the spatial location of spots.  
We found that mean spot speed was significantly lower in one-week-old 
spheroids compared to three-day-old spheroids (Fig 5.12C, D; Video 7) and 
invasion reduced (Fig 5.12A, B). We next examined the spatial distribution of 
spot speeds and found that spot speed was significantly higher in invading 
than non-invading spots (Table 5.3). To determine whether there was a 
relationship between spot speed and the position of the spot within the 
spheroid, we divided spheroids into three regions: core, middle and outer. 
We found that spot speed did not vary between the three regions (Figure 
5.13B) and was consistent throughout the course of the experiment (Fig 
5.13A).  
We next examined track straightness and found that it was significantly 
lower in one-week-old spheroids compared to three-day-old spheroids (Fig 
5.12D). We again found that mean spot straightness was significantly higher 
in invading than in non-invading spots, but remained constant throughout 
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the course of the experiment (Table 5.3; Fig 5.14A). Additionally, we found 
that mean spot straightness was significantly lower in the inner region of the 
spheroid, compared to the middle and outer regions (Fig 5.14B). In summary, 
we conclude that spot speed has been affected by the change in culture 
conditions compared to the three-day-old spheroids, and that spot 
straightness is reduced in the core of larger, hypoxic spheroids. An increase 
in cell stress caused by the oxygen-deprived environment in these spheroids 
may contribute to the changes in speed and straightness that we have 
observed.  
Table 5.3 ǀ One-week-old spheroid spot speed (µm/h) and straightness in 
non-invading and invading cells. The table shows the mean of three 
experiments ± SD.  
 Non-invading  Invading P value 
Spot speed  15.95 ± 0.08 19.46 ± 1.18 .007 
Spot straightness 0.61 ± 0.02 0.70 ± 0.01 .001 
 
  
Chapter 6                                                                                                                   121 
 
Figure 5.12. Spot speed and straightness are reduced in larger, hypoxic spheroids. 
Spheroids were cultured for 6 days in 20% O2 followed by 24 h in 1% O2. (A). Maximum 
intensity projection images of one-week-old spheroids imaged at the indicated time points. 
For imaging parameters, see Chapter 4, section 2.9. Scale bar is 100 µm.  (B). Spot speed and 
straightness (invading and non-invading combined) were significantly reduced compared to 
three-day-old spheroids. Figure shows the mean + SEM of three experiments. (C). Beeswarm 
plot of the speed of every spot in one spheroid (invading and non-invading combined); the 
line indicates the mean value. (D). Mean spot speed and spot straightness in 3 day old and 1 
week old spheroids. * p < .05, ** p > .01.   
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Figure 5.13. One-week-old spheroid spot speed. (A) Normalised distribution of spot speed 
(invading and non-invading combined) in three spheroids as a function of time (t) from the 
start of imaging. (B) Normalised distribution of spot speed in three spheroids as a function 
of the starting position of the spot, defined by radial distance (d) from the centre of the 
spheroid. Spheroids were spatially divided into three regions: core, middle and outer. The 
region outside of the spheroid boundary, represented by the purple line, indicates invading 
spots.  
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Figure 5.14. One-week-old spheroid spot straightness as a function of time and space. (A). 
Normalised distribution of spot straightness (invading and non-invading combined) in three 
spheroids as a function of time (t) from the start of imaging. (B). Normalised distribution of 
spot straightness in three spheroids as a function of the starting position of the spot, defined 
by radial distance (d) from the centre of the spheroid. Spheroids were spatially divided into 
three regions: core, middle and outer. The region outside of the spheroid boundary, 
represented by the purple line, indicates invading spots. 
  
Chapter 6                                                                                                                   124 
5.2.6.1 The effects of 17-AAG treatment in one-week-old spheroids  
We next assessed the response to 17-AAG in one-week-old spheroids that 
had been incubated in 1% O2 for 24 h. We wanted to confirm that the 
effectiveness of 17-AAG was not affected by the increased size of the 
spheroid. We found that, as in the three-day-old spheroids, 17-AAG 
effectively inhibited invasion (Fig 5.15A) and that mean spot speed and 
straightness were decreased compared to untreated spheroids (Fig 5.15B, C). 
As in the untreated one-week-old spheroids, we found that spot straightness 
was reduced in the core of the spheroid compared to the outer two regions, 
while spot speed did not vary (Fig 5.15D). From these results, we can 
conclude that the effect of 17-AAG is not altered in larger, hypoxic spheroids 
compared to three-day-old spheroids.  
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Figure 5.15. 17-AAG inhibits invasion in larger, hypoxic spheroids. Spheroids were 
cultured for 6 days in 20% O2 and 24 h in 1% O2., embedded in 50% Matrigel plus 0.5 μM 
17-AAG and imaged for 16 h. (A). Normalised cumulative number of spots by distance over 
time (t) from the start of imaging. (B). Beeswarm plot of the speed of every spot (invading 
and non-invading) in one spheroid; the line indicates the mean value. (C). 17-AAG treated 
spheroid spot speed and straightness (N = 1) were reduced compared to untreated spheroids 
(N = 3). For untreated spheroids, figure shows the mean + SEM. (D). Normalised 
distribution of spot speed and straightness as a function of the starting position of the spot 
within the spheroid, defined by radial distance (d) from the centre of the spheroid.  
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5.3 Discussion 
To our knowledge, this is the first use of lightsheet microscopy as a tool for 
imaging cellular invasion in multicellular tumour spheroids. We have 
optimised the imaging of spheroids, from sample preparation through to 
image processing and data analyses. We have shown that it is possible to 
track the movement of up to 1200 cells per spheroid, and quantify these 
movements in terms of speed and straightness. While spheroids have 
previously been used to investigate invasion, these investigations have been 
limited by the available imaging techniques. We have been able to track the 
migration of individual cells within spheroids as well as the invasion of cells 
out of spheroids. We have also been able to collect information about the 
movement of cells in the z dimension, making this a truly three-dimensional 
invasion assay. 
Our aim was to conduct a feasibility study to assess the suitability of LSFM 
as a tool for investigating migration and invasion in spheroids; as such, we 
have not investigated the molecular mechanism of the changes we have 
detected. It is clear from our results that 17-AAG prevents the invasion of 
cells into the Matrigel but does not prevent their migration within the 
spheroid. However, the movement of cells inside 17-AAG treated spheroids 
is slower and less direct than in control spheroids. 17-AAG affects many 
signalling proteins through its inhibition of HSP90, including numerous 
proteins involved in cellular adhesion and motility, making it difficult to 
pinpoint the mechanism through which invasion is inhibited (302, 303, 311). 
However, it has been shown that treatment with 17-AAG blocks hyaluronic 
acid-induced MMP-9 secretion, impairing cells ability to degrade the ECM 
and reducing their invasiveness (304). The average pore size of 50% Matrigel 
is 2 µm and it has been shown that at pore sizes of less than 7 μm cells are 
unable to migrate unless they are able to degrade the ECM (312, 313). The 
rate-limiting factor is the nucleus, which can only deform to 10% of its 
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original cross section. This suggests that MMP activity is essential to invasion 
in our experiments due to the small pore size of the Matrigel. The inhibition 
of MMP-9 by 17-AAG may provide an explanation for why cells are able to 
migrate within the spheroid but not invade into the Matrigel; to confirm this 
hypothesis it would be necessary to use a more specific inhibitor of MMP-9 
activity. Although 17-AAG successfully inhibits invasion in vitro, it has been 
unsuccessful in clinical trials due to a poor pharmaceutical and toxicity 
profile. Second-generation HSP90 inhibitors with improved bioavailability 
and reduced toxicity are currently under clinical development  (314).  
In contrast to 17-AAG, we found that cilengitide was not effective in 
inhibiting invasion and, furthermore, we could not detect any differences 
between spheroids treated with cilengitide and control spheroids. It has been 
shown that cilengitide reduces cell viability by causing detachment and 
anoikis. U87 cells are resistant to anoikis and their sensitivity to cilengitide-
induced detachment is dependent on the composition of the ECM. While 
cells cultured on vitronectin-coated plates show increased detachment, cells 
cultured on collagen or fibronectin-coated plates resist detachment (315, 316). 
Blocking the action of integrins reduces cellular adherence, which can have 
different effects depending on the environment. Zaman et al. have shown 
that blocking β1 integrin activity retards the movement of cells in high 
concentrations of Matrigel (>60%); however, invasion speed is significantly 
increased in lower concentrations of Matrigel (312). Several in vitro studies 
have found that cilengitide can increase the speed of migration and invasion 
(309, 316), while studies in animal models have demonstrated an anti-
invasive effect (191, 192). However, despite promising results in phase II 
clinical trials, cilengitide did not improve outcomes in a phase III study and 
is no longer being developed as an anti-cancer drug (317). The effect of 
cilengitide on invasion remains far from clear, although ECM composition 
may be key in determining its effectiveness. The discrepancies in results 
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between studies can most likely be explained by the differences in the 
methods used to investigate invasion.  
We have found that cells in three-day-old spheroids are capable of moving 
up to 214 µm/h, with a mean invading spot speed of 24 µm/h. These 
findings correlate well with the results of an investigation by Farin et al. in 
which glioma cells were injected into neonatal rat forebrains. Glioma cell 
invasion was investigated in slice cultures generated from these brains using 
an inverted microscope. They analysed cells in the infiltrative margins of 
tumours and found that they reached speeds of over 100 µm/h, with an 
average speed of 25 µm/h. They also found that cells migrated in a saltatory 
fashion, with periods of stillness followed by bursts of movement and 
frequent direction changes (172). The similarity of our findings with those of 
Farin et al. suggests that, in certain circumstances, our model could be used 
as an alternative to investigations in animal models.  Indeed, our approach 
has overcome some of the limitations faced by Farin et al. They were unable 
to track cells within the tumour itself and, as data was collected from a single 
focal plane, were only able to track the movements of cells in the x-y plane. 
Alternatives to animal models are necessary not only to fulfil the principles 
of the 3Rs, but also to improve the translation of results from the bench to the 
bedside. Crucial physiological differences between humans and animals, and 
a failure to accurately replicate the disease under investigation, mean that 
less than 8% of the successes achieved in animal studies are translated to 
clinical cancer trials (318). The use of spheroids in preclinical drug screening 
assays can lead to more effective selection of compounds, reducing the 
number of compounds that need to be tested in animals (220).    
We found that spot straightness was consistently increased in cells that were 
invading into the Matrigel compared to cells that were migrating within the 
spheroid. These changes in movement most likely reflect a response to the 
change in microenvironment. The speed and mode of cellular invasion are 
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modulated by properties of the ECM such as composition, matrix stiffness 
and pore size (312, 313, 319, 320). At around 10 Pa, 50% Matrigel is much 
more pliable than brain tissue, which is in the region of 300 Pa (312, 321). 
Although many tumours have been found to be stiffer than the surrounding 
tissue, gliomas are not. This may be because the unique ECM of the brain 
means that the gliomas cannot form the filamentous ECM that is common in 
other tumours (186, 321). Matrigel consists mainly of laminin and collagen, 
which means it does not resemble brain parenchymal ECM but is similar to 
the vascular basement membrane. Therefore, our model mimics the 
composition of the ECM encountered by glioma cells during perivascular 
migration. However, we have not attempted to recreate the mechanical or 
structural properties of this microenvironment.   
We found that cells in one-week-old spheroids that had been incubated in 1% 
O2 for 24 h moved slower and less straight than cells in three-day-old 
spheroids that had been incubated in 20% O2. This is contrary to what we 
expected as hypoxia is known to increase the invasiveness of cells (196). 
However, we did not examine the invasiveness of one-week-old spheroids 
that had not been exposed to hypoxia. It is possible that it is the age and size 
of the spheroid that causes the reduction in cell speed and straightness, 
rather than the exposure to hypoxia. We also found that spot straightness 
was reduced in the core of larger spheroids, although spot speed was 
unaffected. The change in straightness may reflect a response to the harsher 
environment found in the core of spheroids, although further investigations 
would be necessary to confirm whether this is indeed the case.  
Wu et al. examined the migration of single cells through a 3D collagen matrix 
and found that, in contrast to 2D migration, 3D migration does not follow a 
random walk. Rather, cells migrating in 3D show a spatially anisotropic 
velocity pattern; they move faster along their primary migration axis, defined 
by the primary direction of migration, than the perpendicular axis (322). In 
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contrast to our results, they found that migration speed and persistence were 
correlated. However, Wu et al. examined the movement of single cells within 
a matrix, rather than the movement of cells within a large heterogeneous 
spheroid. The movement of cells within spheroids is a topic of interest that 
has previously been difficult to examine experimentally. Early experiments 
by Dorie et al. showed that labelled cells and polystyrene microbeads are 
internalised into the spheroid, suggesting that cells are moving away from 
the nutrient-rich surface of the spheroid towards the necrotic core (323). 
Mathematical models attempting to explain this finding have concluded that 
the mechanical pressure of proliferating cells creates pressure gradients, 
driving cells towards the centre of the spheroid (324). The motility of cells 
within spheroids have been addressed by a number of mathematical models 
which attempt to explain the typical structure of a large spheroid, where the 
majority of cells are quiescent but surrounded by a proliferating rim of cells. 
These models are based on assumptions about pressure gradients, 
chemotaxis and the relationship between cell cycle status and migration, 
often obtained from studies conducted in 2D (324-327). Furthermore, they 
fail to take into account important factors such as the composition and 
mechanical properties of the surrounding ECM. The paucity of experimental 
data on cell motility in 3D, and in spheroids in particular, has hampered the 
development of these models and limited their complexity (328).  
While we have examined the straightness of movement of cells, we have not 
addressed the directionality of their movements in relationship to the core of 
the spheroid. The directionality of the cells can be calculated using the spot 
position information we have collected; however, due to the time-limited 
nature of this project, we have only been able to carry out limited analyses of 
the data. Collaboration with mathematicians would be necessary to facilitate 
the assessment of directionality and enable deeper analyses of the data. A 
further question of interest is the relationship between proliferation status 
and invasion. The ‘go or grow’ hypothesis postulates that cellular 
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proliferation and invasion are mutually exclusive phenotypes. While 
proliferation and invasion have been shown to be temporary mutually 
exclusive, several studies have shown that migratory cells proliferate en 
route (172, 329). Furthermore, some studies have found a positive correlation 
between proliferation and migration, refuting the idea of a dichotomy 
between the states of ‘go’ and ‘grow’ at the population level (330). Using our 
technique, it is possible to test the relationship between proliferation and 
motility in spheroids. It is hoped that further analyses of our data by our 
group and others will address some of the questions that we have as yet been 
unable to address.   
The challenges of manipulating such large files were greater than we 
expected and resolving these issues was time-consuming. Even when we had 
tracked the spheroids and no longer had to deal with large image files, we 
found that data manipulation was slow due to the number of data points, 
which could exceed half a million for a single spheroid (1200 spots x 460 time 
points). We conducted 16–24 h time courses as we did not know how 
spheroids would be affected by the embedding and imaging protocol and 
how motility might change over time.  However, our results indicate that this 
technique is sensitive enough to detect small changes in motility and that 
long time courses are not necessary to characterise the effects of anti-invasive 
drugs. An alternative approach would be to treat spheroids with the 
compound of interest and then image them for 1–2 h only. This would 
significantly reduce file size and processing time, increasing the number of 
spheroids that could be analysed. Another way of reducing the amount of 
data would be to label only a proportion of the cell nuclei. As well as 
reducing the number of cells that need to be tracked this would also enable 
less timepoints to be acquired; as the spheroid would not be as densely 
packed with labelled cells the time interval between image acquisitions could 
be increased without detriment to the cell tracking.  
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We have demonstrated that LSFM is a powerful tool for investigating cellular 
motility and invasion in 3D. Using the technique we have developed, it is 
possible to investigate the effect of different aspects of the tumour 
microenvironment on cellular motility in a spheroid model. It is also possible 
to gain quantitative information about cell movements in a 3D environment. 
This technique holds promise as an assay for screening and investigating the 
mechanism of anti-invasive drugs, contributing to the principles of the 
replacement and reduction of the use of animals in experimental research. 
We hope that this technique will be of use to other investigators and will 
contribute towards furthering our understanding of the mechanisms of 
invasion and the ways in which it can be inhibited.  
Chapter 6                                                                                                            133 
 
 
 
 
 
Chapter 6: 
Discussion 
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6.1 Revisiting the thesis aims   
The overall aim of this thesis was to investigate the effect of the solid tumour 
microenvironment on GBM cells. More specifically, we sought to understand 
how cell proliferation is affected by the low oxygen levels that are 
characteristic of this environment. We performed a systematic investigation 
into the effect of different oxygen levels on cell proliferation and found that, 
in monolayer cultures, pathophysiological levels of hypoxia do not affect cell 
proliferation.  These results were unexpected, as previous investigations had 
indicated that hypoxia causes cell cycle arrest; however, these experiments 
were carried out in near anoxic conditions. Our results demonstrated the 
importance of using physiologically relevant conditions when investigating 
components of the tumour microenvironment.  
We then aimed to improve our model by exploring the effect of hypoxia in 
GBM cells cultured as multicellular tumour spheroids. We had originally 
hoped to characterise spheroids using LSFM; however, we were unsuccessful 
in performing immunofluorescence in whole spheroids. Instead, we 
characterised spheroids by fixing, sectioning and staining them before 
imaging them with confocal microscopy. We were again surprised by our 
results when we found that, in the spheroid model, hypoxia is associated 
with quiescence. Our findings indicate that, in GBM, hypoxia may act as a 
general stressor rather than a specific regulator of cell cycle. They also 
suggest the existence of a threshold which, when reached, informs the cell 
that conditions are unfavourable for proliferation and causes cell cycle arrest. 
While hypoxia alone does not affect cell proliferation, additional stressors 
present in the 3D tumour microenvironment cause this critical threshold to 
be reached.  
Lastly, we aimed to use LSFM to carry out live cell imaging of cellular 
migration and invasion in spheroids. We further aimed to quantify the 
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movements of cells moving within spheroids, as well as the movements of 
cells invading into ECM. We also aimed to assess the suitability of this 
technique as a 3D invasion assay for characterising the effects of drugs that 
target the invasion process. We were successful in achieving these aims; as 
far as we are aware, we are the first to carry out live cell imaging of invasion 
in multicellular tumour spheroids using LSFM. We have developed a novel 
and truly 3D assay, which can be used to investigate the effect of different 
environmental factors or therapeutic compounds on cellular invasion.   
 
6.2 The challenges of 3D cell culture   
3D cell culture is one of the fastest growing areas in biology (331). However, 
despite the development of the multicellular tumour spheroid model 45 
years ago, the overwhelming majority of in vitro investigations into cancer 
cell biology are still carried out in monolayer cultures. A number of factors 
may have contributed to the slow uptake of 3D cell culture. New methods for 
culturing cells in 3D are constantly emerging. However, many of these 
methods, such as magnetic cell levitation, are complicated and have niche 
applications (332). The use of different culture methods by different 
investigators can limit the usefulness of the results obtained; it is important 
that a common approach to 3D cell culture is adopted so that results can be 
compared and replicated. Multicellular tumour spheroids are most well-
characterised 3D cell culture model; although, within this approach there are 
numerous methods for forming spheroids. The choice of culture method can 
be challenging, especially as the most appropriate method varies according 
to the cell line used. For example, some cells will readily form spheroids in 
ultra-low-adherence plates, while others will not. The cost of additional 
equipment, such as rotary cell culture systems or specialised plates, may also 
have hindered the uptake of 3D cell culture. The analyses of 3D cell cultures 
can also be challenging; many assays that have traditionally been used in 
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monolayer cultures are either not compatible with 3D cell cultures, or require 
adaptation. Until recently, high-throughput screening (HTS) has been 
restricted to monolayer cultures (333). However, advances in technology 
have made it possible to automate the production of large numbers of 
homogeneous spheroids and are leading to an increase in the uptake of this 
approach (224, 334-337).  
 
6.3 Increasing the complexity of 3D cultures 
One important aspect of the microenvironment that we did not attempt to 
replicate in this thesis is the interaction between tumour cells and 
parenchymal or stromal cells. Such interactions are known to influence 
important aspects of glioma biology, such as cellular metabolism and 
invasion (Chapter 1, Section 1.5.1). These interactions can be investigated in 
monolayers, spheroids, tissue explants or in vivo (Fig 6.1). While more 
complex models are more physiologically relevant, they are also more 
challenging to investigate. The relevance of cell culture models can also be 
improved by the use of primary cells. We used primary cells to confirm the 
results obtained in cell lines in Chapter 3; with more time, we would have 
liked to have cultured primary cells as spheroids and imaged them using 
LSFM. We would also have liked to carry out co-cultures of GBM cells and 
astrocytes in spheroids. However, as immortalised astrocyte cell lines are not 
available, it is necessary to work with primary cells, which can be difficult to 
obtain and cannot be maintained in culture. While the use of primary cells 
and co-cultures are an important step towards increasing the physiological 
relevance of 3D cell culture models, the inherent heterogeneity of these 
models means that they are less well suited to HTS.  
In vivo investigations in animal models capture aspects of the tumour 
microenvironment that can be difficult to replicate in cell culture. However, 
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animal models are costly and fail to replicate many important aspects of 
human physiology and pathology (318). An investigation into the effect of in 
vivo growth on GBM gene expression by Camphausen et al. demonstrated the 
importance of orthotopic conditions. This refers to the transplantation of cells 
into the organ which they are derived from, which in GBM is the brain. 
Numerous differences in gene expression occur when cells are transplanted 
subcutaneously and intracerebrally, with cells grown intracerebrally 
expressing more genes related to CNS function. Interestingly, U87 and U251 
cells have divergent gene expression profiles in monolayer or subcutaneous 
growth conditions that become more similar when grown intracerebrally. 
These results demonstrate the importance of the tumour microenvironment 
on gene expression. The unique microenvironment of the brain means that it 
is especially important that animal models of GBM are orthotopic. Zebrafish 
are a popular model organism because of their optical clarity and rapid 
development and have been imaged extensively using LSFM (338-340). Lal et 
al. injected U87 cells into the brains of zebrafish, which they imaged using 
confocal microscopy (177). They observed the migration of GBM cells along 
blood vessels and found that cells did not metastasise outside the brain, 
suggesting that zebrafish may be a useful model organism for GBM. As 
LSFM is the ideal technique for the in vivo imaging of zebrafish, an 
interesting and novel approach would be the use of LSFM to investigate 
GBM invasion in a zebrafish model.  
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Figure 6.1. Biological models for cancer research. Cancer biology can be investigated in 
monolayer cell cultures, in 3D cell culture models, in whole organs or sections of organs, in 
animals, or in humans. Each of these models presents its own challenges and advantages. A 
more complex model is not necessarily always a better option than a model of lesser 
complexity, as the most appropriate method is often determined by the hypothesis under 
investigation. Figure produced using images adapted from (341-343).  
 
6.4 Technological advancements in lightsheet 
microscopy  
We were only able to track the movements of around half of the cells present 
in  spheroids, due to a loss of image resolution towards the core of spheroids 
and the difficulty of fusing multiple sample views. Since the development of 
LSFM, investigators have been continuously working to improve the spatial 
resolution and imaging depth penetration of this technique. Increasing the 
number and type of biological samples that can be imaged, in as natural a 
setting as possible, is another area of intensive investigation. The standard 
configuration of a lightsheet microscope, consisting of two excitation 
objectives mounted perpendicularly to a single detection objective, has been 
adapted to suit different aims and sample types. Conventionally mounted 
samples can now be imaged using an inverted lightsheet microscope (iSPIM), 
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removing the need to embed samples in hydrogels. In an iSPIM set-up, the 
illumination pillar of an inverted microscope supports a single excitation 
objective and a detection objective, mounted perpendicular to each other. 
The excitation and detection objectives are positioned above the sample and 
the lightsheet is scanned through the sample using a galvanometric mirror 
(344). The spatiotemporal resolution of this approach has been improved by 
alternating excitation and detection between the two objectives (dual-view 
illumination SPIM [diSPIM]). This allows for fast acquisition of two views of 
the sample (Fig 6.2) (345). However, it is worth noting that the successful 
merging of the two views is required in order to achieve improved spatial 
resolution. Additionally, the acquisition of multiple views by any means will 
increase the amount of data collected. Another approach to improving the 
resolution of LSFM is to combine it with two-photon excitation (346). 
Recently, two-photon excitation has been implemented in an iSPIM set-up 
(347). The development of iSPIM means that more types of biological 
samples can be imaged using LSFM and the advent of 3D printing means 
that it is easier than ever to make custom-built holders for these samples. 
Both iSPIM and diSPIM sets-ups are now available to purchase as a kit (348). 
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Figure 6.2. Dual-view inverted single plane microscopy (diSPIM). Dual objectives are 
mounted perpendicular to each other on the illumination pillar of an inverted microscope. 
Light sheet excitation is produced by objective A and detected on camera B through dichroic 
mirrors, emission filters and lenses. The piezoelectric stage moves the detection objective in 
synchronisation with the light sheet. To obtain a second view, excitation is switched to 
objective A and detection switched to camera B. Adapted by permission from Macmillan 
Publishers Ltd [Nature Biotechnology] (345) © 2013.   
LSFM is being used for diverse applications, from single molecule to whole 
organism imaging (338, 349, 350). For optimal imaging conditions, it has 
become clear that the microscope needs to be adapted to suit the sample of 
interest. One of the disadvantages of purchasing a commercial, rather than a 
home-built, lightsheet microscope is that it cannot be adapted to suit 
different samples or address different questions. However, in multi-user 
microscopy facilities, commercial microscopes have the advantage of being 
simple to use. Furthermore, in this scenario, it is not possible to have a 
purpose-built microscope for each investigator. A major improvement in the 
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field of LSFM would be the development of an instrument that has the 
flexibility to image a broad variety of samples, without compromising image 
quality or sample physiology. One promising approach is swept, confocally-
aligned planar excitation (SCAPE) microscopy, which provides light sheet 
excitation and detection using a single objective. The only component that is 
required to move is the scanning mirror, allowing for high-speed image 
acquisition in a variety of biological samples. SCAPE has been used to image 
whole body movements and muscle and heart contractions in freely moving 
Drosophila larvae, as well as neuronal calcium signalling in the cortex of an 
awake, behaving mouse (351). 
 
6.5 The future: LSFM for 3D high-throughput 
screening 
Conventional LSFM is incompatible with HTS, which requires the analyses 
of 96-well or 386-well plates. While iSPIM is compatible with tissue culture 
dishes and plates, it is not suitable for imaging multi-well plates because of 
their geometry (352). Francesco Pampaloni’s group, who are based at the 
Buchmann Institute for Molecular Life Sciences in Frankfurt, are developing 
an LSFM set-up specifically designed for HTS of 3D cell cultures (353). They 
have pioneered the fabrication of multi-well plates from FEP film and are 
developing a synthetic hydrogel to support the physiological growth of 3D 
cell cultures (354). This approach is being applied to the production of 
pancreas organoids for the cellular therapy of type 1 diabetes 
(http://lsfm4life.eu). As well as contributing to the development of cellular 
therapies, this technique will change the landscape of drug discovery and 
toxicity screening in 3D cell cultures. The use of LSFM for HTS is set to 
become a reality in the near future; however, the enormous amounts of data 
this will generate will be extremely challenging to deal with.  
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The efficient processing of lightsheet data requires investment in computing 
facilities so that processing can be parallelised. Parallel processing can be 
achieved using multiple computers linked together in a cluster, or by using a 
single machine capable of general-purpose computing on graphics 
processing units (GPGPU computing). Neither of these methods was 
accessible during the course of this project; while the processing of lightsheet 
data was still possible, it was extremely time-consuming. Even when parallel 
processing is employed, image processing and data analyses is the main 
obstacle that needs to be overcome in order to increase the throughput of 
LSFM. Ideally, image processing and analyses should be carried out in real 
time. Schmid and Huisken have developed a method of carrying out real-
time multiview deconvolution using GPGPU computing, which reduces 
processing times by a factor of 25 and 75 compared to processing with and 
without GPU support, respectively (355). We have benefited from 
advancements in image analyses software that allow for straightforward, 
automated and reproducible image segmentation and cell tracking. Before 
such technology was available, cell tracking had to be performed manually, 
which is both challenging and extremely slow. The next logical step would 
be to develop online image segmentation and tracking. This would represent 
a major advance in biological imaging and analyses.  
An additional challenge posed by the use of LSFM for HTS is the storage of 
such large amounts of data. Our group are fortunate enough to have access 
to a 60TB server, which was adequate for this project. However, a server of 
this size would be nowhere near adequate for the amount of data generated 
by HTS. The huge amount of data generated by LSFM is forcing the 
lightsheet microscopy community to reassess what we consider to be raw 
data. In some cases, it is simply not possible to store all of the raw image 
files. An alternative option is to keep only the compressed or processed data 
and then delete the original files (293).   
Chapter 6                                                                                                                   143 
6.6 Final remarks 
Initially, the aim of this thesis was to carry out an in-depth investigation into 
the relationship between hypoxia and the cell cycle. However, such 
relationships must always be considered within the broader context of the 
cellular environment. Tumours and their microenvironment are 
characterised by heterogeneity, which is one of the reasons cancer is so 
difficult to treat. Cancer is not a single disease with a single cause, and the 
historical approach of treating cancers of the same tissue as one disease is 
proving to be outdated. Tumours such as GBM can be categorised into 
different molecular subtypes, reflecting different origins and characteristics, 
with important implications for treatment. Thus far, despite many attempts 
to develop new therapies, there has been little progress in treating GBM. 
Tumour heterogeneity, the challenge of developing compounds that cross 
the BBB and the diffuse invasion of cells all contribute to the difficulty of 
treating this disease. As GBM has a diffusely infiltrating pattern from its 
inception, inhibiting invasion may be a case of ‘shutting the stable door after 
the horse has bolted’. However, as invasiveness is a characteristic common to 
residual cells, a better understanding of this process may aid the 
development of therapies that can specifically target residual cells (39).  
We have developed a 3D invasion assay that can be used to investigate the 
mechanisms of invasion. Technological and methodological advances mean 
that, in the near future, this assay could be used in a HTS approach to 
identify molecules that inhibit invasion and provide information on their 
mechanism of action. The use of 3D cell cultures for HTS will improve the 
translation of results from the bed to the bedside and further developments 
in 3D culture systems may allow future investigators to more closely 
replicate the solid tumour microenvironment in vitro. Modern biology 
increasing requires a multi-disciplinary approach. This is well illustrated by 
LSFM, in which the collaboration of physicists, biologists, computational 
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scientists and image analyses experts is required to get the most from the 
technique. Indeed, Reynaud et al. have commented that LSFM demands “a 
level of interdisciplinarity previously unseen in the biological sciences”(293). 
However, while the interdisciplinary nature of this technique can be 
challenging, collaborations between investigators from different 
backgrounds can lead to novel insights and approaches. The rapid pace of 
development in the field of lightsheet microscopy will change the landscape 
of biological imaging for years to come. It has been both challenging and 
exciting to be a part of the lightsheet microscopy community at a time of 
such great change.  
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Appendix 
A.  Fiji macro to reduce lightsheet data file size 
// -------------------------------------------------- 
// DOWN-SAMPLE LIGHTSHEET DATA 
// -------------------------------------------------- 
// 
// Macro to reduce the size of CZI lightsheet data by loading in one 
timepoint at a time and downsampling by decreasing bitdepth and binning. 
// 
// User is asked for a file, then given a dialog to select the range to 
process (this way you can use multiple machines) and how you want to 
downsample. Default is 8bit and 2x bin. 
// 
// A subdirectory of the file's directory is made (called "processed") and 
one tif-stack per timepoint is saved in that folder. 
// 
// A log window shows dimension information as well as the final physical 
size which you will need to enter in post-processing software. 
// 
// Written and Tested in Fiji [http://fiji.sc] 64bit. Paths coded for 
Windows (\). 
// 
//            
// Dave Mason [dnmason@liv.ac.uk]  
// Centre for Cell Imaging [cci.liv.ac.uk] 
// University of Liverpool 
// Written Nov 2015 
// Last Edited Sept 2016 
// 
//--------------------------------------------------- 
 
debugMode=0; 
 
//--------------------------------------------------- 
//-- PART 1: Open a file 
//--------------------------------------------------- 
path = File.openDialog("Select a File"); 
 
if (debugMode==0) {setBatchMode(true);} 
 
dir = File.getParent(path); 
name = File.getName(path); 
title = File.nameWithoutExtension; 
 
//-- Get dimension info on selected file 
run("Bio-Formats Macro Extensions"); 
Ext.setId(path); 
 
//-- Only process the first series 
  Ext.setSeries(0); 
  Ext.getSizeX(sizeX); 
  Ext.getSizeY(sizeY); 
  Ext.getSizeZ(sizeZ); 
  Ext.getSizeC(sizeC); 
  Ext.getSizeT(sizeT); 
  Ext.getDimensionOrder(dimOrder); 
   
//-- Print out dimensions 
  print("- - - - - - - - - - - - - - - - - - - - - -"); 
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  print("Input : "+path); 
  print("- - - - - - - - - - - - - - - - - - - - - -"); 
  print("Image dimensions: " + sizeX + " x " + sizeY); 
  print("Focal plane count = " + sizeZ); 
  print("Channel count = " + sizeC); 
  print("Time point count = " + sizeT); 
  print("- - - - - - - - - - - - - - - - - - - - - -"); 
 
//-- check for the existence of the output directory and make it if 
necessary 
outDir=dir+"\\processed"; 
  if (!File.exists(outDir)){ 
   print("Output Directory does not exist. Creating..."); 
     File.makeDirectory(outDir); 
  } else{ 
   print("Output Directory already exists"); 
  } 
 
//--------------------------------------------------- 
//-- PART 2: Request Processing options 
//--------------------------------------------------- 
 
Dialog.create("Processing options"); 
  Dialog.addNumber("Start Timepoint", 1); 
  Dialog.addNumber("End Timepoint", sizeT); 
    Dialog.addCheckbox("Crop", false); 
  Dialog.addNumber("size in X", sizeX); 
  Dialog.addNumber("size in Y", sizeY); 
  Dialog.addNumber("X offset", 0); 
  Dialog.addNumber("Y offset", 0); 
  Dialog.addCheckbox("8-bit?", true); 
  Dialog.addChoice("Bin Factor", newArray("1","2","4"),"2"); 
    Dialog.show(); 
  startT=Dialog.getNumber(); 
  endT=Dialog.getNumber(); 
  doCrop=Dialog.getCheckbox(); 
  Xdim=Dialog.getNumber(); 
  Ydim=Dialog.getNumber(); 
  Xoff=Dialog.getNumber(); 
  Yoff=Dialog.getNumber(); 
  downsample=Dialog.getCheckbox(); 
  binFactor=Dialog.getChoice(); 
   
  //-- Report Processing options to log 
  if (downsample==true){ 
  print("Downsampling to 8-bit"); 
  } 
  if (binFactor>1){ 
   print("Binning with Factor "+binFactor); 
  } 
  print("- - - - - - - - - - - - - - - - - - - - - -"); 
 
//--------------------------------------------------- 
//-- PART 3: Start processing the data 
//--------------------------------------------------- 
 
//-- For each timepoint open a single timepoint and process. This prevents 
memory overflow on most systems. 
for (i=startT; i<=endT; i++){ 
print("Processing Timepoint "+i); 
run("Bio-Formats Importer", "open=["+path+"] autoscale color_mode=Default 
specify_range view=Hyperstack stack_order=XYCZT z_begin=1 z_end="+sizeZ+" 
z_step=1 t_begin="+i+" t_end="+i+" t_step=1"); 
if (i==startT){ 
 //-- On the first image, get the XYZ calibration 
 getVoxelSize(width, height, depth, unit); 
  } 
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//-- Depending upon the choices made, choose how to process 
if (downsample==true){ 
run("8-bit"); 
} 
if (binFactor>1){ 
run("Bin...", "x="+binFactor+" y="+binFactor+" z=1 bin=Average"); 
} 
if (doCrop==true){ 
makeRectangle(Xoff, Yoff, Xdim, Ydim); 
run("Crop"); 
} 
 
//-- Save timepoint 
saveAs("Tiff", outDir+"\\t"+IJ.pad(i,3)+".tif"); 
} 
print("Original Pixel Size: " + width + " x " + height + " x " + depth + " 
("+unit+")"); 
print("Processed Pixel Size: " + width*binFactor + " x " + height*binFactor 
+ " x " + depth + " ("+unit+")"); 
print("- - - - - - - - - - - - - - - - - - - - - -"); 
print("Finished"); 
print("- - - - - - - - - - - - - - - - - - - - - -"); 
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B. MATLAB scripts 
B.1 Wrapper script (WRAPPER.m) 
%% WRAPPER SCRIPT TO PROCESS A DIRECTORY TREE 
% 
%   A wrapper to find Imaris-exported datasets in a directory tree and call 
a processing script on each one. 
%   Written to accommodate Lightsheet Data Processing script (processData.m) 
and figure plotting script (plotFigures.m) 
% 
%   Must be run from the top level of the directory tree. Make sure any 
called scripts are in the same directory. Only directories containing an 
"XXXX_Overall.csv" file will be processed. 
%    
%   Requires a file called Centroids.csv file with header row 
(filename,x,y,z,t) for the spheroid centroid position and temporal 
calibration (in microns and seconds respectively). 
% 
%   Written By Dave Mason [dnmason@liv.ac.uk], Centre for Cell Imaging 
[cci.liv.ac.uk, University of Liverpool 
% 
%---------------------------------------------------------------------------
----------------------- 
close all 
clear all 
clc 
  
%-- Regular expression for the script files to include in the dialog 
re='^(processData|plotFigures).+(\.m)$'; 
%-- get a directory listing 
d=dir;  
d={d.name}.'; 
f=regexp(d,re,'match'); 
f=[f{:}].'; 
%-- Request the filename of the script to run 
[selection,ok]=listdlg('ListString',f,'SelectionMode','single','Name','Selec
t a script'); 
  
if ok ==0 
    disp('ERROR: Script is required'); 
    return 
else 
    wrapper_script=f{selection}; 
end 
clearvars re d f selection ok 
  
%-- You can run a custom script by uncommenting the line below: 
%wrapper_script='MakeFigs_v3.m'; 
  
%-- list all subdirectories in pwd 
wrapper_startDir=pwd; 
wrapper_dirList=regexp(genpath(wrapper_startDir),['[^;]*'],'match'); 
  
%-- Load an array of filenames, centroids, tCalibs 
fid=fopen('Centroids.csv'); 
wrapper_cents=textscan(fid,'%s','Delimiter', ','); 
fclose(fid); 
  
%-- IMPORTANT !!! ----------------------------------------------------------
----------------------- 
%-- This needs to be adjusted to represent the number of columns (5) and 
rows (14) in the CSV. 
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wrapper_cents=reshape(wrapper_cents{1,1},5,14); 
clearvars fid ans; 
%---------------------------------------------------------------------------
----------------------- 
  
%-- go to each level and look for a set of CSV data 
for wrapper_i=1:size(wrapper_dirList,2) 
cd(wrapper_dirList{wrapper_i}); %-- Does not carry to the new script called 
by run. Must re-issue. 
if ~isempty(dir('*_Overall.csv')) %-- Use the Overall as a marker as it's 
not used in processing 
     
    %-- file exists so call the script in this directory 
     
    disp('------------------------------------------------------------------
------') 
    disp([datestr(datetime) ' - FOUND TRACKING DATA IN:']) 
    disp(wrapper_dirList{wrapper_i}) 
    disp('------------------------------------------------------------------
------') 
     
    if exist(fullfile(wrapper_startDir,wrapper_script),'file') 
        run(fullfile(wrapper_startDir,wrapper_script)); 
    else 
        disp('ERROR: Cannot find script file. Make sure a copy is in the 
starting directory!'); 
        return 
    end 
     
end %-- Data files exist 
  
end %-- All subdirs loop 
  
cd(wrapper_startDir); 
close all 
clearvars 
disp('----------------------------------------------------------------------
--') 
disp([datestr(datetime) ' - WRAPPER IS FINISHED']) 
disp('----------------------------------------------------------------------
--') 
  
                                                                                                                                   173 
B.2 Data processing script (ProcessData.m) 
%% POST-PROCESSING SCRIPT FOR LIGHTSHEET DATA TRACKED IN IMARIS 
% 
%   Script to calculate various stats from Imaris tracking data output. 
% 
%   USAGE: 
%   ====== 
%   Can be run stand alone or through the WRAPPER script. 
% 
% 
%   Written By Dave Mason [dnmason@liv.ac.uk] 
%   Centre for Cell Imaging [cci.liv.ac.uk] 
%   University of Liverpool 
%   Written: May 2016 
%   Latest update: September 2016 
% 
%---------------------------------------------------------------------------
----------------------- 
%% -- Load in the data 
clearvars -except wrapper_* 
close all 
  
%-- Store the warning state, then turn off all warnings 
w=warning; 
warning('off','all'); 
  
%-- if called from WRAPPER, PWD is the location of the script, so CD into 
the active data directory 
if exist('wrapper_i','var') 
    cd(wrapper_dirList{wrapper_i}); 
end 
  
%-- Find the _Overall.csv file and use the filename as an anchor from which 
to find the base name 
inFileDir=dir('*_Overall.csv'); 
inFile=inFileDir.name; 
clearvars inFileDir; 
  
%-- Rename the file so you can run the same script in the same directory 
structure and not double-up processing 
movefile(inFile,strrep(inFile,'_Overall.csv','_Overall_RUNNING.csv')); 
  
if exist('wrapper_i','var') 
%-- RUNNING FROM WRAPPER SCRIPT 
     
    %-- Find index of this folder 
    centIndex=strcmp(inFile,wrapper_cents); 
    centIndex=find(centIndex(1,:)); 
  
    %-- Pull the coordinates and time calibration 
    
centrePosXYZ=[str2num(wrapper_cents{2,centIndex}),str2num(wrapper_cents{3,ce
ntIndex}),str2num(wrapper_cents{4,centIndex})]; 
    tCalib=str2num(wrapper_cents{5,centIndex}); 
    clearvars centIndex; 
else 
%-- RUNNING STAND-ALONE 
     
    %-- Get user input for centroid position 
    inCentroid=inputdlg({'Centroid X position','Centroid Y 
position','Centroid Z position','Time Interval (s)'},'Enter Parameters',1); 
     
    if isempty(inCentroid) 
        disp('Error! Centroid Coordinates Required for processing'); 
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        return 
    end 
     
    
centrePosXYZ=[str2num(inCentroid{1}),str2num(inCentroid{2}),str2num(inCentro
id{3})]; 
    tCalib=str2num(inCentroid{4}); 
end 
clearvars inCentroid; 
  
%-- Sanity check 
if isempty(centrePosXYZ) || isempty(tCalib) 
    disp('Error! Centroid Coordinates Required for processing'); 
    return 
end 
  
  
%% -- Drop a timestamp 
disp([datestr(datetime) ' - Starting Import -------------------------------
']) 
  
%% -- Import the Data 
  
disp([datestr(datetime) ' - Importing Spot Position']) 
data_sPos = xlsread(strrep(inFile,'_Overall.csv','_Position.csv')); 
disp([datestr(datetime) ' - ... done']) 
  
disp([datestr(datetime) ' - Importing Spot Speed']) 
data_sSpeed = xlsread(strrep(inFile,'_Overall.csv','_Speed.csv')); 
disp([datestr(datetime) ' - ... done']) 
  
disp([datestr(datetime) ' - Importing Track Position']) 
data_tPosStart = 
xlsread(strrep(inFile,'_Overall.csv','_Track_Position_Start.csv')); 
disp([datestr(datetime) ' - ... done']) 
  
disp([datestr(datetime) ' - Importing Track Straightness']) 
data_tStraight = 
xlsread(strrep(inFile,'_Overall.csv','_Track_Straightness.csv')); 
disp([datestr(datetime) ' - ... done']) 
  
disp([datestr(datetime) ' - Importing Mean Track Speed']) 
data_tSpeedMean = 
xlsread(strrep(inFile,'_Overall.csv','_Track_Speed_Mean.csv')); 
disp([datestr(datetime) ' - ... done']) 
  
  
%% -- Drop a timestamp 
disp([datestr(datetime) ' - Import Complete, Starting Processing ----------
']) 
  
%% -- Match Spot Speed to Radial Distance 
t1=tic; 
disp([datestr(datetime) ' - Processing Spot Speed vs Radial Distance']) 
  
%-- Correct speed from um/1s to um/tCalib 
data_sSpeed(:,1)=data_sSpeed(:,1)/tCalib; 
%-- Turn it into um/hour 
data_sSpeed(:,1)=data_sSpeed(:,1)*3600; 
  
%-- Preallocate array 
arrLen=length(data_sPos(:,1)); 
%-- columns (for each feature): 1=distance from centre, 2=Speed, 
3=Straightness 
calc_SpotData=zeros([arrLen 3]); 
h1 = waitbar(0,'Initialising...'); 
%-- Loop through position file and collate corresponding speed value 
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for i=1:arrLen; 
    %-- Update waitbar every 100 feats 
        if mod(i, 100) == 0 
            waitbar(i/arrLen,h1,sprintf('%0.2f%% done analysing Spot 
Parameters',(i/arrLen)*100)); 
        end 
    %-- Calculate the absolute distance of the spot from the centre 
    calc_SpotData(i,1)=sqrt(((centrePosXYZ(1)-
data_sPos(i,1))^2)+((centrePosXYZ(2)-data_sPos(i,2))^2)+((centrePosXYZ(3)-
data_sPos(i,3))^2)); 
    searchTID=data_sPos(i,8); 
    searchT=data_sPos(i,7); 
    %-- Look up and record the corresponding speed, final '1' is not 
necessary (for first value) but added for clarity 
    calc_SpotData(i,2)=data_sSpeed(data_sSpeed(:,5)==searchTID & 
data_sSpeed(:,4)==searchT,1); 
end 
close(h1); 
  
%-- Concat the Time and Track ID values onto the array 
calc_SpotData=horzcat(calc_SpotData,data_sPos(:,7),data_sPos(:,8)); 
  
  
disp([datestr(datetime) ' - Finished processing ' 
num2str(length(calc_SpotData(:,1))) ' tracks in ' 
sprintf('%0.f%',toc(t1)/60) ' minutes.']) 
  
  
%% -- Match Track Straightness to Radial Distance 
t1=tic; 
disp([datestr(datetime) ' - Processing Track Straightness vs Radial 
Distance']) 
  
%-- Preallocate array 
arrLen=length(data_tPosStart(:,1)); 
%-- columns (for each feature): 1=distance from centre, 2=Speed, 
3=straightness 
calc_TrackData=zeros([arrLen 4]); 
h1 = waitbar(0,'Initialising...'); 
%-- Loop through position file and collate corresponding speed value 
for i=1:arrLen; 
    %-- Update waitbar 
    waitbar(i/arrLen,h1,sprintf('%0.2f%% done analysing Track 
Parameters',(i/arrLen)*100)); 
     
    %-- Pull the distance from the spot values (first spot in a track) 
    calc_TrackData(i,1)=calc_SpotData( 
find(calc_SpotData(:,5)==data_tPosStart(i,7),1)); 
     
    calc_TrackData(i,4)=data_tPosStart(i,7); %-- Record the track number 
  
    searchTID=data_tPosStart(i,7); 
    %-- Look up and record the corresponding track speed and straightness 
    calc_TrackData(i,2)=data_tSpeedMean(data_tSpeedMean(:,4)==searchTID,1); 
    calc_TrackData(i,3)=data_tStraight(data_tStraight(:,4)==searchTID,1); 
end 
close(h1); 
  
disp([datestr(datetime) ' - Finished processing ' 
num2str(length(calc_TrackData(:,1))) ' tracks in ' 
sprintf('%0.f%',toc(t1)/60) ' minutes.']) 
  
%% -- Calculate the instantaneous Straightness of spots 
  
disp([datestr(datetime) ' - Processing Spot Straightness']) 
t1=tic; 
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%-- What window should be used to calculate the spots? Note that there is no 
edge processing. Edge values are zeroed 
windNum=5; 
  
h1=waitbar(0,'Initialising...'); 
  
for i=1:length(calc_SpotData(:,1)) 
     
    %-- Check to make sure that there are features two forward and two back 
    missingFeats=0; 
    for j=[-2 -1 1 2] %-- THIS NEEDS TO BE CORRECTED IF windNum IS ALTERED 
        if isempty(data_sPos(data_sPos(:,8)==calc_SpotData(i,5) & 
data_sPos(:,7)==calc_SpotData(i,4)+j,1:3));  
            missingFeats=1; 
            break %-- found one, so don't bother searching the others 
        end 
    end 
     
    % If any are absent, skip to the next spot 
    if missingFeats==1; 
        continue 
    end 
     
    %-- calculate $windNum sets of coordinates 
    c=zeros(windNum,3); 
    for j=1:windNum 
        c(j,:)=data_sPos(data_sPos(:,8)==calc_SpotData(i,5) & 
data_sPos(:,7)==calc_SpotData(i,4)+(j-3),1:3); 
    end 
     
    %-- Should only have got here if there are indeed windNum sets of coords 
in 'c' 
     
    %-- Calculate the end-to-end displacement 
    c1=sqrt( (c(1,1)-c(windNum,1))^2 + (c(1,2)-c(windNum,2))^2 + (c(1,3)-
c(windNum,3))^2); 
     
    %-- Calculate the path length (ahead) 
    c2=0; 
    for j=1:windNum-1 
        c2=c2+sqrt( (c(j,1)-c(j+1,1))^2 + (c(j,2)-c(j+1,2))^2 + (c(j,3)-
c(j+1,3))^2); 
    end 
     
    %-- Record the straightness 
    calc_SpotData(i,3)=c1/c2; 
     
    %-- update the waitbar every 100 tracks (every 1 slows processing too 
much) 
    if mod(i, 100) == 0 
    waitbar(i/length(calc_SpotData(:,1)),h1,sprintf('%0.2f%% done analysing 
Spot Parameters',(i/length(calc_SpotData(:,1)))*100)); 
    end 
end 
close(h1); 
  
disp(['Finished processing ' num2str(length(calc_SpotData(:,1))) ' spots in 
' sprintf('%0.f%',toc(t1)/60) ' minutes.']) 
clearvars i xrand missingFeats searchT searchTID j h1 t1 zzz_yVals h51 c c1 
c2; 
  
  
%% -- Calculate the Cumlulative Distribution by distance over time 
  
disp([datestr(datetime) ' - Processing Cumulative Distribution by 
Distance']) 
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binNum=50; 
numPointsArray=[1 160 320 480]; %-- Timepoints are hardcoded for comparison 
of data between experiments 
  
%-- Set up array with bins 
calc_CDF(:,1)=[0:(max(calc_SpotData(:,1))*1.1)/binNum:max(calc_SpotData(:,1)
)*1.1]; 
  
%-- concat T and tID columns onto outSpotData 
calc_SpotData=horzcat(calc_SpotData,data_sPos(:,7),data_sPos(:,8)); 
  
%-- Figure out how many bins we have 
arrLen=length(calc_CDF(:,1)); 
  
%-- Do numPoints worth of timepoints 
for j=numPointsArray; 
%-- Loop through position file and collate corresponding speed value 
for i=1:arrLen; 
     
    %-- For each bin step, calculate the cululative number of spots within 
that range 
    
calc_CDF(i,find(numPointsArray==j)+1)=length(calc_SpotData(calc_SpotData(:,1
)<calc_CDF(i,1) & calc_SpotData(:,4)==j) ); 
     
end %-- i loop 
  
end %-- j loop 
  
  
%-- Normalise the data in Y for comparison 
calc_CDFnorm(:,1)=calc_CDF(:,1); 
  
for j=2:length(calc_CDF(1,:)) 
  
    calc_CDFnorm(:,j)=(calc_CDF(:,j)-
min(calc_CDF(:,j)))/(max(calc_CDF(:,j))-min(calc_CDF(:,j))); 
  
end 
  
disp([datestr(datetime) ' - ... done']) 
clearvars i j; 
  
%% -- Refine Data matrices to 'OUTSIDE' spots only 
disp([datestr(datetime) ' - Refining to outer tracks']) 
%-- Calculate the 10 furthest out in the first frame and use the mean as the 
in/out boundary 
tmp1=sort(calc_SpotData(calc_SpotData(:,4) == 1),1,'descend'); 
eventHorizon=mean(tmp1(1:10,1)); 
clearvars tmp1; 
  
%-- Refine the Event Horizon here (add 5% to distance) 
eventHorizon=eventHorizon*1.05; 
  
%-- Now refine the outSpotData to only include the values outside the 
boundary 
%-- Find the indices 
tmp_ind=calc_SpotData(:,1)>eventHorizon; 
%-- Pull the rows based on the indexing 
calc_SpotData_outside=calc_SpotData(tmp_ind,:); 
clearvars tmp_ind; 
  
%-- Now refine the outTrackData to only include the values outside the 
boundary 
%-- Find the indices 
tmp_ind=calc_TrackData(:,1)>eventHorizon; 
%-- Pull the rows based on the indexing 
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calc_TrackData_outside=calc_TrackData(tmp_ind,:); 
clearvars tmp_ind; 
  
disp([datestr(datetime) ' - ... done']) 
  
%% -- Finished 
%-- Save the workspace variables using the base filename 
save(strrep(inFile,'_Overall.csv','_MATLAB_data.mat')); 
% -- rename the Input file so that the dataset won't be re-analysed 
movefile(strrep(inFile,'_Overall.csv','_Overall_RUNNING.csv'),strrep(inFile,
'_Overall.csv','_Overall_DONE.csv')); 
%-- set the warning state back to original 
warning(w); 
%-- Let the user know we're done 
disp([datestr(datetime) ' - Finished --------------------------------------
']); 
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B.3 Figure plotting script (PlotFigures.m) 
%% POST-PROCESSING SCRIPT FOR LIGHTSHEET DATA TRACKED IN IMARIS - PLOT 
FIGURES 
% 
% Script to plot figures from post-processed lightsheet data 
% 
% 
% Written By Dave Mason [dnmason@liv.ac.uk] 
% Centre for Cell Imaging [cci.liv.ac.uk] 
% University of Liverpool 
% Written: May 2016 
% Latest update: September 2016 
% 
%---------------------------------------------------------------------------
----------------------- 
  
%-- Usual tidy up before IMPORT 
clearvars -except wrapper_* 
close all 
  
if exist('wrapper_i','var') 
    %-- if called from WRAPPER, PWD is the location of the script, so CD 
into the active data directory 
    cd(wrapper_dirList{wrapper_i}); 
end 
  
%-- Get the mat file 
    tA=dir('*MATLAB_data.mat'); 
  
%-- load the CDF array 
load(tA.name, '-regexp', '^(?!wrapper_)...'); 
inFile=tA.name; 
clearvars tA 
  
%- Store the warning state, then turn off all warnings 
w=warning; 
warning('off','all'); 
  
%% -- GLOBAL VARIABLES FOR PLOTTING --------------------------------------- 
%-------------------------------------------------------------------------- 
  
axisFontSize=20;            %-- Size of Font used in Axis labels. Default = 
12 
axisLineWidth=2;            %-- Axis line width. Default = 0.5 
plotLineThickness=2;        %-- Default = 0.5 
plotLineThicknessHisto=2;   %-- Default = 0.5 (You might want a thinner line 
for histograms cf CDF graphs) 
plotMarkerSize=2;           %-- Default = 6 
sameAxes=1;                 %-- [0/1] Use consistant axis scaling [1] or 
autoscale [0]? 
  
bigSpheroids=0;             %-- [0/1] Determines how the 
SpotSpeed/SpotStraightness by Distance bins are calculated.  
                            %         [0]= Use 2 bins (in/out) for distance 
graphs [1]= Use 6 bins for distance (3 in / 3 out) 
minSpots=1000;              %-- Need at least this many Spots to plot a line 
graph - prevents crappy-looking normalised histograms 
  
%-- OUTPUTS --------------------------------------------------------------- 
saveFIG=1;          %-- [0/1] Save a matlab FIG file? 
savePNG=0;          %-- [0/1] Save a PNG file? 
addGraphTitle=0;    %-- [0/1] Add a title to the graphs (IE "Spot Speed by 
Radial Distance" &c.) 
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addFileNameTitle=0; %-- [0/1] Do you want to add a FileName title to each 
plot? Recomended to TURN OFF for fig files as it changes the axis layout 
  
  
%% -- Cumlulative Distribution by distance over time - CURVES 
  
%-- CDF GRAPH ------------------------------------------------------------- 
fig01=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
  
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
hold on; 
for j=2:length(calc_CDF(1,:)) 
plot(calc_CDF(:,1),calc_CDF(:,j),'LineWidth',plotLineThickness) 
end 
xlabel('Radial Distance (um)'); 
ylabel('Cumulative Number of Features'); 
if sameAxes==1 
    xlim([0 400]); 
end 
if addGraphTitle==1 
    title(['Spatial Distribution of Features by Time']); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth) 
%-- Create the legend string 
numPointsArray=[1 160 320 480]; %-- provide time points 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','SE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%-- NORMALISED CDF GRAPH -------------------------------------------------- 
fig02=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
hold on 
for j=2:length(calc_CDFnorm(1,:)) 
plot(calc_CDFnorm(:,1),calc_CDFnorm(:,j),'LineWidth',plotLineThickness) 
end 
ylim([0 1.1]); 
xlabel('Radial Distance (um)'); 
ylabel('Norm Cumulative Number of Features'); 
if sameAxes==1 
    xlim([0 400]); 
end 
if addGraphTitle==1 
    title(['Spatial Distribution of Features by Time']); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth) 
%-- Create the legend string 
numPointsArray=[1 160 320 480]; %-- provide time points 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','SE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
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set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Speed by Time - ALL - LINE HISTOGRAM 
  
fig06=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
fig07=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
binNum=100; %-- How smooth should the distribution be? 
numPointsArray=[1 160 320 480]; %-- provide time points 
  
for j=1:length(numPointsArray)-1; 
[freq,bins]=hist(calc_SpotData(calc_SpotData(:,4)<numPointsArray(j+1) & 
calc_SpotData(:,4)>=numPointsArray(j),2),binNum); 
figure(fig06); 
plot(bins,freq,'LineWidth',plotLineThicknessHisto); 
hold on 
freqNorm=(freq-min(freq))/(max(freq)-min(freq)); 
  
figure(fig07); 
plot(bins,freqNorm,'LineWidth',plotLineThicknessHisto); 
hold on 
  
end 
  
figure(fig06); 
xlabel('Spot Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Frequency'); 
if addGraphTitle==1 
    title('Distribution of Spot Speed by Timepoint'); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','SE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
figure(fig07); 
ylim([0 1.1]); 
xlabel('Spot Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Normalised Frequency'); 
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if addGraphTitle==1 
    title('Normalised Distribution of Spot Speed by Timepoint'); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','SE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Speed by Space - ALL - LINE HISTOGRAM 
  
fig08=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
fig09=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
binNum=100; %-- How smooth should the distribution be? 
numPointsArray=[0 100 200 300 400]; %-- provide spatial bins 
  
%-- this is for big spheroids. 
if bigSpheroids==1 
    %-- Break down into 3 in and 3 out 
    numPointsArray=round([0:eventHorizon/3:eventHorizon*2],-1); 
else 
    %-- Just use in / out 
    numPointsArray=round([0:eventHorizon:eventHorizon*2],-1); 
end 
  
for j=1:length(numPointsArray)-1; 
[freq,bins]=hist(calc_SpotData(calc_SpotData(:,1)<numPointsArray(j+1) & 
calc_SpotData(:,1)>=numPointsArray(j),2),binNum); 
  
    if sum(freq)>minSpots %-- only plot if there are enough values for a 
reasonable graph 
  
        figure(fig08); 
        plot(bins,freq,'LineWidth',plotLineThicknessHisto); 
        hold on 
  
        freqNorm=(freq-min(freq))/(max(freq)-min(freq)); 
  
        figure(fig09); 
        plot(bins,freqNorm,'LineWidth',plotLineThicknessHisto); 
        hold on 
  
    end 
  
end 
figure(fig08); 
xlabel('Spot Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
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ylabel('Frequency'); 
if addGraphTitle==1 
    title('Distribution of Spot Speed by Radial Distance') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
legendCell = cellstr([num2str(numPointsArray', 'd=%-d-') 
num2str(circshift(numPointsArray,[0 -1])', ' %-d um')]); 
legend(legendCell,'Location','NE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
figure(fig09); 
ylim([0 1.1]); 
xlabel('Spot Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Normalised Frequency'); 
if addGraphTitle==1 
    title('Normalised Distribution of Spot Speed by Radial Distance') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
  
legend(legendCell,'Location','NE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Straightness by Time - ALL - LINE HISTOGRAM 
  
fig10=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
fig11=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
  
binNum=200; %-- How smooth should the distribution be? 
numPointsArray=[1 160 320 480]; %-- provide time points 
  
for j=1:length(numPointsArray)-1; 
[freq,bins]=hist(calc_SpotData(calc_SpotData(:,4)<numPointsArray(j+1) & 
calc_SpotData(:,3)~=0 & calc_SpotData(:,4)>=numPointsArray(j),3),binNum);  
figure(fig10); 
plot(bins,freq,'LineWidth',plotLineThicknessHisto); 
hold on 
freqNorm=(freq-min(freq))/(max(freq)-min(freq)); 
  
figure(fig11); 
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plot(bins,freqNorm,'LineWidth',plotLineThicknessHisto); 
hold on 
  
end 
  
figure(fig10); 
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Frequency'); 
if addGraphTitle==1 
    title('Distribution of Spot Straightness by Timepoint'); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','NW'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
figure(fig11); 
ylim([0 1.1]); 
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Normalised Frequency'); 
if addGraphTitle==1 
    title('Normalised Distrib^N of Spot Straightness by Timepoint'); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','NW'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Straightness by Space - ALL - LINE HISTOGRAM 
  
fig12=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
fig13=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
binNum=200; %-- How smooth should the distribution be? 
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numPointsArray=[0 100 200 300 400]; %-- provide spatial bins 
  
%-- this is for big spheroids. 
if bigSpheroids==1 
    %-- Break down into 3 in and 3 out 
    numPointsArray=round([0:eventHorizon/3:eventHorizon*2],-1); 
else 
    %-- Just use in / out 
    numPointsArray=round([0:eventHorizon:eventHorizon*2],-1); 
end 
  
for j=1:length(numPointsArray)-1; 
[freq,bins]=hist(calc_SpotData(calc_SpotData(:,1)<numPointsArray(j+1) & 
calc_SpotData(:,3) ~=0 & calc_SpotData(:,1)>=numPointsArray(j),3),binNum); 
  
    if sum(freq)>minSpots %-- only plot if there are enough values for a 
reasonable graph 
  
        figure(fig12); 
        plot(bins,freq,'LineWidth',plotLineThicknessHisto); 
        hold on 
  
        freqNorm=(freq-min(freq))/(max(freq)-min(freq)); 
  
        figure(fig13); 
        plot(bins,freqNorm,'LineWidth',plotLineThicknessHisto); 
        hold on 
    end 
end 
figure(fig12); 
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Frequency'); 
if addGraphTitle==1 
    title('Distrib^N of Spot Straightness by Radial Distance') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
  
legendCell = cellstr([num2str(numPointsArray', 'd=%-d-') 
num2str(circshift(numPointsArray,[0 -1])', ' %-d um')]); 
legend(legendCell,'Location','NW'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
figure(fig13); 
ylim([0 1.1]); 
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Normalised Frequency'); 
if addGraphTitle==1 
    title('Normalised Distribution of Spot Straightness by Radial Distance') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
legend(legendCell,'Location','NW'); 
  
if addFileNameTitle==1 
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%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
pause(3); %-- Have no idea why this is required but without it the axes get 
borked when running the whole script 
  
%% -- Spot Speed - ALL - LINE HISTOGRAM 
  
fig14=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
binNum=100; %-- How smooth should the distribution be? 
  
[freq,bins]=hist(calc_SpotData(:,2),binNum); 
plot(bins,freq,'LineWidth',plotLineThickness); %-- because there's only one 
use the thicker line 
  
xlabel('Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Frequency'); 
ylim([0 max(freq)*1.05]); 
if addGraphTitle==1 
    title('Distrib^N of Spot Speed') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
  
%% -- Spot Straightness - ALL - LINE HISTOGRAM 
  
fig15=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
binNum=100; %-- How smooth should the distribution be? 
  
[freq,bins]=hist(calc_SpotData(calc_SpotData(:,3) ~=0,3),binNum); 
plot(bins,freq,'LineWidth',plotLineThickness); %-- because there's only one 
use the thicker line 
  
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Frequency'); 
ylim([0 max(freq)*1.05]); 
if addGraphTitle==1 
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    title('Distrib^N of Spot Straightness') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Speed - ALL - BEEHIVE 
  
xrand=0.1.*randn(size(calc_SpotData,1),1)+1; 
  
%-- Plot the graph 
fig16=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
plot(xrand,calc_SpotData(:,2),'.','MarkerSize',plotMarkerSize); 
xlim([0 2]); 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth,'XTick', []) 
  
ylim([0 250]); 
ylabel('Speed (um/h)'); 
if addGraphTitle==1 
    title('Spot Speed (All Cells)','FontSize',12); 
end 
hold on 
plot([0.4 1.6],[mean(calc_SpotData(:,2)) mean(calc_SpotData(:,2))],'r-
','LineWidth',1, 'HandleVisibility','off'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
  
%% -- Spot Straightness - ALL - BEEHIVE 
  
%-- Prepare the data for plotting (strip zeros) 
zzz_yVals=calc_SpotData(calc_SpotData(:,3)~=0,3); 
xrand=0.1.*randn(size(zzz_yVals,1),1)+1; 
  
%-- Plot the graph 
fig17=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
plot(xrand,zzz_yVals,'.','MarkerSize',plotMarkerSize); 
xlim([0 2]); 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth,'XTick', []) 
  
ylabel('Straightness'); 
if addGraphTitle==1 
    title('Spot Straightness (All Cells)','FontSize',12); 
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end 
hold on 
meanStraight=mean(zzz_yVals); 
plot([0.4 1.6],[mean(zzz_yVals) mean(zzz_yVals)],'r-','LineWidth',1, 
'HandleVisibility','off'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
  
  
  
%% -- NOW DO THE SAME AGAIN BUT WITH INVADING ONLY ------------------------- 
% -- Spot Speed by Time - INVADING - LINE HISTOGRAM 
  
fig30=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
fig31=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
  
binNum=100; %-- How smooth should the distribution be? 
numPointsArray=[1 160 320 480]; %-- provide time points 
  
for j=1:length(numPointsArray)-1; 
[freq,bins]=hist(calc_SpotData_outside(calc_SpotData_outside(:,4)<numPointsA
rray(j+1) & calc_SpotData_outside(:,4)>=numPointsArray(j),2),binNum); 
figure(fig30); 
plot(bins,freq,'LineWidth',plotLineThicknessHisto); 
hold on 
freqNorm=(freq-min(freq))/(max(freq)-min(freq)); 
  
figure(fig31); 
plot(bins,freqNorm,'LineWidth',plotLineThicknessHisto); 
hold on 
  
end 
  
figure(fig30); 
xlabel('Spot Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Frequency'); 
if addGraphTitle==1 
    title('Distribution of Invading Spot Speed by Timepoint'); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','SE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
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ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
figure(fig31); 
ylim([0 1.1]); 
xlabel('Spot Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Normalised Frequency'); 
if addGraphTitle==1 
    title('Normalised Distribution of Invading Spot Speed by Timepoint'); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','SE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Speed by Space - INVADING - LINE HISTOGRAM 
  
fig32=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
fig33=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
binNum=100; %-- How smooth should the distribution be? 
numPointsArray=[0 100 200 300 400]; %-- provide spatial bins 
  
for j=1:length(numPointsArray)-1; 
[freq,bins]=hist(calc_SpotData_outside(calc_SpotData_outside(:,1)<numPointsA
rray(j+1) & calc_SpotData_outside(:,1)>=numPointsArray(j),2),binNum); 
  
        figure(fig32); 
        plot(bins,freq,'LineWidth',plotLineThicknessHisto); 
        hold on 
  
        freqNorm=(freq-min(freq))/(max(freq)-min(freq)); 
  
        figure(fig33); 
        plot(bins,freqNorm,'LineWidth',plotLineThicknessHisto); 
        hold on 
  
end 
figure(fig32); 
xlabel('Spot Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Frequency'); 
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if addGraphTitle==1 
    title('Distribution of Invading Spot Speed by Radial Distance') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendCell = cellstr([num2str(numPointsArray', 'd=%-d-') 
num2str(circshift(numPointsArray,[0 -1])', ' %-d um')]); 
legend(legendCell,'Location','NE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
figure(fig33); 
ylim([0 1.1]); 
xlabel('Spot Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Normalised Frequency'); 
if addGraphTitle==1 
    title('Normalised Distribution of Invading Spot Speed by Radial 
Distance') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
  
legend(legendCell,'Location','NE'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Straightness by Time - INVADING - LINE HISTOGRAM 
  
fig34=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
fig35=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
  
binNum=200; %-- How smooth should the distribution be? 
numPointsArray=[1 160 320 480]; %-- provide time points 
  
for j=1:length(numPointsArray)-1; 
[freq,bins]=hist(calc_SpotData_outside(calc_SpotData_outside(:,4)<numPointsA
rray(j+1) & calc_SpotData_outside(:,3)~=0 & 
calc_SpotData_outside(:,4)>=numPointsArray(j),3),binNum);  
figure(fig34); 
plot(bins,freq,'LineWidth',plotLineThicknessHisto); 
hold on 
freqNorm=(freq-min(freq))/(max(freq)-min(freq)); 
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figure(fig35); 
plot(bins,freqNorm,'LineWidth',plotLineThicknessHisto); 
hold on 
  
end 
  
figure(fig34); 
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Frequency'); 
if addGraphTitle==1 
    title('Distrib^N of Invading Spot Straightness by Timepoint'); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','NW'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
figure(fig35); 
ylim([0 1.1]); 
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Normalised Frequency'); 
if addGraphTitle==1 
    title('Normalised Distrib^N of Invading Spot Straightness by 
Timepoint'); 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendStr = num2str(floor(numPointsArray'*3/60), 't=%2d h'); 
legend(legendStr,'Location','NW'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Straightness by Space - INVADING - LINE HISTOGRAM 
  
fig36=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
fig37=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
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binNum=30; %-- How smooth should the distribution be? 
  
numPointsArray=[0 100 200 300 400]; %-- provide spatial bins 
  
for j=1:length(numPointsArray)-1; 
[freq,bins]=hist(calc_SpotData_outside(calc_SpotData_outside(:,1)<numPointsA
rray(j+1) & calc_SpotData_outside(:,3) ~=0 & 
calc_SpotData_outside(:,1)>=numPointsArray(j),3),binNum); 
figure(fig36); 
plot(bins,freq,'LineWidth',plotLineThicknessHisto); 
hold on 
  
freqNorm=(freq-min(freq))/(max(freq)-min(freq)); 
  
figure(fig37); 
plot(bins,freqNorm,'LineWidth',plotLineThicknessHisto); 
hold on 
     
end 
figure(fig36); 
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Frequency'); 
if addGraphTitle==1 
    title('Distrib^N of Invading Spot Straightness by Radial Distance') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
%-- Create the legend string 
legendCell={'d=0-100 um';'d=100-200 um';'d=200-300 um';'d=300-400 
um';'d=400-500 um'}; 
legend(legendCell,'Location','NW'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
figure(fig37); 
ylim([0 1.1]); 
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Normalised Frequency'); 
if addGraphTitle==1 
    title('Normalised Distrib^N of Invading Spot Straightness by Radial 
Distance') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
legend(legendCell,'Location','NW'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
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pause(3); %-- Have no idea why this is required but without it the axes get 
borked 
  
%% -- Spot Speed - INVADING - LINE HISTOGRAM 
  
fig38=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
binNum=100; %-- How smooth should the distribution be? 
  
[freq,bins]=hist(calc_SpotData_outside(:,2),binNum); 
plot(bins,freq,'LineWidth',plotLineThickness); %-- because there's only one 
use the thicker line 
  
xlabel('Speed (um/h)'); 
if sameAxes==1 
    xlim([0 150]); 
end 
ylabel('Frequency'); 
ylim([0 max(freq)*1.05]); 
if addGraphTitle==1 
    title('Distrib^N of Invading Spot Speed') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
  
%% -- Spot Straightness - INVADING - LINE HISTOGRAM 
  
fig39=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
binNum=100; %-- How smooth should the distribution be? 
  
[freq,bins]=hist(calc_SpotData_outside(calc_SpotData_outside(:,3) 
~=0,3),binNum); 
plot(bins,freq,'LineWidth',plotLineThickness); %-- because there's only one 
use the thicker line 
  
xlabel('Straightness'); 
if sameAxes==1 
    xlim([0 1.1]); 
end 
ylabel('Frequency'); 
ylim([0 max(freq)*1.05]); 
if addGraphTitle==1 
    title('Distrib^N of Invading Spot Straightness') 
end 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
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ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
%% -- Spot Speed - INVADING - BEEHIVE 
  
xrand=0.1.*randn(size(calc_SpotData_outside,1),1)+1; 
  
%-- Plot the graph 
fig40=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
plot(xrand,calc_SpotData_outside(:,2),'.','MarkerSize',plotMarkerSize); 
xlim([0 2]); 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth,'XTick', []) 
  
ylabel('Speed (um/h)'); 
if addGraphTitle==1 
    title('Spot Speed (Invading)','FontSize',axisFontSize); 
end 
hold on 
plot([0.4 1.6],[mean(calc_SpotData_outside(:,2)) 
mean(calc_SpotData_outside(:,2))],'r-','LineWidth',1, 
'HandleVisibility','off'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
  
%% -- Spot Straightness - INVADING - BEEHIVE 
  
%-- Prepare the data for plotting (strip zeros) 
zzz_yVals=calc_SpotData_outside(calc_SpotData_outside(:,3)~=0,3); 
xrand=0.1.*randn(size(zzz_yVals,1),1)+1; 
  
%-- Plot the graph 
fig41=figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) %-- Set the figure position and size 
of the figure 
movegui(gcf,'center') %-- Do this to make sure that the figure isn't cut off 
(or including other windows) when exporting 
  
plot(xrand,zzz_yVals,'.','MarkerSize',plotMarkerSize); 
xlim([0 2]); 
set(gca,'fontsize',axisFontSize, 'LineWidth',axisLineWidth,'XTick', []) 
  
ylabel('Straightness'); 
if addGraphTitle==1 
    title('Spot Straightness (Invading)','FontSize',axisFontSize); 
end 
hold on 
plot([0.4 1.6],[mean(zzz_yVals) mean(zzz_yVals)],'r-','LineWidth',1, 
'HandleVisibility','off'); 
  
if addFileNameTitle==1 
%-- Add a FileName title 
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set(gca, 'OuterPosition', [0 0 1 .95]); 
ha = axes('Position',[0 0 1 1],'Xlim',[0 1],'Ylim',[0 
1],'Box','off','Visible','off','Units','normalized', 'clipping' , 'off'); 
text(0.5, 1,inFile,'HorizontalAlignment','center','VerticalAlignment', 
'top','interpreter','none','FontSize',12) 
end 
  
  
  
%% -- Save the figures and tidy up 
  
if saveFIG==1 
%-- Save the figures as fig files 
savefig(fig01,strrep(inFile,'_MATLAB_data.mat','_ALL_CDF.fig')); 
savefig(fig02,strrep(inFile,'_MATLAB_data.mat','_ALL_CDF_norm.fig')); 
savefig(fig06,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_byTime.fig')); 
savefig(fig07,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_byTime_Norm.fig')
); 
savefig(fig08,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_bySpace.fig')); 
savefig(fig09,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_bySpace_Norm.fig'
)); 
savefig(fig10,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_byTime.fig')); 
savefig(fig11,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_byTime_Norm.fi
g')); 
savefig(fig12,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_bySpace.fig'))
; 
savefig(fig13,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_bySpace_Norm.f
ig')); 
savefig(fig14,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED.fig')); 
savefig(fig15,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT.fig')); 
savefig(fig16,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_BH.fig')); 
savefig(fig17,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_BH.fig')); 
%-- Invading 
savefig(fig30,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_byTime.fig')); 
savefig(fig31,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_byTime_Norm.fig')
); 
savefig(fig32,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_bySpace.fig')); 
savefig(fig33,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_bySpace_Norm.fig'
)); 
savefig(fig34,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_byTime.fig')); 
savefig(fig35,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_byTime_Norm.fi
g')); 
savefig(fig36,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_bySpace.fig'))
; 
savefig(fig37,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_bySpace_Norm.f
ig')); 
savefig(fig38,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED.fig')); 
savefig(fig39,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT.fig')); 
savefig(fig40,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_BH.fig')); 
savefig(fig41,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_BH.fig')); 
end 
  
if savePNG==1 
%-- Save the figures as PNG files 
saveas(fig01,strrep(inFile,'_MATLAB_data.mat','_ALL_CDF.png')); 
saveas(fig02,strrep(inFile,'_MATLAB_data.mat','_ALL_CDF_norm.png')); 
saveas(fig06,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_byTime.png')); 
saveas(fig07,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_byTime_Norm.png'))
; 
saveas(fig08,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_bySpace.png')); 
saveas(fig09,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_bySpace_Norm.png')
); 
saveas(fig10,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_byTime.png')); 
saveas(fig11,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_byTime_Norm.png
')); 
saveas(fig12,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_bySpace.png')); 
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saveas(fig13,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_bySpace_Norm.pn
g')); 
saveas(fig14,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED.png')); 
saveas(fig15,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT.png')); 
saveas(fig16,strrep(inFile,'_MATLAB_data.mat','_ALL_SPEED_BH.png')); 
saveas(fig17,strrep(inFile,'_MATLAB_data.mat','_ALL_STRAIGHT_BH.png')); 
%-- Invading 
saveas(fig30,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_byTime.png')); 
saveas(fig31,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_byTime_Norm.png'))
; 
saveas(fig32,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_bySpace.png')); 
saveas(fig33,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_bySpace_Norm.png')
); 
saveas(fig34,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_byTime.png')); 
saveas(fig35,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_byTime_Norm.png
')); 
saveas(fig36,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_bySpace.png')); 
saveas(fig37,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_bySpace_Norm.pn
g')); 
saveas(fig38,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED.png')); 
saveas(fig39,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT.png')); 
saveas(fig40,strrep(inFile,'_MATLAB_data.mat','_INV_SPEED_BH.png')); 
saveas(fig41,strrep(inFile,'_MATLAB_data.mat','_INV_STRAIGHT_BH.png')); 
end 
  
clearvars i j xrand zzz_yVals; 
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